
<html lang="en"     class="pb-page"  data-request-id="f1dd39eb-f269-432d-995d-79d69897093d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c01773;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Niklas M.  Tormählen" /></meta><meta name="dc.Creator" content="Mariella  Martorelli" /></meta><meta name="dc.Creator" content="Annette  Kuhn" /></meta><meta name="dc.Creator" content="Florian  Maier" /></meta><meta name="dc.Creator" content="Jamil  Guezguez" /></meta><meta name="dc.Creator" content="Michael  Burnet" /></meta><meta name="dc.Creator" content="Wolfgang  Albrecht" /></meta><meta name="dc.Creator" content="Stefan A.  Laufer" /></meta><meta name="dc.Creator" content="Pierre  Koch" /></meta><meta name="dc.Description" content="Stress-induced p38α mitogen-activated protein (MAP) kinase activation modulates cytokine overproduction and is associated with neuroinflammation and neurodegeneration. As a potential therapeutic ap..." /></meta><meta name="Description" content="Stress-induced p38α mitogen-activated protein (MAP) kinase activation modulates cytokine overproduction and is associated with neuroinflammation and neurodegeneration. As a potential therapeutic ap..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 11, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01773" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01773" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01773" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01773" /></link>
        
    
    

<title>Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01773" /></meta><meta property="og:title" content="Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0024.jpeg" /></meta><meta property="og:description" content="Stress-induced p38α mitogen-activated protein (MAP) kinase activation modulates cytokine overproduction and is associated with neuroinflammation and neurodegeneration. As a potential therapeutic approach, novel Skepinone-based p38α MAP kinase inhibitors were optimized to cross the blood–brain barrier via either amino acid transporters or hydrophobic diffusion. To enhance absorption from the oral route, we used methyl ester prodrugs of the active carboxy analogs. Of these, 3-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)propanoic acid (43; p38α, IC50 = 5.5 nM) and 4-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)butanoic acid (44; p38α, IC50 = 12 nM) had brain-to-plasma ratios of 1.4 and 4.4, respectively. Compound 70, 3-(8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)propanoic acid (p38α, IC50 = 1.0 nM), the Skepinone-N counterpart of 43, was most present in the mouse brain (brain-to-plasma ratio of 4.7; 0.4 mg/kg p.o., 2 h, 580 nmol/kg). Compounds 43, 44, and 70 were p38α-MAP-kinase-selective, metabolically stable, hERG nonbinding, and able to modulate IL-6 and TNF-α production in cell-based assays." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01773"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01773">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01773&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01773&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01773&amp;href=/doi/10.1021/acs.jmedchem.0c01773" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00146" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00302" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Niklas M. Tormählen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Niklas M. Tormählen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Niklas+M.++Torm%C3%A4hlen">Niklas M. Tormählen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariella Martorelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariella Martorelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Synovo GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariella++Martorelli">Mariella Martorelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annette Kuhn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annette Kuhn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annette++Kuhn">Annette Kuhn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florian Maier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florian Maier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Synovo GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florian++Maier">Florian Maier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jamil Guezguez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jamil Guezguez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Synovo GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jamil++Guezguez">Jamil Guezguez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Burnet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Burnet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Synovo GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Burnet">Michael Burnet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wolfgang Albrecht</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wolfgang Albrecht</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Teva-ratiopharm, Graf-Arco-Str. 3, 89079 Ulm, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wolfgang++Albrecht">Wolfgang Albrecht</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan A. Laufer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan A. Laufer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan+A.++Laufer">Stefan A. Laufer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Pierre Koch</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre Koch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</div><div class="loa-info-affiliations-info">Department of Pharmaceutical/Medicinal Chemistry II, Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#81f1e8e4f3f3e4afeaeee2e9c1f4efe8acf5f4e4e3e8efe6e4efafe5e4"><span class="__cf_email__" data-cfemail="ea9a838f98988fc481858982aa9f8483c79e9f8f8883848d8f84c48e8f">[email protected]</span></a>; <a href="/cdn-cgi/l/email-protection#f4849d91868691da9f9b979cb48186da9091"><span class="__cf_email__" data-cfemail="2a5a434f58584f04414549426a5f58044e4f">[email protected]</span></a>. Tel: +49 941 943 4827.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Koch">Pierre Koch</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4620-4650" title="Orcid link">http://orcid.org/0000-0003-4620-4650</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01773&amp;href=/doi/10.1021%2Facs.jmedchem.0c01773" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 11, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 October 2020</li><li><span class="item_label"><b>Published</b> online</span>11 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01773" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01773</a></div><div class="article_header-article-copyright"><strong>© 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNiklas%2BM.%2BTorm%25C3%25A4hlen%252C%2BMariella%2BMartorelli%252C%2BAnnette%2BKuhn%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.0c01773%26title%3DDesign%2Band%2BSynthesis%2Bof%2BHighly%2BSelective%2BBrain%2BPenetrant%2Bp38%25CE%25B1%2BMitogen-Activated%2BProtein%2BKinase%2BInhibitors%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D18%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01773"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1017</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01773" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Niklas&quot;,&quot;last_name&quot;:&quot;M. Tormählen&quot;},{&quot;first_name&quot;:&quot;Mariella&quot;,&quot;last_name&quot;:&quot;Martorelli&quot;},{&quot;first_name&quot;:&quot;Annette&quot;,&quot;last_name&quot;:&quot;Kuhn&quot;},{&quot;first_name&quot;:&quot;Florian&quot;,&quot;last_name&quot;:&quot;Maier&quot;},{&quot;first_name&quot;:&quot;Jamil&quot;,&quot;last_name&quot;:&quot;Guezguez&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Burnet&quot;},{&quot;first_name&quot;:&quot;Wolfgang&quot;,&quot;last_name&quot;:&quot;Albrecht&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;A. Laufer&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Koch&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01773&quot;},&quot;abstract&quot;:&quot;Stress-induced p38α mitogen-activated protein (MAP) kinase activation modulates cytokine overproduction and is associated with neuroinflammation and neurodegeneration. As a potential therapeutic approach, novel Skepinone-based p38α MAP kinase inhibitors were optimized to cross the blood–brain barrier via either amino acid transporters or hydrophobic diffusion. To enhance absorption from the oral route, we used methyl ester prodrugs of the active carboxy analogs. Of these, 3-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)propanoic acid (43; p38α, IC50 = 5.5 nM) and 4-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)butanoic acid (44; p38α, IC50 = 12 nM) had brain-to-plasma ratios of 1.4 and 4.4, respectively. Compound 70, 3-(8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamido)propanoic acid (p38α, IC50 = 1.0 nM), the Skepinone-N counterpart of 43, was most present in the mouse brain (brain-&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01773&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01773" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01773&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01773" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01773&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01773" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01773&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01773&amp;href=/doi/10.1021/acs.jmedchem.0c01773" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01773" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01773" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01773%26sid%3Dliteratum%253Aachs%26pmid%3D33974419%26genre%3Darticle%26aulast%3DTorm%25C3%25A4hlen%26date%3D2021%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BHighly%2BSelective%2BBrain%2BPenetrant%2Bp38%25CE%25B1%2BMitogen-Activated%2BProtein%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Stress-induced p38α mitogen-activated protein (MAP) kinase activation modulates cytokine overproduction and is associated with neuroinflammation and neurodegeneration. As a potential therapeutic approach, novel Skepinone-based p38α MAP kinase inhibitors were optimized to cross the blood–brain barrier via either amino acid transporters or hydrophobic diffusion. To enhance absorption from the oral route, we used methyl ester prodrugs of the active carboxy analogs. Of these, 3-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-<i>5H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoic acid (<b>43</b>; p38α, IC<sub>50</sub> = 5.5 nM) and 4-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)butanoic acid (<b>44</b>; p38α, IC<sub>50</sub> = 12 nM) had brain-to-plasma ratios of 1.4 and 4.4, respectively. Compound <b>70</b>, 3-(8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoic acid (p38α, IC<sub>50</sub> = 1.0 nM), the Skepinone-N counterpart of <b>43</b>, was most present in the mouse brain (brain-to-plasma ratio of 4.7; 0.4 mg/kg p.o., 2 h, 580 nmol/kg). Compounds <b>43</b>, <b>44</b>, and <b>70</b> were p38α-MAP-kinase-selective, metabolically stable, hERG nonbinding, and able to modulate IL-6 and TNF-α production in cell-based assays.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The p38α mitogen-activated protein (MAP) kinase catalyzes the transfer of the γ-phosphate of its natural cosubstrate ATP to the hydroxyl group of serine and threonine side chains of its substrates, thereby activating cell signaling cascades, in particular, during inflammation. This central role made it an early choice as a drug target for chronic inflammatory diseases as target-based screening evolved in the mid-1990s.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> p38α MAP kinase is also expressed in glia and neurons, making it potentially relevant for central nervous system (CNS) disorders and associated neuroinflammatory responses.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8">(2−8)</a></div><div class="NLM_p">Increased activity of p38α MAP kinase was found in post-mortem brain tissue from Alzheimer’s disease (AD) patients.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> In microglia, p38α MAP kinase stimulates the release of the pro-inflammatory cytokines interleukin (IL)-1β and tumor necrosis factor α (TNF-α) in response to stressors including amyloid-β42<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> as well as during tau localization and neuronal plasticity.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Given this association with CNS inflammation, three phase II trials on the selective p38α MAP kinase inhibitor Neflamapimod (<b>1a</b>, VX-745)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) for the treatment of AD were completed (NCT02423200, NCT02423122, and NCT03402659), and another one on brain inflammation in AD (NCT03435861) was launched in 2018.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In 2019, an additional phase II study began on the cognitive effects of Neflamapimod in early-stage Huntington’s disease (NCT03980938). According to the sponsors, these trials yielded significant improvements in cognition using a dose of 40 mg of Neflamapimod three times daily versus b.i.d. (twice a day) or placebo (EIP Pharma, Inc., 13th Clinical Trials in Alzheimer’s Disease (CTAD) meeting, AscenD-LB study). These data suggest that whereas there is potential to improve AD signs with compounds from this class, those optimized for peripheral diseases like rheumatoid arthritis (RA) require frequent dosing to exert central effects. When applied at 1.5 mg/kg in rats, Neflamapimod reached 33 ng/mL (76 nM) in plasma, which corresponds to 129 nmol/g in brain. This was the dose reported to improve results in the Morris water maze model.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> At 4.5 mg/kg, the substance was able to influence hippocampal IL-1β, and exposure was reported to be 92 ng/mL in plasma corresponding to 359 nmol/kg in brain. These data suggest that depending on the parameter used, the effective dose corresponds to peak brain levels in the range of 13–36 times the IC<sub>50</sub> value for p38α MAP kinase.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of p38α MAP kinase inhibitors Neflamapimod (<b>1a</b>, VX-745),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> MW150 (<b>1b</b>),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Skepinone-L (<b>2a</b>), and Skepinone-N (<b>2b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using the same rationale, the brain penetrant pyridinylpyridazine-based p38α MAP kinase inhibitor MW150 (<b>1b</b>) was investigated in diverse animal models of neurologic disorders including AD and has now progressed to clinical trials.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20">(16−20)</a> When applied at 6 mg/kg, reported plasma concentrations are in the range of 390 to 650 ng/mL,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> corresponding to brain concentrations of 1030 to 1693 nmol/kg. The effective dose recorded for APP/PS1 mice was 2.5 mg/kg, suggesting that at effective doses, the peak levels in brain would likely be two to three times the IC<sub>50</sub> value for p38α MAP kinase.</div><div class="NLM_p">In 2012, we reported the development of dibenzosuberone derivatives Skepinone-L (<b>2a</b>) and Skepinone-N (<b>2b</b>) as potent selective p38α MAP kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> The prototypic compound Skepinone-L has been used as a probe to further investigate the role of p38α MAP kinase in various disorders.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27">(23−27)</a> X-ray analysis of this inhibitor complexed with the target enzyme suggests that it acts as a type I kinase inhibitor, inducing a glycine flip at the hinge region and binding hydrophobic region (HR) I and HR II (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Skepinone-L has served as a starting point for the design of type I 1/2 p38α MAP kinase inhibitors with improved binding kinetics.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of Skepinone-L (<b>2a</b>) within the ATP binding site of p38α MAP kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE">3QUE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The aim of the present study was to identify selective and metabolically stable Skepinone-based inhibitors of p38α MAP kinase, which also have the ability to cross the blood–brain barrier (BBB) <i>in vivo</i> in mouse models. To this end, we employed amino acid transporters and passive diffusion mechanisms. The ether function at position C-7 of the dibenzosuberone core targeting the HR II was replaced by amide moieties to increase interaction possibilities with the enzyme. Lipophilic and basic moieties, (amino) acids, biogenic amines, amino alcohols, and glucosamine were introduced as amide moieties with the potential for active transport into the brain as amino acid or carbohydrate mimics. In many analogs, these mimics gave rise to terminal carboxy groups. Given that carboxy species may be poorly resorbed in the gut, we also formed ester prodrugs of these compounds to compare with the free acids in both enzyme inhibition and oral pharmacokinetic studies .</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57073" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57073" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis</h3><div class="NLM_p">The novel dibenzosuberone derivatives <b>6</b>–<b>51</b> (Skepinone-L series) and <b>54</b>–<b>72</b> (Skepinone-N series) were synthesized by a linear approach starting from the reported methyl 8-chloro-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<b>3</b>). The amide moiety targeting HR II of p38α MAP kinase was introduced in the last steps of the synthetic sequences (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). The synthesis of dibenzosuberones <b>6</b>–<b>51</b> is depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a> and Schemes S1–S6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). In the first step, the amino function at position C-8 of the dibenzosuberone core was introduced by the coupling of <b>3</b> to 2,4-difluoroaniline under Buchwald–Hartwig conditions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Basic hydrolysis of <b>4</b> resulted in dibenzosuberone <b>5</b> bearing a free carboxylic acid function in position C-3. Activation of the carboxylic acid with 1,1′-carbonyldiimidazole (CDI) and conversion with the respective amines resulted in compounds <b>6</b>–<b>40</b>. The detailed syntheses of dibenzosuberones <b>45</b>–<b>51</b> are depicted in Schemes S1–S6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">Supporting Information, SI</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dibenzosuberones <b>6</b>–<b>40</b> (Skepinone-L Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2,4-difluoroaniline, Cs<sub>2</sub>CO<sub>3</sub>, XPhos, Pd(OAc)<sub>2</sub>, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 110 °C. (ii) KOH, MeOH, reflux temperature. (iii) CDI, DMF, 50 °C. For the detailed structures of compounds <b>6</b>–<b>51</b>, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.</p></p></figure><div class="NLM_p">The Boc group present in dibenzosuberone <b>23</b> was cleaved under acidic conditions to yield the corresponding amino derivative <b>41</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2,2,2-trifluoroacetic acid (TFA), dichloromethane (DCM), room temperature (rt).</p></p></figure><div class="NLM_p">Carboxylic acids <b>42</b>–<b>44</b> were obtained by treatment of the corresponding esters <b>31</b>, <b>33</b>, and <b>34</b> with methanolic potassium hydroxide solution at reflux temperature (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>42</b>–<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><div class="NLM_p">Dibenzosuberones <b>54</b>–<b>72</b> having an <i>o</i>-phenylenediamine moiety at position C-8 were prepared using an analogous synthetic strategy, as in the case of compounds <b>6</b>–<b>51</b> (<a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a>–<a class="ref internalNav" href="#sch7" aria-label="7">7</a> and Scheme S7 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>)). Buchwald–Hartwig coupling of ester <b>3</b> with <i>o</i>-phenylenediamine yielded diarylamine <b>52</b>, which was subsequently transferred into carboxylic acid <b>53</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The amide moiety at position C-3 of the dibenzosuberone core was installed using CDI as a coupling reagent. The modification of dibenzosuberone <b>67</b> into compounds <b>71</b> and <b>72</b> is shown in Scheme S7 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Dibenzosuberones <b>54</b>–<b>67</b> (Skepinone-N Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>o</i>-phenylenediamine, Cs<sub>2</sub>CO<sub>3</sub>, XPhos-Pd second generation, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 60 °C. (ii) KOH, MeOH, reflux temperature. (iii) CDI, DMF, 50 °C. For the detailed structures of compounds <b>54</b>–<b>67</b> and <b>71</b>–<b>72</b>, see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.</p></p></figure><div class="NLM_p">Dibenzosuberone <b>68</b> was obtained in excellent yield by treatment of Boc-protected derivative <b>58</b> with TFA at ambient temperature (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TFA, DCM, rt.</p></p></figure><div class="NLM_p">Dicarboxylic acid <b>69</b> and carboxylic acid <b>70</b> were synthesized from the corresponding diester <b>64</b> and ester <b>65</b>, respectively, using similar conditions as described for compounds <b>42</b>–<b>44</b> of the Skepinone-L series (<a class="ref internalNav" href="#sch6" aria-label="Schemes 6">Schemes 6</a> and <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>70</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><div class="NLM_p">Dibenzosuberone <b>76</b> bearing an <i>N</i>-methyl carboxamide moiety at position C-3 was synthesized using a slightly different synthetic strategy (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). The aniline moiety targeting HR I was installed via the Buchwald–Hartwig coupling reaction of aryl chloride <b>3</b> with 2-nitroaniline. After the subsequent hydrolysis of ester <b>73</b>, the methyl amide moiety was introduced by treatment of carboxylic acid <b>74</b> with methylamine in the presence of CDI as a coupling reagent. Finally, compound <b>76</b> was obtained by reduction of the nitro group present in compound <b>75</b> with tin(II) chloride in ethanol.</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0011.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Dibenzosuberone <b>76</b> (Skepinone-N Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2-nitroaniline, Cs<sub>2</sub>CO<sub>3</sub>, XPhos, Pd(OAc)<sub>2</sub>, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 110 °C. (ii) KOH, MeOH, reflux temperature. (iii) Methylamine (2 N THF), CDI, DMF, 50 °C. (iv) SnCl<sub>2</sub>, EtOH, reflux temperature.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Biological Evaluation</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Kinase Activity Assay</h4><div class="NLM_p">The dibenzosuberones <b>6</b>–<b>37</b>, <b>41</b>−<b>51</b>, <b>54</b>–<b>66</b>, <b>68</b>−<b>72</b>, and <b>76</b> were evaluated for their ability to inhibit p38α MAP kinase.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The nature of the amide was essential for the inhibitory activity. Secondary amide <b>7</b> (IC<sub>50</sub> = 21 nM) showed an almost 20 times lower IC<sub>50</sub> value compared with tertiary amide <b>8</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Similarly, the tertiary amides <b>6</b> (IC<sub>50</sub> = 95 nM) and <b>24</b> (IC<sub>50</sub> = 120 nM) were less potent than the corresponding secondary <i>N</i>-methylamide (IC<sub>50</sub> = 3 nM).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> For hydrophobic moieties, the inhibitory activity decreased with chain lengths over two methylene groups: Compounds <b>7</b>, <b>16</b>, and <b>25</b> had lower IC<sub>50</sub> values than compounds <b>14</b>, <b>21</b>, and <b>22</b>. The introduction of a fluorine atom at the para position of the benzene ring of inhibitor <b>7</b> resulted in an equipotent compound <b>9</b>. The introduction of a hydroxyl group in this position (compound <b>10</b>) or the bioisosteric replacement of the benzene ring by a thiophene ring (compound <b>12</b>) resulted in a three times lower IC<sub>50</sub> value. Compound <b>15</b> bearing a spirocyclic morpholine isostere was also a potent inhibitor (IC<sub>50</sub> = 5.9 nM). Compound <b>17</b> having a branched moiety was intermediate in potency—the racemic mixture <b>17</b> (IC<sub>50</sub> = 22 nM) was more potent than the (R)-enantiomer (IC<sub>50</sub> 89 nM),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> suggesting that the (S)-enantiomer is worthy of purification. Compounds <b>18</b> and <b>20</b> (IC<sub>50</sub> = 2.5 and 3.5 nM, respectively) bearing an 2-aminoethyl and a 2,2,2-trifluoroethyl moiety at the dibenzosuberone-C3-carboxamide function, respectively, were likewise potent.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Activities of 3-Substituted 2-((2,4-Difluorophenyl)amino)-5-dibenzosuberones <b>6–30</b> and <b>41</b> (Skepinone-L Series) (<i>n</i> = 3)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0013.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">The hydroxamic acid derivative <b>26</b> (IC<sub>50</sub> = 5.2 nM) and compounds having a (poly-)alcohol (<b>27</b> (IC<sub>50</sub> = 3.0 nM), <b>29</b> (IC<sub>50</sub> = 10 nM), <b>30</b> (IC<sub>50</sub> = 1.7 nM)) or a glucosamine moiety (<b>28</b> (IC<sub>50</sub> = 5.2 nM)) were also potent p38α MAP kinase inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">The introduction of amino acid derivatives (<b>31</b>–<b>37</b> and <b>42</b>–<b>51</b>) provided consistently potent inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Assuming that interaction with transporters for central nervous system (CNS) uptake required the physiological (S)-configuration, all amino acid derivatives were assayed in this form. The ester prodrugs were, in most cases, slightly more inhibitory than their corresponding carboxylic acids (compare <b>33</b> vs <b>43</b>, <b>34</b> vs <b>44</b>, <b>35</b> vs <b>45</b>, <b>36</b> vs <b>46</b>, <b>37</b> vs <b>47</b>, <b>48</b> vs <b>51</b>); however, in the case of ester <b>31</b> and carboxylic acid <b>42</b>, the reverse was apparent. Ester <b>33</b> (IC<sub>50</sub> = 1.2 nM) was the most potent inhibitor of this series.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Activities of 3-Substituted 2-((2,4-Difluorophenyl)amino)-5-dibenzosuberones <b>31–37</b> and <b>42–51</b> (Ester Prodrugs and Corresponding Acids of Skepinone-L Series) (<i>n</i> = 3)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0015.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">As observed in the case of Skepinone-L (<b>2a</b>) and Skepinone-N (<b>2b</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), most dibenzosuberone derivatives of our study bearing an <i>o</i>-phenylenediamine substituent at position C-8 (Skepinone-N series) were less active than their corresponding Skepinone-L counterparts (compare <b>63</b> vs <b>18</b>, <b>65</b> vs <b>33</b>, <b>57</b> vs <b>11</b>, <b>64</b> vs <b>36</b>, <b>69</b> vs <b>46</b>, <b>68</b> vs <b>41</b>, <b>66</b> vs <b>37</b>, <b>71</b> vs <b>48</b>, <b>72</b> vs <b>51</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). In the case of inhibitors <b>55</b>, <b>58</b>, and <b>70</b>, the Skepinone-N analog was, however, equal to or more potent than the corresponding Skepinone-L derivatives <b>7</b>, <b>23</b>, and <b>43</b>, respectively.</div><div class="NLM_p">In the series presented in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the secondary amides <b>58</b>, <b>63</b>, and <b>76</b> having an <i>N</i>-Boc-protected piperazinoethyl, a 2-aminoethyl, or a methyl moiety at the carboxamide group, respectively, have an equal or a better inhibitory activity than primary amide <b>62</b>. Hydroxyethyl-substituted dibenzosuberone <b>59</b> as well as diols <b>60</b> and <b>61</b> have similar inhibitory activities in the low double-digit nanomolar range. Cleavage of the Boc-group present in compound <b>58</b> resulted in a nine-fold loss of inhibitory activity (compound <b>68</b>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Activities of 3-Substituted 2-((2-Aminophenyl)amino)-5-dibenzosuberones <b>54</b>–<b>63</b>, <b>68</b>, and <b>76</b> (Skepinone-N Series) (<i>n</i> = 3)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0017.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">Esters <b>64</b> and <b>71</b> are approximately 1.5 times more active than their corresponding carboxylic acids <b>69</b> and <b>72</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In the case of ester <b>65</b>, however, the corresponding acid <b>70</b> displays a 30 times lower IC<sub>50</sub> value. Dibenzosuberone <b>70</b> represents the most potent p38α MAP kinase inhibitor of our study.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Activities of 3-Substituted 2-((2-Aminophenyl)amino)-5-dibenzosuberones <b>64</b>–<b>66</b> and <b>69</b>–<b>72</b> (Ester Prodrugs and Corresponding Acids of Skepinone-N Series) (<i>n</i> = 3)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0018.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0019.gif" alt="" id="fx8" /></img><div></div></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Metabolism</h4><div class="NLM_p">Inhibitors <b>11</b>, <b>13</b>, <b>15</b>, <b>19</b>, <b>26</b>, <b>31</b>–<b>33</b>, <b>41</b>–<b>44</b>, <b>46</b>, <b>49</b>, <b>50</b>, <b>54</b>, <b>56</b>, <b>59</b>, <b>66</b>, <b>70</b>, and <b>76</b> were further evaluated for their metabolic stability in human liver microsomes (HLMs) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, Figures S1–S21, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Metabolic Stability of Selected Dibenzosuberone Inhibitors after 120 min of Incubation with HLMs (% Parent Remaining)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0020.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0021.gif" alt="" id="fx10" /></img><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Metabolic Stability of Selected Dibenzosuberone Inhibitors after 120 min of Incubation with HLMs (% Parent Remaining)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0022.gif" alt="" id="fx11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0023.gif" alt="" id="fx12" /></img><div></div></div><div class="NLM_p">The ester prodrugs were converted into the free carboxylic acids. Simple esters such as <b>31</b> and <b>33</b> were cleaved within a few minutes. Their resulting acids <b>42</b> and <b>43</b>, respectively, were metabolically stable. Carboxylic acids <b>44</b> and <b>70</b> also displayed excellent metabolic stability. Sterically hindered esters with terminal amino acids such as <b>49</b> and <b>50</b> were cleaved more slowly. Compound <b>32</b>, whose additional methyl group may shield the ester function from enzymatic hydrolysis, was degraded by <10% within 2 h. Compound <b>66</b> bearing a methionine methyl ester substituent formed the sulfoxide in addition to the carboxylic acid.</div><div class="NLM_p">In both series, the aromatic moiety used to fill HR I and the dibenzosuberone core remained stable, whereas the moiety targeting HR II was labile.</div><div class="NLM_p">Dibenzosuberone analog <b>13</b> bearing a tryptamine at the C-3 amide function underwent a slow oxidative biotransformation (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). After an incubation time of 120 min, 71% of <b>13</b> was present. In contrast, compound <b>11</b> having a histamine moiety in the same position was stable to HLMs (5% degradation after 120 min).</div><div class="NLM_p">Morpholino derivative <b>56</b> (Skepinone-N series) had an <i>in vitro</i> half life in HLMs of <1 h. After an incubation time of 2 h, <38% of <b>56</b> remained. The supposedly metabolically more stable 2-oxa-6-azaspiro[3.3]heptan-6-yl derivative <b>15</b> (Skepinone-L series) had a half life of 113 min and was more stable than <b>56</b>, but more varied metabolites were formed during the incubation.</div><div class="NLM_p last">The aliphatic dimethylethylamino moiety present in compound <b>54</b> was transformed by HLMs to the <i>N</i>-demethylated and a hydroxylated metabolite. Compound <b>19</b> was stable (94% remaining). Hydroxamic acid <b>26</b> and <i>N</i>-methylamide <b>76</b> were rapidly metabolized in HLMs (<i>in vitro</i> half life of 22 and 12 min, respectively) to the corresponding acids: <b>5</b> (<i>m</i>/<i>z</i> 380.3 [M + H<sup>+</sup>]) and <b>53</b> (<i>m</i>/<i>z</i> 359.3 [M + H<sup>+</sup>]), respectively.</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Pharmacokinetic and CNS Penetration Study in RjOrl:Swiss CD-1 Mice</h4><div class="NLM_p">To evaluate brain penetration and plasma stability, compounds <b>15</b>, <b>16</b>, <b>28</b>, <b>30</b>, <b>31</b>, <b>33</b>–<b>36</b>, <b>41</b>, <b>48</b>, <b>49</b>, <b>54</b>, <b>56</b>, and <b>57</b>, were tested in adult male RjOrl:Swiss CD-1 mice. The mice were treated with a single intravenous (i.v.) injection (10 mg/kg), and plasma samples were collected 10, 30, and 120 min after the treatment. After the last sample was obtained, the mice were sacrificed for sampling of the brains. Blood and brain samples were analyzed via liquid chromatography mass spectrometry/mass spectrometry (LC-MS/MS) after preparation. (See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.)</div><div class="NLM_p">Consistent with the HLM study, esters <b>31</b> and <b>33</b> underwent a very fast metabolism and are no longer detectable 10 min after i.v. administration (Table S5, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Their active metabolites (corresponding acids <b>42</b> and <b>43</b>, respectively) were detected after 2 h at a concentration of 8.2 and 102.9 ng/g, which corresponds to a brain-to-plasma ratio of 0.13 and 1.25, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and Table S5, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). A similar level of the carboxy product <b>44</b> was detected in the brain (98.2 ng/g), which corresponds to a brain-to-plasma ratio of 4.4. Because passive transport of the charged compounds <b>43</b> and <b>44</b> seems unlikely under physiological conditions, these inhibitors may have crossed the BBB via transporter systems.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Brain-to-Plasma Ratio of i.v. Administered Prodrugs (Esters <b>31</b>, <b>33</b>–<b>36</b>, <b>48</b>, and <b>49</b>) and Their Corresponding Acids (<b>42</b>–<b>46</b>, <b>51</b>, and <b>S2</b>) after 2 h</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">prodrug</th><th class="colsep0 rowsep0" align="center"><b>31</b></th><th class="colsep0 rowsep0" align="center"><b>33</b></th><th class="colsep0 rowsep0" align="center"><b>34</b></th><th class="colsep0 rowsep0" align="center"><b>35</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th><th class="colsep0 rowsep0" align="center"><b>48</b></th><th class="colsep0 rowsep0" align="center"><b>49</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain-to-plasma</td><td class="colsep0 rowsep0" align="center">NA<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">active metabolite</th><th class="colsep0 rowsep0" align="center"><b>42</b></th><th class="colsep0 rowsep0" align="center"><b>43</b></th><th class="colsep0 rowsep0" align="center"><b>44</b></th><th class="colsep0 rowsep0" align="center"><b>45</b></th><th class="colsep0 rowsep0" align="center"><b>46</b></th><th class="colsep0 rowsep0" align="center"><b>51</b></th><th class="colsep0 rowsep0" align="center"><b>S2</b><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain-to-plasma</td><td class="colsep0 rowsep0" align="center">0.13</td><td class="colsep0 rowsep0" align="center">1.25</td><td class="colsep0 rowsep0" align="center">4.38</td><td class="colsep0 rowsep0" align="center">0.31</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">0.01</td><td class="colsep0 rowsep0" align="center">0.003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">NA, not applicable.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">For the structure of <b>S2</b>, see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.</p></div></div></div><div class="NLM_p">Compared with <b>31</b> and <b>34</b>, esters <b>35</b> and <b>36</b> were hydrolyzed more slowly to their corresponding acids <b>45</b> and <b>46</b>. Only low levels of acid <b>45</b> (15.0 ng/g) were detected in the brain (Table S5, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>); however, glutamic acid derivative <b>46</b> did not penetrate into the brain (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and Table S6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><div class="NLM_p">As observed in the <i>in vitro</i> metabolism study of <b>49</b> (Figure S14, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>), the esters of α-amino acids (compounds <b>48</b> and <b>49</b>) were not fully converted into their corresponding free α-amino acids <b>51</b> and <b>S2</b> after 2 h. Only traces of both acids were detected in the brain (Table S6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><div class="NLM_p">Concentrations of 68 and 49 ng/g of compounds <b>15</b> and <b>16</b> (Table S3, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>), respectively, were found in the brain after 2 h; this corresponds, in the case of <b>16</b>, to a brain-to-plasma ratio of 0.51 (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The spirocyclic moiety present in <b>15</b> as well as the lipophilic moiety of <b>16</b> are unlikely to be recognized by specific transporters. Therefore, these inhibitors are expected to cross the BBB only via passive diffusion.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Brain-to-Plasma Ratio of i.v. Administered Inhibitors <b>15</b>, <b>16</b>, <b>28</b>, <b>30</b>, <b>41</b>, <b>54</b>, <b>56</b>, and <b>57</b> after 2 h</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center" char="."><b>15</b></th><th class="colsep0 rowsep0" align="center" char="."><b>16</b></th><th class="colsep0 rowsep0" align="center" char="."><b>28</b></th><th class="colsep0 rowsep0" align="center" char="."><b>30</b></th><th class="colsep0 rowsep0" align="center" char="."><b>41</b></th><th class="colsep0 rowsep0" align="center" char="."><b>54</b></th><th class="colsep0 rowsep0" align="center" char="."><b>56</b></th><th class="colsep0 rowsep0" align="center" char="."><b>57</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">brain-to-plasma</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td></tr></tbody></table></div></div><div class="NLM_p">Dibenzosuberones <b>28</b>, <b>30</b>, and <b>41</b> showed a fast degradation or elimination (Tables S3 and S4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Inhibitor <b>28</b> bearing a glucosamine residue may be transported by the glucose transporter. However, only 5.9 ng/g of <b>28</b> was detected after 2 h, which correlates to a low brain-to-plasma ratio of 0.09. Brain-to-plasma ratios of 0.17 and 0.24 were observed for compounds <b>30</b> and <b>41</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_p">Within the Skepinone-N series, only low amounts of morpholino-containing inhibitor <b>56</b> were detected in the brain. Compound <b>54</b>, having a tertiary amine in the amide chain, showed a four times higher concentration in the brain accompanied by a higher brain-to-plasma ratio.</div><div class="NLM_p last">Dibenzosuberone <b>57</b> bearing the biogenic histamine substituent was eliminated relatively quickly and is not able to cross the BBB (Table S4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> In Vitro and in Vivo Study in Balb/c and C57BL/6 Mice</h4><div class="NLM_p">Effects in disease models can be influenced by partition to specific cell types and degrees of inhibition in these cells (i.e., due to acid trapping in myeloid cells vs lymphoid cells). To assess effects in different cells, selected compounds (<b>18</b>, <b>25</b>, <b>27</b>, <b>29</b>, <b>33</b>, <b>34</b>, <b>43</b>, <b>44</b>, <b>50</b>, <b>65</b>, <b>70</b>, <b>76</b>) were further evaluated in <i>in vitro</i> and <i>in vivo</i> studies.</div><div class="NLM_p">First, the selected inhibitors were characterized in splenocytes isolated from female Balb/c mice. In total, three different assays were done in mouse splenocytes stimulated with 500 ng/mL lipopolysaccharide (LPS), and the release of pro-inflammatory cytokines IL-6 and TNF-α was quantified. The metabolic activity in these cells was measured via (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction to formazan to control for cytotoxic effects.</div><div class="NLM_p">There was a trend for the tested compounds to increase the metabolic activity of splenocytes at a concentration of 100 nM (66–176% relative to LPS-stimulated splenocytes) (Figure S23, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). At concentrations of 1 and 10 nM, there was no effect on the metabolic activity of splenocytes. No cytotoxicity was observed, whereas the anti-inflammatory activity of all investigated compounds was dose-dependent, with reductions in both IL-6 and TNF-α (Figure S24, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Inhibitor <b>70</b> increased IL-6 at concentrations of 1 and 10 nM (138 and 118%, respectively), then decreased it to 29% at 100 nM relative to PBS-treated LPS-stimulated splenocytes. Compound <b>25</b> caused moderate inhibition of LPS-stimulated IL-6 release (51% at 100 nM). Compound <b>50</b> caused the highest reductions in IL-6 (Figure S24a, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Compounds <b>18</b>, <b>25</b>, <b>27</b>, <b>29</b>, <b>43</b>, <b>50</b>, <b>70</b>, and <b>76</b> were potent inhibitors of the LPS-stimulated TNF-α release (Figure S24b, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Compounds <b>18</b>, <b>27</b> and <b>76</b> were most potent, whereas compounds <b>33</b>, <b>34</b>, <b>44</b>, and <b>65</b> were only moderate to poor inhibitors.</div><div class="NLM_p">Heparinized whole blood was prepared from C57BL/6 mice (MWB) stimulated with 500 ng/mL LPS. As for mouse splenocytes, all tested compounds reduced the release of IL-6 and TNF-α dose-dependently (Figure S25, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Compounds <b>27</b>, <b>29</b>, and <b>50</b> caused the highest reductions in IL-6 release (Figure S25a, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>), whereas compounds <b>33</b>, <b>34</b>, <b>44</b>, and <b>65</b> were moderate (85, 64, 71, and 81%, respectively). Dibenzosuberones <b>18</b>, <b>25</b>, <b>27</b>, <b>29</b>, <b>43</b>, <b>50</b>, <b>70</b>, and <b>76</b> were potent inhibitors of LPS-stimulated TNF-α from MWB (range: 5–23% at 1 nM in comparison with LPS-stimulated MWB). Compounds <b>27</b>, <b>43</b>, and <b>76</b> (Figure S25b, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>) were most potent in this assay. Compounds <b>33</b>, <b>34</b>, <b>44</b>, and <b>65</b> had lower activity in this assay (∼50% inhibition at 10 nM). Consistent with mouse splenocytes, compound <b>33</b> was the least active of the series in MWB.</div><div class="NLM_p">Cellular compound uptake using human buffy coat (HBC) was also evaluated. Cells (1 × 10<sup>6</sup> HBC cells/mL) were treated with compounds at a final concentration of 100 μM, and cell culture supernatants were collected at different time points and analyzed for compound concentration (Tables S24 and S25, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><div class="NLM_p">The effects of compounds on cytokine release were also assessed in LPS-stimulated HBC cells in the same format as mouse splenocytes and whole blood. All compounds had dose-dependent effects, with <b>50</b> being most active (Figure S26, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>) and <b>33</b> being the least active, suggesting broadly similar data in the human and murine systems.</div><div class="NLM_p">Because most transgenic animal models of neurodegenerative disorders are on a C57BL/6 background, this strain was used for further pharmacokinetic studies including penetration of the BBB of a second set of inhibitors (<b>18</b>, <b>25</b>, <b>27</b>, <b>29</b>, <b>50</b>, <b>70</b>, and <b>76</b>) to augment data from CD1 mice. Blood samples were taken at 5, 15, 30, 60, 120, and 240 min. Animals were terminated for brain sampling at 120 and 240 min post substance application. The substance was quantified in peripheral plasma, heart-derived plasma, liver, kidney, brain right hemisphere, and brain left hemisphere by LC-MS/MS. Compounds were administered (0.4 mg/kg) in mixtures to reduce the number of animals used. (See the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a> for details.) The rationale for the lower dose was to model the likely concentrations following oral application and thus to simulate the likely conditions for transport systems in long-term neurodegenerative models in C57BL/6.</div><div class="NLM_p last">The compounds from the Skepinone-L series (<b>18</b>, <b>25</b>, <b>27</b>, <b>29</b>, <b>47</b>, <b>50</b>) showed no or only low brain uptake after i.v. or p.o. application (Tables S9–S13 and S16–S20, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Compound <b>76</b> was BBB-penetrant after i.v. and p.o. application (∼20 nM in brain at 2 h), exceeding the IC<sub>50</sub> value for free p38α MAP kinase (Tables S15 and S22, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Compound <b>70</b> (∼590 nM in brain, 2 h p.o.) had a brain-to-plasma ratio of 4.7 (Table S21, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>) and the highest levels in all organs after 4 h (heart ∼120 nM, liver ∼330 nM, kidney ∼380 nM, and brain ∼540 nM). When used in the context of tissue, “nM” is shorthand for nmol/kg tissue fresh weight and is used in this way to allow direct comparison to values for inhibition of the enzyme.</div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Human Whole Blood Assay</h4><div class="NLM_p last">The human whole blood (HWB) assay is a means to evaluate the effectiveness of p38α MAP kinase inhibitors in modulating pro-inflammatory cytokine secretion in a primary cell system. In this <i>ex vivo</i> assay, the efficacy is estimated with <i>in vivo</i> relevant parameters like plasma protein binding and cellular permeability. Thus the IC<sub>50</sub> values are typically higher than those for the direct enzyme inhibition assay. Ester <b>34</b> is a potent inhibitor of the LPS-stimulated TNF-α release displaying an IC<sub>50</sub> value of 64 nM (Table S23, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). Its active metabolite, the corresponding acid <b>44</b>, shows a two-fold decrease in inhibitory activity. The release of LPS-stimulated TNF-α from HWB was inhibited by compound <b>15</b> at concentrations in the double-digit nanomolar range.</div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> CYP and hERG Assay</h4><div class="NLM_p">The p38α MAP kinase inhibitors <b>15</b>, <b>33</b>, <b>34</b>, <b>43</b>, <b>44</b>, and <b>70</b> were tested for the inhibition of hERG and relevant CYP isoforms (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). At a test concentration of 10 μM, both esters <b>33</b> and <b>34</b> display a 59.9 and 49.7% inhibition of hERG and inhibit the tested CYP isoforms 2C9 and 2C19 by more than 98%. At the same concentration, their active metabolites <b>43</b> and <b>44</b> that are formed within a few minutes show no interaction with hERG and a reduced CYP inhibition. No affinity toward CYP2D6 (a significant CNS CYP) was observed in the case of <b>43</b> and <b>44</b>. Compound <b>70</b>, the Skepinone-N counterpart of <b>44</b>, had no or a limited effect on CYP and hERG activity. In contrast, compound <b>15</b> had both a higher inhibition of hERG (76.6%) and an elevated CYP inhibition profile for isoforms CYP2C9, CYP2C19, CYP2D6, and CYP3A4 compared with carboxylic acids <b>43</b>, <b>44</b>, and <b>70</b>. No inhibition of CYP1A2 was observed for <b>15</b>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. <i>In vitro</i> CYP and hERG Inhibition Data of Inhibitors <b>15</b>, <b>33</b>, <b>43</b>, <b>34</b>, <b>44</b>, and <b>70</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">% inhibition @ 10 μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center" char=".">hERG</th><th class="colsep0 rowsep0" align="center" char=".">CYP1A2</th><th class="colsep0 rowsep0" align="center" char=".">CYP2C9</th><th class="colsep0 rowsep0" align="center" char=".">CYP2C19</th><th class="colsep0 rowsep0" align="center" char=".">CYP2D6</th><th class="colsep0 rowsep0" align="center" char=".">CYP3A4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">76.6</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">88.7</td><td class="colsep0 rowsep0" align="char" char=".">93.6</td><td class="colsep0 rowsep0" align="char" char=".">18.3</td><td class="colsep0 rowsep0" align="char" char=".">83.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">59.9</td><td class="colsep0 rowsep0" align="char" char=".">27.3</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">73.7</td><td class="colsep0 rowsep0" align="char" char=".">68.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">11.8</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">68.4</td><td class="colsep0 rowsep0" align="char" char=".">60.4</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">34.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">49.7</td><td class="colsep0 rowsep0" align="char" char=".">33.6</td><td class="colsep0 rowsep0" align="char" char=".">98.5</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">36.6</td><td class="colsep0 rowsep0" align="char" char=".">54.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">14.4</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="char" char=".">66.0</td><td class="colsep0 rowsep0" align="char" char=".">63.2</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">38.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="char" char=".">22.5</td><td class="colsep0 rowsep0" align="char" char=".">28.1</td><td class="colsep0 rowsep0" align="char" char=".">13.1</td><td class="colsep0 rowsep0" align="char" char=".">21.8</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last"><i>n</i> = 2.</p></div></div></div></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Kinome Selectivity</h4><div class="NLM_p">Compounds <b>31</b>, <b>42</b>–<b>44</b>, and <b>57</b> were tested at 1 and 5 μM against a panel of 320 kinases to evaluate their selectivity (Tables S26 and S27, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><div class="NLM_p">Ester <b>31</b> is a highly selective p38α MAP kinase inhibitor. At both concentrations, only the closely related kinases p38β MAP kinase, JNK2, and JNK3<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> are inhibited by more than 60% (Table S26, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>), resulting in an <i>S</i><sub>60</sub> selectivity score of 0.013. At 1 μM, the active metabolite of <b>31</b>, carboxylic acid <b>42</b>, had similar selectivity, interacting only with p38β MAP kinase, JNK3, and ACV-R2B (Table S26, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). At a higher concentration (5 μM), CAMK2G, EGF-R, EIF2AK2, JNK2, and MYLK were additionally inhibited by more than 60% by <b>42</b>. Inhibitor <b>43</b>, having an additional methylene unit between the carboxylic group and the amide function compared with <b>42</b>, was similar to <b>42</b> (Table S26, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>). At 1 μM, the main target kinase p38α MAP kinase and the MAP kinase family members p38β MAP kinase, JNK2, and JNK3 as well as the tyrosine kinase-like kinase ACV-R2B were inhibited by <b>43</b> by more than 60% (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). At 5 μM (900 times its IC<sub>50</sub>), <b>43</b> inhibited the tyrosine kinases EGF-R, VEGF-R2, and MYLC as well as the serine/threonine kinase JNK1. Carboxylic acid <b>44</b> interacted with p38β MAP kinase, JNK3, and TLK2) at 1 μM (Table S27, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>) but inhibited 14 kinases by more than 60% at 5 μM with an <i>S</i><sub>60</sub> selectivity score of 0.044. Compound <b>57</b> was similar to <b>31</b> with an <i>S</i><sub>60</sub> selectivity score of 0.013 at both concentrations (Table S27, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>).</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0003.jpeg" id="GRAPHIC-d7e2752-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity profile of carboxylic acids <b>43</b> (left) and <b>70</b> (right). Tested kinases are highlighted with circles and colored according to their inhibition at 1 μM inhibitor concentration. This figure was generated with the help of the KinMap.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Inhibitor <b>70</b> was tested at concentrations of 1 and 5 μM against a panel of 65 kinases consisting of all kinases that were inhibited in the previous screening by more than 40% by compounds <b>31</b>, <b>42</b>–<b>44</b>, and <b>57</b> and all members of the p38 MAP kinase family (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">Table S28</a>). Besides the target kinase p38α MAP kinase, only the closely related p38β MAP kinase was inhibited by more than 60% by <b>70</b> at test concentrations of 1 and 5 μM.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">62 novel Skepinone-based p38α MAP kinase inhibitors with IC<sub>50</sub> values down to the low single-digit nanomolar range were characterized. Various substituents (lipophilic and basic moieties, (amino) acid derivatives, biogenic amines, amino alcohols, and carbohydrates) at position C-3 of the dibenzosuberone core remained inhibitory. Ester prodrugs <b>33</b> and <b>34</b> were rapidly converted into their corresponding carboxylic acids <b>43</b> and <b>44</b>, respectively. The active metabolites <b>43</b> (p38α, IC<sub>50</sub> = 6 nM) and <b>44</b> (p38α, IC<sub>50</sub> = 12 nM) crossed the BBB (concentration in brain after 2 h, ∼100 ng/g, ∼220 nM) and displayed promising brain-to-plasma ratios of 1.4 and 4.4, respectively. Skepinone-L-derived inhibitors <b>43</b> and <b>44</b> were selective and metabolically stable and had low hERG affinity. Compound <b>70</b> (p38α, IC<sub>50</sub> = 1 nM), the Skepinone-N counterpart of <b>43</b>, had the highest concentrations in the brain 2 h after p.o. application (580 nM) (brain-to-plasma ratio of 4.7).</div><div class="NLM_p">Given its very good general attributes (selectivity, CYP, and hERG interaction), this very high partition to the CNS makes compound <b>70</b> a promising candidate for the study of the role of p38α MAP kinase in the development of CNS pathology in murine models of CNS degeneration. The combination of a high affinity for p38α MAP kinase and very high central exposure has not been obtained in either Neflamapimod (p38α, IC<sub>50</sub> = 10 nM) or MW150 (p38α, IC<sub>50</sub> = 230 nM). Reported brain exposure for Neflamapimod in the rat was approximately 130 to 360 nmol/kg at effective doses (1.5 to 4.5 mg/kg), corresponding to a 13- to 36-fold IC<sub>50</sub> value for p38α MAP kinase. The data for MW150 were not directly reported (pharmacokinetics at 5 or 6 mg/kg in rat) but, as calculated in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, vary between two and three times the IC<sub>50</sub> value for p38α MAP kinase at an effective dose of 2.5 mg/kg in the APP/PS1 mouse.</div><div class="NLM_p last">Compound <b>70</b> (1 nM) reached 580 times the IC<sub>50</sub> value for p38α MAP kinase at 0.4 mg/kg in the C57BL/6 mouse brain, suggesting that it and its near analogs have adequate potency and physical properties to effectively modulate p38α MAP kinase activity in the brain.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Part</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General</h3><div class="NLM_p last">All reagents and solvents were commercially available and were used without further purification. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained with a Bruker Avance 200 or Bruker Avance 400 apparatus. The spectra were obtained in the indicated solvent and calibrated against the residual proton peak of the deuterated solvent. Chemical shifts (δ) are reported in parts per million. Mass spectra were performed on an Advion Expression S electrospray ionization mass spectrometer (ESI-MS) with an Advion Plate Express (TLC interface) apparatus. TLC analysis was performed on fluorescent silica gel 60 F254 plates (Merck) and visualized under UV illumination at 254 and 366 nm. Column chromatography was performed using an Interchim PuriFlash 430 automated flash chromatography system. The purity of all compounds was, unless otherwise stated, >95% and was determined via reverse-phase high-performance liquid chromatography on a Hewlett-Packard HP 1090 series II LC equipped with a UV diode array detector (DAD, detection at 230 and 254 nm). The chromatographic separation was performed on a Phenomenex Luna 5u C8 column (150 mm × 4.6 mm, 5 μm) at a 35 °C oven temperature. The injection volume was 5 μL, and the gradient of the used method was as follows (flow, 1.5 mL/min), with 0.01 M KH<sub>2</sub>PO<sub>4</sub>, pH 2.3 (solvent A) and methanol (solvent B): from 40 to 85% B in 8 min, 85% B for 5 min, from 85 to 40% B in 1 min, 40% B for 2 min, stop time 16 min.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedures</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure A</h4><div class="NLM_p last">The carboxylic ester was dissolved in methanol, and KOH (2.5 equiv) was added. The reaction mixture was heated to reflux temperature until completion of the reaction. After cooling to rt, the solvent was removed under reduced pressure, and the residue was taken up in ethyl acetate. The organic phase was washed with a diluted HCl solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under reduced pressure, yielding a solid product. If the purity of the product was <95%, then the product was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH/formic acid 94:4:2).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure B</h4><div class="NLM_p last">The carboxylic acid <b>5</b>, <b>53</b>, or <b>75</b> was dissolved in 5 mL of DMF under an argon atmosphere with gentle heating (50 °C). CDI (2 equiv) was added, and the reaction mixture was stirred for 2 h. The corresponding amine or alcohol was added to the reaction mixture, and it was stirred for 1 h at 50 °C. Then, the reaction was stopped by adding H<sub>2</sub>O (10 mL) and extracted with either ethyl acetate or DCM (three times). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure C</h4><div class="NLM_p last">The Boc-protected compound was dissolved in dry DCM (5 mL), and TFA (1.5 mL) was added. The reaction mixture was stirred at rt until completion; then, a saturated aq. NaHCO<sub>3</sub> solution was carefully added. The reaction was extracted with DCM (three times). The organic extracts were collected, and the solvent was removed in vacuo. The product was purified by flash chromatography.</div></div></div><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Methyl 8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>4</b>)</h3><div class="NLM_p last">2,4-Difluoroaniline (0.23 g, 1.79 mmol) was dissolved in 12 mL of 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v) under an argon atmosphere. XPhos (0.025 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv), and Pd(OAc)<sub>2</sub> (0.05 equiv) followed by aryl chloride <b>3</b> (0.50 g, 1.79 mmol) were added, and the reaction mixture was heated for 1 h to 110 °C. The reaction was cooled to rt and filtered. The residue was washed several times with DCM, MeOH, and EtOAc. The combined organic extracts were evaporated, and the brown-black residue was purified by flash chromatography (SiO<sub>2</sub>, petroleum ether/ethyl acetate 4:1) to yield <b>4</b> as a yellow solid (0.52 g, 89%).<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.66 (d, <i>J</i> = 1.8 Hz, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 8.06 (dd, <i>J</i> = 1.9 Hz, 8.0 Hz, 1H), 7.41–7.25 (m, 2H), 6.81–6.99 (m, 3H), 6.66 (d, <i>J</i> = 2.4 Hz, 1H), 6.00 (s, 1H), 3.92 (s, 3H), 3.23–3.06 (m, 4H). Analytical data are in agreement with the literature.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic Acid (<b>5</b>)</h3><div class="NLM_p last">Compound <b>5</b> was prepared according to General Procedure A starting from carboxylic ester <b>4</b> (1.00 g, 2.54 mmol). Yield: 0.96 g (99%), yellow solid. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) 13.02 (br. s, 1H), 8.60 (s, 1H), 8.43 (d, <i>J</i> = 1.6 Hz, 1H), 7.95–8.03 (m, 2H), 7.30–7.49 (m, 3H), 7.04–7.16 (m, 1H), 6.75 (d, <i>J</i> = 7.5 Hz, 1H), 6.62 (s, 1H), 3.03–3.18 (m, 4H). Analytical data are in agreement with the literature.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec4_2_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>6</b>)</h3><div class="NLM_p last">Compound <b>6</b> was prepared according to General Procedure B using <b>5</b> (0.050 g, 0.13 mmol) and dimethylamine hydrochloride (0.012 g, 0.14 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.041 g (77%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 404.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3247, 2921, 2852, 1621, 1589, 1500, 1392, 1358, 1257, 1212, 1138, 965, 866, 601. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.00–7.97 (m, 1H), 7.86 (s, 1H), 7.51–7.50 (m, 1H), 7.48–7.34 (m, 3H), 7.13–7.09 (m, 1H), 6.75 (d, <i>J</i> = 8.7 Hz, 1H), 6.63 (s, 1H), 3.12–3.04 (m, 4H), 2.98–2.93 (m, 6H).</div></div><div id="sec4_2_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-phenethyl-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>7</b>)</h3><div class="NLM_p last">Compound <b>7</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and 2-phenylethylamine (0.026 g, 0.22 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.043 g (45%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 481.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3283, 2923, 1632, 1338, 1314, 1258, 1141, 965, 851, 599. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69–8.64 (m, 1H), 8.58 (s, 1H), 8.33 (s, 1H), 8.00 (d, <i>J</i> = 9.1 Hz, 1H), 7.90 (d, <i>J</i> = 7.3 Hz, 1H), 7.41–7.36 (m, 2H), 7.29–7.18 (m, 6H), 7.15–7.06 (m, 2H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 6.63 (s, 1H), 3.51–3.48 (m, 2H), 3.14–3.02 (m, 4H), 2.89–2.85 (m, 2H).</div></div><div id="sec4_2_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-methyl-5-oxo-<i>N</i>-phenethyl-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8</b>)</h3><div class="NLM_p last">Compound <b>8</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and <i>N</i>-methyl-2-phenylethylamine (0.029 g, 0.21 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.029 g (55%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 495.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1602, 1579, 1500, 1397, 1354, 1258, 1214, 1139, 964, 842, 698. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.00–7.97 (m, 1H), 7.43–7.36 (m, 3H), 7.27 (d, <i>J</i> = 22.0 Hz, 3H), 7.17–7.07 (m, 4H), 6.98–6.96 (m, 1H), 6.77–6.75 (m, 1H), 6.63 (s, 1H), 3.68–3.64 (m, 2H), 3.09–3.02 (m, 7H), 2.91–2.88 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.6, 170.5, 159.0 (dd, <i>J</i> = 11.2, 241.9 Hz), 156.2 (dd, <i>J</i> = 12.5, 246.7 Hz), 149.8, 145.7, 143.3, 139.9, 139.1, 135.3, 133.9, 129.2, 129.1, 128.8, 128.7, 127.7, 126.7, 126.6, 125.3 (dd, <i>J</i> = 3.3, 13.3 Hz), 114.0, 112.8, 112.3 (dd, <i>J</i> = 3.4, 21.8 Hz), 105.2 (dd, <i>J</i> = 26.0, 27.0 Hz), 52.7, 51.8, 48.9, 35.9, 34.3.</div></div><div id="sec4_2_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-(4-fluorophenethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>9</b>)</h3><div class="NLM_p last">Compound <b>9</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and 2-(4-fluorophenyl)ethylamine (0.138 g, 0.99 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.037 g (39%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 499.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3280, 2923, 2853, 1602, 1580, 1257, 1139, 1094, 964, 846, 783, 518. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69–8.66 (m, 1H), 8.60 (s, 1H), 8.31 (s, 1H), 8.00 7.97 (m, 1H), 7.89 (d, <i>J</i> = 7.3 Hz, 1H), 7.43–7.30 (m, 4H), 7.13–7.00 (m, 4H), 6.76 (d, <i>J</i> = 8.3 Hz, 1H), 6.62 (s, 1H), 3.53–3.48 (m, 2H), 3.13–3.03 (m, 4H), 2.89–2.86 (m, 2H).</div></div><div id="sec4_2_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-(4-hydroxyphenethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>10</b>)</h3><div class="NLM_p last">Compound <b>10</b> was prepared according to General Procedure B using <b>5</b> (0.050 g, 0.13 mmol) and tyramine hydrochloride (0.069 g, 0.40 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.018 g (28%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 497.5 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3292, 2922, 2852, 1601, 1505, 1360, 1260, 1097, 967, 843, 540. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (s, 1H), 8.66–8.62 (m, 1H), 8.60 (s, 1H), 8.32 (s, 1H), 8.01–7.98 (m, 1H), 7.90–7.88 (m, 1H), 7.44–7.33 (m, 3H), 7.12–7.10 (m, 1H), 7.02 (d, <i>J</i> = 7.7 Hz, 2H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 6.69–6.66 (m, 2H), 6.62 (s, 1H), 3.53–3.48 (m, 2H, overlain by water peak), 3.12–3.03 (m, 4H), 2.74–2.70 (m, 2H).</div></div><div id="sec4_2_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(2-(1<i>H</i>-Imidazol-4-yl)ethyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>11</b>)</h3><div class="NLM_p last">Compound <b>11</b> was prepared according to General Procedure B using <b>5</b> (0.050 g, 0.13 mmol) and histamine dihydrochloride (0.049 g, 0.26 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.018 g (29%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 471.5 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2921, 2851, 1603, 1579, 1505, 1354, 1258, 1094, 964, 801, 621. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69–8.66 (m, 1H), 8.60 (s, 1H), 8.32 (s, 1H), 8.00–7.98 (m, 1H), 7.91–7.89 (m, 1H), 7.57 (s, 5H), 7.43–7.34 (m, 4H), 7.13–7.09 (m, 1H), 6.83 (s, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 3.49–3.46 (m, 2H, overlain by water peak), 3.12–3.03 (m, 4H), 2.78–2.74 (m, 2H).</div></div><div id="sec4_2_3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-(2-(thiophen-2-yl)ethyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>12</b>)</h3><div class="NLM_p last">Compound <b>12</b> was prepared according to General Procedure B using <b>5</b> (0.030 g, 0.08 mmol) and 2-(thiophen-2-)ethylamine (0.015 g, 0.12 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.021 g (53%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 486.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1602, 1580, 1504, 1354, 1258, 1139, 964, 845, 696, 594. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.77–8.74 (m, 1H), 8.60 (s, 1H), 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.91 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.42–7.32 (m, 4H), 7.13–7.09 (m, 1H), 6.96–6.91 (m, 2H), 6.77–6.74 (m, 1H), 6.62 (d, <i>J</i> = 1.4 Hz, 1H), 3.53–3.48 (m, 2H), 3.13–3.05 (m, 6H).</div></div><div id="sec4_2_3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-(1<i>H</i>-Indol-3-yl)ethyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>13</b>)</h3><div class="NLM_p last">Compound <b>13</b> was prepared according to General Procedure B using <b>5</b> (0.050 g, 0.13 mmol) and tryptamine hydrochloride (0.106 g, 0.66 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.053 g (81%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 520.7 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2916, 2850, 1633, 1567, 1486, 1259, 1092, 964, 741, 461. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.81 (s, 1H), 8.75–8.72 (m, 1H), 8.60 (s, 1H), 8.35 (s, 1H), 8.01–7.91 (m, 2H), 7.58 (d, <i>J</i> = 7.7 Hz, 1H), 7.46–7.31 (m, 4H), 7.17 (s, 1H), 7.13–7.03 (m, 2H), 7.00–6.96 (m, 1H), 6.76 (d, <i>J</i> = 8.5 Hz, 1H), 6.63 (s, 1H), 3.57–3.52 (m, 2H), 3.14–3.03 (m, 4H), 2.97–2.93 (m, 2H).</div></div><div id="sec4_2_3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-(3-phenylpropyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>14</b>)</h3><div class="NLM_p last">Compound <b>14</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and 3-phenylpropylamine (0.134 g, 0.99 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.023 g (23%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 495.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3315, 1581, 1603, 1527, 1504, 1262, 1141, 964, 854, 700, 631. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s, 2H), 8.34 (s, 1H), 8.02 (d, <i>J</i> = 8.5 Hz, 1H), 7.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.45–7.35 (m, 3H), 7.30–7.21 (m, 4H), 7.19–7.15 (m, 1H), 7.13–7.09 (m, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 3.30–3.26 (m, 2H), 3.13–3.03 (m, 4H), 2.65–2.60 (m, 2H), 1.83 (quin, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 165.5, 149.3, 145.2, 144.5, 141.7, 138.9, 133.3, 133.0, 130.4, 129.1, 128.8, 128.3 (2× C), 128.2 (2× C), 127.2, 126.2 (dd, <i>J</i> = 2.5, 9.8 Hz), 125.7, 124.8 (dd, <i>J</i> = 2.9, 12.2 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.0, 21.8 Hz), 104.9 (dd, <i>J</i> = 24.0, 26.2 Hz), 38.9, 35.4, 33.7, 32.6, 30.8, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(2-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)ethyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> was prepared according to General Procedure B using <b>5</b> (0.060 g, 0.16 mmol) and 2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethylamine (0.034 g, 0.24 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.063 g (79%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 502.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3291, 2924, 2854, 1634, 1603, 1580, 1505, 1355, 1259, 1093, 963, 761, 520. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.31 (d, <i>J</i> = 1.3 Hz, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 7.97 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.39–7.32 (m, 1H), 7.29 (d, <i>J</i> = 7.9 Hz, 1H), 6.96–6.83 (m, 3H), 6.77–6.74 (m, 1H), 6.66–6.65 (m, 1H), 5.96 (s, 1H), 4.74 (s, 4H), 3.43–3.39 (m, 6H), 3.19–3.16 (m, 2H), 3.11–3.09 (m, 2H), 2.62 (t, <i>J</i> = 5.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.5, 166.7, 158.8 (dd, <i>J</i> = 11.5, 244.8 Hz), 155.3 (dd, <i>J</i> = 12.8, 248.3 Hz), 148.1, 145.3, 145.1, 138.9, 134.2, 133.0, 131.4, 129.4, 129.3, 128.6, 124.8 (dd, 3.9, 11.9 Hz), 123.9 (dd, <i>J</i> = 2.5, 9.3 Hz), 114.6, 113.3, 111.4 (dd, <i>J</i> = 3.7, 22.1 Hz), 104.8 (dd, <i>J</i> = 23.6, 26.2 Hz), 81.2 (2× C), 63.7 (2× C), 57.9, 39.2, 37.7, 35.8, 34.7.</div></div><div id="sec4_2_3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-(1-phenylcyclopropyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>16</b>)</h3><div class="NLM_p last">Compound <b>16</b> was prepared according to General Procedure B using <b>5</b> (0.030 g, 0.08 mmol) and 1-phenyl-1-cyclopropylamine (0.017 g, 0.10 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.017 g (44%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 493.0 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3268, 2922, 2850, 1632, 1603, 1581, 1505, 1353, 1257, 1139, 964, 844, 598. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 8.11 (d, <i>J</i> = 8.6 Hz, 1H), 7.98 (d, <i>J</i> = 7.4 Hz, 1H), 7.36–7.22 (m, 6H + solvent peak), 7.16–7.14 (m, 2H), 6.93–6.87 (m, 2H), 6.79 (d, <i>J</i> = 8.5 Hz, 1H), 6.63 (s, 1H), 6.00 (s, 1H), 3.15–3.13 (m, 2H), 3.07–3.04 (m, 2H), 1.37–1.30 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.4, 166.6, 158.8 (dd, <i>J</i> = 10.1, 244.5 Hz), 155.4 (dd, <i>J</i> = 12.2, 246.3 Hz), 148.2, 145.4, 145.3, 142.3, 138.8, 134.2, 132.9, 131.6, 129.6, 129.2, 128.4 (2× C), 128.3, 126.4, 125.7 (2× C), 124.8 (dd, <i>J</i> = 3.8, 11.8 Hz), 124.0 (dd, <i>J</i> = 2.3 Hz, 9.4 Hz), 114.6, 113.3, 111.4 (dd, <i>J</i> = 3.9, 22.1 Hz), 104.8 (dd, <i>J</i> = 23.5, 26.1 Hz), 35.8, 35.4, 34.7, 17.8 (2× C).</div></div><div id="sec4_2_3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(1-Cyclohexylethyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>17</b>)</h3><div class="NLM_p last">Compound <b>17</b> was prepared according to General Procedure B using <b>5</b> (0.030 g, 0.08 mmol) and 1-cyclohexylethylamine (0.012 g, 0.08 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.012 g (31%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 487.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3268, 2922, 2850, 2361, 1633, 1603, 1581, 1505, 1257, 1139, 1094, 964, 598. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 8.11 (d, <i>J</i> = 8.2 Hz, 1H), 7.94 (d, <i>J</i> = 6.6 Hz, 1H), 7.32–7.24 (m, 2H), 6.92–6.79 (m, 3H), 6.62 (s, 1H), 6.13 (d, <i>J</i> = 8.1 Hz, 1H), 6.07 (s, 1H), 4.07–3.99 (m, 1H), 3.14–3.12 (m, 2H), 3.06–3.04 (m, 2H), 1.77–1.62 (m, 3H), 1.21–1.10 (m, 8H), 1.05–0.96 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.5, 165.9, 160.0 (dd, <i>J</i> = 10.9, 244.7 Hz), 155.4 (dd, <i>J</i> = 12.3, 246.5 Hz), 148.2, 145.4, 144.9, 138.9, 134.2, 133.5, 131.5, 129.4, 129.1, 128.0, 124.9 (dd, <i>J</i> = 3.9, 11.5 Hz), 124.0 (dd, <i>J</i> = 2.3 Hz, 9.4 Hz), 114.6, 113.2, 111.5 (dd, <i>J</i> = 3.7, 22.1 Hz), 104.8 (dd, <i>J</i> = 23.7, 26.0 Hz), 50.0, 43.3, 38.6, 35.9, 34.7, 29.3, 29.2, 26.4, 26.2, 18.0.</div></div><div id="sec4_2_3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-(2-Aminoethyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>18</b>)</h3><div class="NLM_p last">Compound <b>18</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and ethylene-1,2-diamine (0.015 g, 0.26 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.027 g (61%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 420.0 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1602, 1577, 1504, 1354, 1258, 1214, 1114, 1094, 964, 844, 516. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.56–8.53 (m, 1H), 8.34–8.33 (m, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (dd, <i>J</i> = 1.5, 7.8 Hz, 1H), 7.45–7.34 (m, 3H), 7.13–7.09 (m, 1H), 6.76 (d, <i>J</i> = 8.5 Hz, 1H), 6.63 (s, 1H), 3.38–3.16 (m, 2H + 2H, overlain by water), 3.12–3.03 (m, 4H), 2.69 (t, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 165.7, 149.3, 145.2, 144.5, 138.8, 133.3, 132.9, 130.4, 129.2, 128.8, 127.2, 126.2 (dd, <i>J</i> = 2.6, 9.2 Hz), 124.8 (dd, <i>J</i> = 2.6, 11.5 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.7, 21.9 Hz), 104.9 (dd, <i>J</i> = 24.0, 26.2 Hz), 42.8, 41.1, 35.4, 33.8, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(3-Amino-3-oxopropyl)-8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>19</b>)</h3><div class="NLM_p last">Compound <b>19</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and 3-aminopropanamide (0.035 g, 0.28 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.042 g (82%), yellow solid. <b>C</b><sub><b>25</b></sub><b>H</b><sub><b>21</b></sub><b>F</b><sub><b>2</b></sub><b>N</b><sub><b>3</b></sub><b>O</b><sub><b>3</b></sub> (<i>M</i> = 449.16 g/mol). MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 448.2 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1654, 1602, 1544, 1504, 1361, 1258, 1113, 968, 847, 569, 470. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64–8.60 (m, 2H), 8.32 (s, 2H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.90 (dd, <i>J</i> = 1.4, 7.7 Hz, 1H), 7.45–7.35 (m, 4H), 7.13–7.09 (t, <i>J</i> = 8.2 Hz, 1H), 6.84 (s, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 3.50–3.45 (m, 2H, overlain by water), 3.13–3.10 (m, 2H), 3.05–3.03 (m, 2H), 2.36 (t, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 172.6, 165.5, 149.3, 145.2, 144.6, 138.8, 133.3, 132.8, 130.3, 129.1, 128.9, 127.2, 126.2 (dd, <i>J</i> = 2.9, 10.0 Hz), 124.8 (dd, <i>J</i> = 2.5, 11.8 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.6, 22.1 Hz), 104.9 (dd, <i>J</i> = 24.1, 26.8 Hz), 36.0, 35.4, 34.9, 33.8 (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-(2,2,2-trifluoroethyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>20</b>)</h3><div class="NLM_p last">Compound <b>20</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and 2,2,2-trifluoroethylamine (0.120 g, 0.99 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.057 g (63%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 459.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1668, 1604, 1539, 1355, 1243, 1151, 964, 833, 729. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22–9.20 (m, 1H), 8.60 (s, 1H), 8.39 (s, 1H), 8.01–7.96 (m, 2H), 7.46–7.34 (m, 3H), 7.12–7.08 (m, 1H), 6.78 (s, 1H), 6.63 (s, 1H), 4.14–4.04 (m, 2H), 3.15–3.12 (m, 2H), 3.06–3.04 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.6, 166.3, 159.8 (dd, <i>J</i> = 11.1, 243.6 Hz), 154.5 (dd, <i>J</i> = 12.6, 248.6 Hz), 149.4, 145.4, 145.3, 139.0, 133.4, 131.5, 130.6, 129.4, 129.1, 127.1, 126.3 (dd) 124.9 (dd), 123.4, 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.6, 22.1 Hz), 104.9 (dd <i>J</i> = 24.4, 26.3 Hz), 40.2 (q, <i>J</i> = 33.7 Hz), 35.3, 33.8.</div></div><div id="sec4_2_3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-octyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>21</b>)</h3><div class="NLM_p last">Compound <b>21</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and octylamine (0.240 g, 1.98 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.024 g (25%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 489.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3274, 2923, 2853, 1603, 1505, 1257, 1139, 1094, 964, 845, 597. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58–8.54 (m, 2H), 8.33 (s, 1H), 8.01–7.90 (m, 2H), 7.42–7. 32 (m, 3H), 7.11–7.07 (m, 1H), 6.76 (d, <i>J</i> = 8.0 Hz, 1H), 6.63 (s, 1H), 3.27–3.21 (m, 2H), 3.12–3.02 (m, 4H), 1.50 (br. s, 2H), 1.25–1.23 (s, 10H), 0.83 (br. s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 165.4, 158.4 (dd, <i>J</i> = 11.3, 240.9 Hz), 155.7 (dd, <i>J</i> = 12.6, 246.6 Hz), 149.2, 145.2, 144.4, 138.9, 133.3, 130.3, 133.0, 129.1, 128.8, 127.2, 126.2 (dd, <i>J</i> = 2.7, 9.6 Hz), 124.8 (dd, <i>J</i> = 3.2, 12.1 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.4, 21.7 Hz), 105.0 (dd, <i>J</i> = 24.0, 25.9 Hz), 39.2, 35.4, 33.8, 31.1, 29.0, 28.7, 28.6, 26.4, 22.0, 13.8.</div></div><div id="sec4_2_3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-hexadecyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>22</b>)</h3><div class="NLM_p last">Compound <b>22</b> was prepared according to General Procedure B using <b>5</b> (0.075 g, 0.20 mmol) and hexadecylamine (0.955 g, 3.95 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.055 g (46%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 602.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3345, 2919, 2847, 1631, 1604, 1495, 1358, 1265, 963, 858, 624. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.30 (br. s, 1H), 8.16 (d, <i>J</i> = 8.8 Hz, 1H), 8.01–7.97 (m, 1H), 7.40–7.30 (m, 2H), 6.98–6.85 (m, 3H), 6.69–6.68 (m, 1H), 6.30 (br. s, 1H), 5.81 (br. s, 1H), 3.48–3.43 (m, 2H), 3.21–3.18 (m, 2H), 3.13–3.11 (m, 2H), 1.65–1.58 (m, 2H), 1.37–1.26 (m, 26H), 0.88 (d, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec4_2_3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>tert</i>-Butyl 4-(2-(8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)ethyl)piperazine-1-carboxylate (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> was prepared according to General Procedure B using <b>5</b> (0.125 g, 0.33 mmol) and <i>tert</i>-butyl 4-(2-aminoethyl)piperazine-1-carboxylate (0.378 g, 1.65 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.094 g (49%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 598.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1634, 1581, 1505, 1354, 1259, 1165, 1002, 964, 845, 517. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.54 (s, 1H), 8.32 (s, 1H), 8.00 (d, <i>J</i> = 8.7 Hz, 1H), 7.90 (d, <i>J</i> = 7.7 Hz, 1H), 7.49–7.31 (m, 3H), 7.11 (t, <i>J</i> = 7.8 Hz, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 3.42–3.40 (m, 2H), 3.31–3.28 (s, 4H), 3.13–3.10 (m, 2H), 3.05–3.03 (s, 2H), 2.50–2.48 (m, 2H), 2.40–2.37 (m, 4H), 1.39 (s, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 165.5, 153.8, 149.3, 145.2, 144.5, 138.9, 133.3, 132.8, 130.3, 129.1, 128.9, 127.2, 126.2 (<i>J</i> = 3.3, 9.6 Hz), 124.8 (dd, <i>J</i> = 3.8, 12.2 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.8, 22.0 Hz), 104.9 (dd, <i>J</i> = 24.3, 26.3 Hz), 78.7, 56.8, 52.4 (2× C), 36.7 (2× C), 35.4, 33.8, 28.0 (3× C), (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2-((2,4-Difluorophenyl)amino)-7-(piperidine-1-carbonyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-5-one (<b>24</b>)</h3><div class="NLM_p last">Compound <b>24</b> was prepared according to General Procedure B using <b>5</b> (0.011 g, 0.03 mmol) and piperidine (0.018 g, 0.07 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.007 g (40%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 445.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2922, 2852, 2359, 2341, 1602, 1579, 1506, 1437, 1353, 1255, 1093, 799. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 1H), 7.82 (s, 1H), 7.47–7.35 (m, 4H), 7.12–7.09 (m, 1H), 6.75 (d, <i>J</i> = 8.5 Hz, 1H), 6.62 (s, 1H), 3.73–3.55 (m, 4H), 3.11–3.06 (m, 4H), 1.60–1.45 (m, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.1, 168.3, 149.3, 145.3, 142.9, 138.6, 134.6, 133.5, 130.1, 129.0, 128.5, 127.1, 126.2 (<i>J</i> = 2.6, 9.8 Hz), 124.8 (dd, <i>J</i> = 3.3, 12.0 Hz), 113.5, 112.2, 111.8 (dd, <i>J</i> = 3.8, 21.7 Hz), 104.9 (dd, <i>J</i> = 24.2, 27.4 Hz), 48.0 (2× C), 35.4, 33.2, 25.9 (2× C), 24.0, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-phenyl-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>25</b>)</h3><div class="NLM_p last">Compound <b>25</b> was prepared according to General Procedure B using <b>5</b> (0.043 g, 0.11 mmol) and aniline (0.026 g, 0.28 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.050 g (97%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 453.0 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 8.62 (s, 1H), 8.44 (d, <i>J</i> = 1.6 Hz, 1H), 8.05–8.00 (m, 2H), 7.77 (d, <i>J</i> = 7.8 Hz, 2H), 7.49–7.33 (m, 5H), 7.14–7.09 (m, 2H), 6.77 (dd, <i>J</i> = 1.3, 8.8 Hz, 1H), 6.64 (s, 1H), 3.17–3.15 (m, 2H), 3.08–3.06 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 164.8, 149.4, 145.3, 145.1, 139.1, 138.9, 133.4, 133.2, 130.8, 129.6, 129.0, 128.6 (2× C), 127.1, 126.3 (dd, <i>J</i> = 2.6, 10.0 Hz), 124.8 (dd, <i>J</i> = 3.3, 12.4 Hz), 123.7, 120.4 (2× C), 113.5, 112.3, 111.9 (dd, <i>J</i> = 3.7, 21.8 Hz), 105.0 (dd, <i>J</i> = 24.5, 26.3 Hz), 35.4, 33.8, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-hydroxy-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>26</b>)</h3><div class="NLM_p last">Compound <b>26</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and hydroxylamine hydrochloride (0.009 g, 0.13 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.034 g (77%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 392.5 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2920, 2851, 1602, 1505, 1354, 1258, 1093, 1028, 839, 596, 451. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.30 (s, 1H), 9.07 (s, 1H), 8.60 (s, 1H), 8.25 (s, 1H), 7.99 (d, <i>J</i> = 8.7 Hz, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 1H), 7.45–7.35 (m, 3H), 7.13–7.09 (m, 1H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 6.62 (s, 1H), 3.12–3.02 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.7, 163.6, 160.4, 158.5 (dd, <i>J</i> = 11.0, 244.2 Hz), 155.7 (dd, <i>J</i> = 11.7, 248.0 Hz), 149.8, 145.2, 144.6, 138.9, 133.4, 131.4, 129.9, 129.0, 127.1, 126.1, 124.7, 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.3, 21.9 Hz), 104.9 (dd, <i>J</i> = 22.1, 26.5 Hz), 35.3, 33.8.</div></div><div id="sec4_2_3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>27</b>)</h3><div class="NLM_p last">Compound <b>27</b> was prepared according to General Procedure B using <b>5</b> (0.080 g, 0.21 mmol) and tris(hydroxymethyl)aminomethane hydrochloride (0.083 g, 0.53 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.023 g (23%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 480.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3300, 1602, 1580, 1505, 1403, 1354, 1258, 1214, 1042, 846, 595. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.27 (d, <i>J</i> = 1.5 Hz, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.88 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.45–7.35 (m, 4H), 7.13–7.08 (m, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.62 (s, 1H), 4.77 (t, <i>J</i> = 5.7 Hz, 3H), 3.70 (d, <i>J</i> = 5.7 Hz, 6H), 3.13–3.11 (m, 2H), 3.05–3.03 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 166.6, 158.5 (dd, <i>J</i> = 11.5, 241.8 Hz), 155.7 (dd, <i>J</i> = 12.2, 246.4 Hz), 149.3, 145.3, 144.6, 138.8, 133.5, 133.4, 130.6, 129.2, 128.7, 127.1, 126.2 (dd, <i>J</i> = 3.2, 9.6 Hz), 124.8 (dd, <i>J</i> = 3.1, 12.2 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.3, 21.9 Hz), 104.9 (dd, <i>J</i> = 24.3, 26.3 Hz), 62.7, 60.5, 35.4, 33.8.</div></div><div id="sec4_2_3_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-((<i>2R</i>,<i>3R</i>,<i>4R</i>,<i>5S</i>,<i>6R</i>)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2<i>H</i>-pyran-3-yl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>28</b>)</h3><div class="NLM_p last">Compound <b>28</b> was prepared according to General Procedure B using <b>5</b> (0.060 g, 0.16 mmol) and <span class="smallcaps smallerCapital">d</span>-glucosamine hydrochloride (0.038 g, 0.17 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.048 g (56%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 538.7 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3300, 1633, 1603, 1505, 1355, 1259, 1094, 1027, 965, 845, 516. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s,1H), 8.37–8.36 (m, 1H), 8.32 (d, <i>J</i> = 8.8 Hz, 0.3H), 8.20 (d, <i>J</i> = 7.1 Hz, 0.7H), 8.01–7.93 (m, 2H), 7.45–7.34 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.63 (s, 1H), 6.58 (d, <i>J</i> = 6.2 Hz, 0.3H), 6.48 (d, <i>J</i> = 4.2 Hz, 0.7H), 5.10–5.08 (s, 0.7H), 4.99–4.97 (m, 1H), 4.93 (d, <i>J</i> = 5.1 Hz, 0.3H), 4.72 (d, <i>J</i> = 4.6 Hz, 0.7H), 4.64–4.56 (m, 0.6H), 4.50–4.47 (m, 0.7H), 3.81–3.63 (m, 3H), 3.54–3.48 (m, 1H), 3.22–3.17 (m, 1H), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.6, 165.9, 158.5 (dd, <i>J</i> = 11.3, 241.9 Hz), 155.7 (dd, <i>J</i> = 12.6, 246.8 Hz), 149.3, 145.2, 144.5, 138.9, 133.3, 132.8, 130.7, 129.4, 128.7, 127.2, 126.2 (dd, <i>J</i> = 3.0, 9.7 Hz), 124.9 (dd, <i>J</i> = 3.6, 12.1 Hz), 113.6, 112.3, 111.8 (dd, <i>J</i> = 3.3, 21.9 Hz), 104.9 (dd, <i>J</i> = 24.1, 26.2 Hz), 90.5, 72.1, 71.1, 70.0, 61.2, 55.5, 35.5, 33.8.</div></div><div id="sec4_2_3_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-(2-(2-hydroxyethoxy)ethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>29</b>)</h3><div class="NLM_p last">Compound <b>29</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and 2-(2-aminoethoxy)ethanol (0.027 g, 0.26 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.017 g (34%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 464.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2950, 1651, 1601, 1578, 1506, 1348, 1261, 1211, 1133, 1095, 966, 844, 784. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64–8.60 (m, 2H), 8.34 (d, <i>J</i> = 1.5 Hz, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.45–7.34 (m, 3H), 7.13–7.09 (m, 1H), 6.76 (d, <i>J</i> = 1.3, 8.9 Hz, 1H), 6.63 (s, 1H), 4.63 (t, <i>J</i> = 5.3 Hz, 1H), 3.55–3.52 (m, 2H), 3.50–3.48 (m, 2H), 3.45–3.41 (m, 4H), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 165.7, 158.5 (dd, <i>J</i> = 11.3, 241.8 Hz), 156.7 (dd, <i>J</i> = 12.6, 245.4 Hz), 149.3, 145.3, 144.6, 138.9, 133.3, 132.7, 130.4, 129.2, 128.9, 127.1, 126.2 (dd, <i>J</i> = 3.0, 9.8 Hz), 124.8 (dd, <i>J</i> = 3.5, 12.2 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.4, 21.9 Hz), 104.9 (dd, <i>J</i> = 24.5, 26.6 Hz), 72.1, 68.8, 60.2, 38.2, 35.4, 33.8.</div></div><div id="sec4_2_3_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 8-((2,4-Difluorophenyl)amino)-<i>N</i>-(2-((2-hydroxyethyl)amino)ethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>30</b>)</h3><div class="NLM_p last">Compound <b>30</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and 2-((2-aminoethyl)amino)ethanol (0.027 g, 0.26 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.025 g (51%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 463.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1601, 1557, 1524, 1439, 1354, 1257, 1140, 848, 754, 687. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.57 (t, <i>J</i> = 5.3 Hz, 1H), 8.34 (d, <i>J</i> = 1.3 Hz, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.45–7.34 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.63 (s, 1H), 4.55 (br. s, 1H), 3.46 (t, <i>J</i> = 5.7 Hz, 2H), 3.39–3.35 (m, 2H, overlain by water), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H), 2.73 (t, <i>J</i> = 6.4 Hz, 2H), 2.64 (t, <i>J</i> = 5.7 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 165.6, 158.5 (dd, <i>J</i> = 11.1, 241.9 Hz), 155.7 (dd, <i>J</i> = 12.5, 246.5 Hz), 149.3, 145.2, 144.5, 138.9, 133.3, 132.9, 130.4, 129.2, 128.8, 127.2, 126.2 (dd, <i>J</i> = 2.9, 9.6 Hz) 124.8 (dd, <i>J</i> = 3.6, 12.1 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.4, 22.1 Hz), 104.9 (dd, <i>J</i> = 24.4, 26.5 Hz), 60.1, 51.2, 48.3, 35.4, 33.8, 30.6.</div></div><div id="sec4_2_3_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Methyl (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)glycinate (<b>31</b>)</h3><div class="NLM_p last">Compound <b>31</b> was prepared according to General Procedure B using <b>5</b> (0.060 g, 0.16 mmol) and glycine methyl ester hydrochloride (0.024 g, 0.19 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.041 g (58%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 448.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3383, 3278, 1758, 1650, 1606, 1575, 1258, 1195, 962, 760, 512. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32–8.30 (s, 1H), 8.05–8.03 (d, <i>J</i> = 7.5 Hz, 1H), 7.87–7.85 (m, 1H), 7.34–7.28 (m, 2H), 6.87–6.84 (m, 2H), 6.76–6.74 (m, 1H), 6.57 (s, 1H), 4.11 (s, 2H), 3.70 (s, 3H), 3.20 (s, 1H), 3.10–3.04 (m, 4H).</div></div><div id="sec4_2_3_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Methyl (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-alaninate (<b>32</b>)</h3><div class="NLM_p last">Compound <b>32</b> was prepared according to General Procedure B using <b>5</b> (0.050 g, 0.13 mmol) and <span class="smallcaps smallerCapital">l</span>-alanine methyl ester hydrochloride (0.092 g, 0.66 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.023 g (38%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 463.6 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3304, 2921, 2852, 1738, 1634, 1603, 1505, 1454, 1354, 1172, 1212, 1140, 845. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.94 (d, <i>J</i> = 6.7 Hz, 1H), 8.61 (s, 1H), 8.39 (s, 1H), 8.02 – −8.00 (m, 1H), 7.97–7.94 (m, 1H), 7.43–7.35 (m, 3H), 7.13–7.09 (m, 1H), 6.77 (d, <i>J</i> = 8.7 Hz, 1H), 6.63 (s, 1H), 4.53–4.46 (m, 1H), 3.65 (s, 3H), 3.14–3.12 (m, 2H), 3.06–3.04 (m, 2H), 1.41 (d, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 173.1, 165.6, 149.3, 145.2, 144.9, 139.0, 133.3, 132.0, 130.6, 129.4, 128.9, 127.1, 126.2 (dd, <i>J</i> = 3.4, 9.4 Hz), 124.9 (dd, <i>J</i> = 3.2, 12.1 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.7, 22.1 Hz), 104.9 (dd, <i>J</i> = 24.7, 26.5 Hz), 51.8, 48.3, 35.4, 33.8, 16.7, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl 3-(8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoate (<b>33</b>)</h3><div class="NLM_p last">Compound <b>33</b> was prepared according to General Procedure B using <b>5</b> (0.060 g, 0.16 mmol) and methyl 3-aminopropanoate hydrochloride (0.024 g, 0.17 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.075 g (95%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 462.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1717, 1602, 1581, 1525, 1434, 1244, 1116, 915, 842, 718, 508. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69–8.66 (s, 1H), 8.60 (s, 1H), 8.31 (s, 1H), 8.01–7.98 (m, 1H), 7.91–7.89 (m, 1H), 7.45–7.35 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 3.61–3.60 (m, 3H), 3.51–3.46 (m, 2H), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H), 2.62–2.55 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 171.7, 165.6, 149.3, 145.2, 144.7, 138.8, 133.3, 132.6, 130.4, 129.1, 128.9, 127.1, 126.2 (dd, <i>J</i> = 3.0, 9.5 Hz), 124.8 (dd, <i>J</i> = 3.7, 12.0 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.6, 22.1 Hz), 104.9 (dd, <i>J</i> = 24.2, 26.7 Hz), 51.3, 35.5, 35.4, 33.8, 33.5, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Methyl 4-(8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)butanoate (<b>34</b>)</h3><div class="NLM_p last">Compound <b>34</b> was prepared according to General Procedure B using <b>5</b> (0.040 g, 0.11 mmol) and methyl 4-aminobutanoate hydrochloride (0.027 g, 0.17 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.070 g (86%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 476.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3290, 1728, 1601, 1505, 1437, 1357, 1261, 1097, 967, 850, 528. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.31 (d, <i>J</i> = 1.2 Hz, 1H), 8.10 (d, <i>J</i> = 8.7 Hz, 1H), 7.94–7.92 (m, 1H), 7.36–7.31 (m, 1H), 7.27–7.25 (m, 1H + solvent peak), 6.93–6.76 (m, 4H), 6.64 (s, 1H), 6.11 (br. s, 1H), 3.66 (s, 3H), 3.51–3.46 (m, 2H), 3.15–3.13 (m, 2H), 3.07–3.05 (m, 2H), 2.42 (t, <i>J</i> = 7.1 Hz, 2H), 1.95 (quin, <i>J</i> = 6.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.3, 173.9, 166.8, 158.8 (dd, <i>J</i> = 10.7, 244.5 Hz), 155.4 (dd, <i>J</i> = 11.5, 246.2 Hz), 148.1, 145.2, 145.1, 138.9, 134.2, 133.0, 131.2, 129.4, 129.2, 128.5, 124.9 (dd, <i>J</i> = 3.1, 11.4 Hz), 124.0 (dd, <i>J</i> = 2.3, 9.4 Hz), 114.6, 113.3, 111.d (dd, <i>J</i> = 3.7, 22.0 Hz), 104.8 (dd, <i>J</i> = 23.7, 26.2 Hz), 51.7, 39.6, 35.8, 34.7, 31.6, 24.6.</div></div><div id="sec4_2_3_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Methyl (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-phenylalaninate (<b>35</b>)</h3><div class="NLM_p last">Compound <b>35</b> was prepared according to General Procedure B using <b>5</b> (0.080 g, 0.21 mmol) and <span class="smallcaps smallerCapital">l</span>-phenylalanine methyl ester hydrochloride (0.068 g, 0.32 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.103 g (90%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 538.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2157, 2006, 1738, 1651, 1603, 1581, 1258, 1434, 1177, 1118, 1140, 699. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (d, <i>J</i> = 7.5 Hz, 1H), 8.61 (s, 1H), 8.33 (s, 1H), 8.01 (d, <i>J</i> = 8.1 Hz, 1H), 7.88–7.86 (m, 1H), 7.45–7.34 (m, 3H), 7.30–7.17 (m, 5H), 7.13–7.09 (m, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.62 (s, 1H), 4.71–4.66 (m, 1H), 3.64 (s, 3H), 3.20–3.10 (m, 4H), 3.05–3.03 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 172.1, 165.7, 158.5 (dd, <i>J</i> = 11.6, 243.5 Hz), 155.7 (dd, <i>J</i> = 12.6, 248.5 Hz), 149.3, 145.8, 145.0, 139.0, 137.6, 133.3, 131.9, 130.5, 129.3, 129.0 (2× C), 128.9, 128.2 (2× C), 127.1, 126.4, 126.2 (dd, <i>J</i> = 3.0, 9.6 Hz), 124.8 (dd, <i>J</i> = 3.1, 11.9 Hz), 113.5, 112.3, 111.8 (dd, <i>J</i> = 3.4, 22.1 Hz), 104.9 (dd, <i>J</i> = 24.4, 26.5 Hz), 54.2, 51.9, 36.2, 35.3, 34.7.</div></div><div id="sec4_2_3_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Dimethyl (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-glutamate (<b>36</b>)</h3><div class="NLM_p last">Compound <b>36</b> was prepared according to General Procedure B using <b>5</b> (0.080 g, 0.21 mmol) and dimethyl <span class="smallcaps smallerCapital">l</span>-glutamate hydrochloride (0.049 g, 0.23 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.110 g (97%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 534.7 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1732, 1633, 1603, 1505, 1435, 1354, 1258, 1211, 1094, 964, 846. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.90 (d, <i>J</i> = 7.4 Hz, 1H), 8.61 (s, 1H), 8.37 (d, <i>J</i> = 1.8 Hz, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.96–7.93 (m, 1H), 7.47–7.36 (m, 3H), 7.13–7.09 (m, 1H), 6.76 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 6.63 (d, <i>J</i> = 1.6 Hz, 1H), 4.50–4.45 (m, 1H), 3.64 (s, 3H), 3.58 (s, 3H), 3.14–3.12 (m, 2H), 3.06–3.04 (m, 2H), 2.45 (t, <i>J</i> = 7.5 Hz, 2H), 2.15–2.08 (m, 1H), 2.06–1.97 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) 190.5, 172.7, 172.2, 166.0, 149.4, 145.3, 145.0, 139.0, 133.4, 131.2, 130.7, 129.4, 128.9, 127.1, 126.2 (dd, <i>J</i> = 3.0, 9.7 Hz), 113.6, 112.3, 111.8 (dd, <i>J</i> = 3.7, 22.0 Hz), 105.0 (dd, <i>J</i> = 24.6, 26.9 Hz), 52.0, 52.0, 51.3, 35.4, 33.8, 30.0, 25.7, (C<sup>1′</sup>, C<sup>2′</sup>-F, and C<sup>4′</sup>-F not visible).</div></div><div id="sec4_2_3_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-methioninate (<b>37</b>)</h3><div class="NLM_p last">Compound <b>37</b> was prepared according to General Procedure B using <b>5</b> (0.080 g, 0.21 mmol) and <span class="smallcaps smallerCapital">l</span>-methionine methyl ester hydrochloride (0.105 g, 0.53 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.043 g (39%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 523.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2921, 2852, 1737, 1635, 1602, 1505, 1435, 1354, 1257, 1213, 1094, 845. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (d, <i>J</i> = 7.4 Hz, 1H), 8.60 (s, 1H), 8.38 (s, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.96 (d, <i>J</i> = 7.8 Hz, 1H), 7.44–7.35 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.63 (s, 1H), 4.62–4.57 (m, 1H), 3.65 (s, 3H), 3.14–3.12 (m, 2H), 3.06–3.04 (m, 2H), 2.63–2.53 (m, 2H), 2.08–2.03 (m, 5H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.9, 172.9, 166.5, 149.9, 145.8, 145.5, 139.5, 133.8, 132.5, 131.2, 129.9, 129.4, 127.6, 126.7 (dd, <i>J</i> = 2.9, 9.7 Hz), 125.3 (dd, <i>J</i> = 3.2, 11.2 Hz), 114.0, 112.8, 112.3 (dd, <i>J</i> = 3.3, 22.0 Hz), 105.4 (dd, <i>J</i> = 23.8, 26.4 Hz), 52.4, 52.2, 35.9, 34.3, 30.6, 30.4, 15.0, (C2′-F and C4′-F not visible).</div></div><div id="sec4_2_3_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Methyl <i>N</i>2-(((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)-<i>N</i>6-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-lysinate (<b>38</b>)</h3><div class="NLM_p last">Compound <b>38</b> was prepared according to General Procedure B using <b>5</b> (0.10 g, 0.26 mmol) and <i>N</i>-α-Fmoc-<span class="smallcaps smallerCapital">l</span>-lysine methyl ester (<b>S1</b>) (0.221 g, 0.53 mmol). Product was used in the next step without further purification.</div></div><div id="sec4_2_3_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoic Acid (<b>39</b>)</h3><div class="NLM_p last">Compound <b>39</b> was prepared according to General Procedure B using <b>5</b> (0.066 g, 0.17 mmol) and (<i>S</i>)-3-amino-2-((<i>tert</i>-butoxycarbonyl)amino)propanoic acid (0.053 g, 0.26 mmol). Product was used in the next step without further purification.</div></div><div id="sec4_2_3_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-4-(8-((2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)butanoic Acid (<b>40</b>)</h3><div class="NLM_p last">Compound <b>40</b> was prepared according to General Procedure B using <b>5</b> (0.066 g, 0.17 mmol) and (<i>S</i>)-4-amino-2-((<i>tert</i>-butoxycarbonyl)amino)butanoic acid (0.057 g, 0.26 mmol). Product was used in the next step without further purification.</div></div><div id="sec4_2_3_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 8-((2,4-Difluorophenyl)amino)-5-oxo-<i>N</i>-(2-(piperazin-1-yl)ethyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>41</b>)</h3><div class="NLM_p last">Compound <b>41</b> was prepared according to General Procedure C starting from <b>23</b> (0.113 g, 0.19 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.089 g (95%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 491.9 [M + H]<sup>+</sup>. IR (ATR) [cm<sup>–1</sup>] 1632, 1603, 1577, 1584, 1354, 1258, 1139, 964, 844, 729. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.52–8.49 (m, 1H), 8.31 (s, 1H), 7.99 (t, <i>J</i> = 8.7 Hz, 1H), 7.90 (d, <i>J</i> = 7.5 Hz, 1H), 7.45–7.35 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.62 (s, 1H), 3.16 (s, 1H), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H), 2.82–2.76 (m, 2H), 2.45–2.40 (m, 10H).</div></div><div id="sec4_2_3_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)glycine (<b>42</b>)</h3><div class="NLM_p last">Compound <b>42</b> was prepared according to General Procedure A starting from carboxylic ester <b>31</b> (0.020 g, 0.04 mmol). Yield: 0.012 g (62%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 434.7 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3292, 1715, 1601, 1519, 1397, 1284, 1260, 1211, 1138, 964, 841. <sup>1</sup>H NMR (400 MHz, MeOD-<i>d</i><sub>4</sub>) δ 8.43 (d, <i>J</i> = 1.6 Hz, 1H), 8.07 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.42–7.36 (m, 2H), 7.10–7.04 (m, 1H), 7.00–6.95 (m, 1H), 6.80–6.77 (m, 1H), 6.65 (s, 1H), 4.10 (s, 2H), 3.18–3.16 (m, 2H), 3.10–3.08 (m, 2H). <sup>13</sup>C NMR (100 MHz, MeOD-<i>d</i><sub>4</sub>) δ 193.1, 173.2, 169.7, 160.7 (dd, <i>J</i> = 10.6, 243.6 Hz), 157.7 (dd, <i>J</i> = 12.0, 246.7 Hz), 151.4, 147.2, 147.1, 140.8, 134.9, 133.7, 131.8, 130.7, 130.3, 129.0, 127.1 (dd, <i>J</i> = 2.8, 9.4 Hz), 126.5 (dd, <i>J</i> = 3.6, 12.1 Hz), 115.0, 113.7, 112.4 (dd, <i>J</i> = 3.8, 22.2 Hz), 105.6 (dd, <i>J</i> = 24.2, 26.4 Hz), 42.4, 37.0, 35.6.</div></div><div id="sec4_2_3_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-(8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoic Acid (<b>43</b>)</h3><div class="NLM_p last">Compound <b>43</b> was prepared according to General Procedure A starting from carboxylic ester <b>33</b> (0.043 g, 0.09 mmol). Yield: 0.029 g (68%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 448.8 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1644, 1601, 1549, 1519, 1188, 1260, 968, 839, 804, 731, 604. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.24 (br. s, 1H), 8.67–8.64 (m, 1H), 8.60 (s, 1H), 8.32 (d, <i>J</i> = 1.7 Hz, 1H), 7.97 (d, <i>J</i> = 8.8 Hz, 1H), 7.90 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.54–7.34 (m, 3H), 7.13–7.08 (m, 1H), 6.76 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 6.62 (s, 1H), 3.48–3.43 (m, 2H), 3.12–3.10 (m, 2H), 3.05–3.03 (m, 2H), 2.55–2.51 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.7, 173.1, 165.8, 158.7 (dd, <i>J</i> = 11.5, 241.8 Hz), 155.9 (dd. <i>J</i> = 12.2, 246.5 Hz), 149.6, 145.5, 144.9, 139.1, 133.6, 132.9, 130.6, 129.4, 129.1, 127.4, 126.5 (dd, <i>J</i> = 3.2, 9.7 Hz), 125.0 (dd, <i>J</i> = 3.4, 12.2 Hz), 113.8, 112.5, 112.1 (dd, <i>J</i> = 3.6, 21.9 Hz), 105.1 (dd, <i>J</i> = 23.9, 26.4 Hz), 35.8, 35.6, 34.0, 33.9.</div></div><div id="sec4_2_3_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 4-(8-((2,4-Difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)butanoic Acid (<b>44</b>)</h3><div class="NLM_p last">Compound <b>44</b> was prepared according to General Procedure A starting from carboxylic ester <b>34</b> (0.026 g, 0.05 mmol). Yield: 0.010 g (41%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 462.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3281, 1733, 1645, 1601, 1519, 1264, 1096, 969, 850, 571. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.45 (s, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 8.05–8.03 (m, 1H), 7.39–7.29 (m, 3H), 6.96–6.88 (m, 2H), 6.83 (d, <i>J</i> = 8.3 Hz, 1H), 6.65 (s, 1H), 5.97 (br. s, 1H), 3.56–3.51 (m, 2H), 3.17–3.15 (m, 2H), 3.10–3.08 (m, 2H), 2.50 (t, <i>J</i> = 6.7 Hz, 2H), 2.05–1.97 (m, 2H), (COOH not visible). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 192.1, 176.2, 166.9, 148.4, 145.8, 145.3, 138.5, 134.6, 132.8, 132.0, 129.5, 128.8, 128.7, 124.1 (dd, <i>J</i> = 2.2, 9.4 Hz), 114.5, 113.3, 111.5 (dd, <i>J</i> = 3.5, 22.3 Hz), 104.8 (dd, <i>J</i> = 23.8, 26.2 Hz), 39.6, 35.9, 34.7, 31.4, 24.6, (C<sup>1′</sup>, C<sup>2′</sup>-F, and C<sup>4′</sup>-F not visible).</div></div><div id="sec4_2_3_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Methyl 8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>52</b>)</h3><div class="NLM_p last">In a three-necked round-bottomed flask, <i>o</i>-phenylenediamine (0.194 g, 1.79 mmol), XPhos-Pd second generation (0.03 equiv), and aryl chloride <b>3</b> were dissolved in 12 mL of 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v) by gentle heating. Then, Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv) was added, and the reaction mixture was heated to 60 °C for 4 h. After cooling to rt, the reaction mixture was filtered, and the residue was washed several times with DCM, MeOH, and ethyl acetate. The combined organic extracts were evaporated under reduced pressure. The dark-brown residue was purified by flash chromatography (SiO<sub>2</sub>, petroleum ether/ethyl acetate 3:1) to yield <b>52</b> as a yellow solid (0.53 g, 95%). MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 370.9 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1714, 1602, 1577, 1498, 1353, 1242, 1116, 837, 743, 626. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45 (d, <i>J</i> = 1.6 Hz, 1H), 8.06 (s, 1H), 8.00–7.96 (m, 2H), 7.43 (d, <i>J</i> = 7.9 Hz, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.97–6.93 (m, 1H), 6.79 (d, <i>J</i> = 7.9 Hz, 1H), 6.64 (dd, <i>J</i> = 8.9, 1.5 Hz, 1H), 6.61–6.57 (m, 1H), 6.47 (d, <i>J</i> = 1.3 Hz, 1H), 4.86 (s, 2H), 3.86 (s, 3H), 3.12–3.10 (m, 2H), 3.00–2.97 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 189.1, 165.7, 151.1, 146.9, 145.3, 143.7, 139.3, 133.7, 131.8, 131.3, 129.4, 127.9, 126.2, 125.9, 125.5, 124.7, 116.5, 115.5, 112.7, 111.9, 52.1, 35.4, 34.1.</div></div><div id="sec4_2_3_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic Acid (<b>53</b>)</h3><div class="NLM_p last">Compound <b>53</b> was prepared according to General Procedure A starting from <b>52</b> (0.26 g, 0.70 mmol). Yield: 0.24 g (96%). MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 357.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1682, 1579, 1505, 1454, 1353, 1239, 1108, 831, 745, 622. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.04 (br. s, 1H), 9.70 (s, 1H), 8.44 (s, 1H), 8.26 (s, 1H), 8.03–7.98 (m, 3H), 7.44 (s, 1H), 7.36–7.30 (m, 1H), 7.18 (s, 1H), 7.03–6.93 (m, 1H), 6.79–6.47 (m, 3H), 3.14–3.12 (m, 2H), 3.04–3.01 (m, 2H).</div></div><div id="sec4_2_3_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 8-((2-Aminophenyl)amino)-<i>N</i>-(2-(dimethylamino)ethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>54</b>)</h3><div class="NLM_p last">Compound <b>54</b> was prepared according to General Procedure B using <b>53</b> (0.025 g, 0.07 mmol) and 3-aminopropanamide (0.012 g, 0.14 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.018 g (60%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 429.1 [M + H]<sup>+</sup>. IR (ATR) [cm<sup>–1</sup>] 2921, 2852, 1633, 1603, 1574, 1455, 1353, 1262, 1112, 852, 744, 543. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (s, 1H), 8.13 (d, <i>J</i> = 8.7 Hz, 1H), 7.96 (d, <i>J</i> = 7.6 Hz, 1H), 7.26–7.24 (m, 1H), 7.15–7.08 (m, 2H), 6.84–6.76 (m, 2H), 6.65 (dd, <i>J</i> = 8.7, 2.0 Hz, 1H), 6.43 (d, <i>J</i> = 1.9 Hz, 1H), 5.71 (s, 1H), 3.62–3.58 (m, 2H), 3.14–3.12 (m, 2H), 3.06–3.04 (m, 2H), 2.67–2.65 (m, 2H), 2.37 (s, 6H), (NH, NH, NH<sub>2</sub> not visible). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.3, 166.9, 150.0, 145.5, 145.0, 142.8, 139.3, 134.3, 132.9, 131.0, 129.1, 128.9, 128.1, 127.3, 126.9, 125.8, 119.1, 116.4, 113.5, 112.7, 57.9, 44.9 (2× C), 37.0, 35.9, 34.7.</div></div><div id="sec4_2_3_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 8-((2-Aminophenyl)amino)-5-oxo-<i>N</i>-phenethyl-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>55</b>)</h3><div class="NLM_p last">Compound <b>55</b> was prepared according to General Procedure B using <b>53</b> (0.043 g, 0.12 mmol) and 2-phenylethylamine (0.013 g, 0.03 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.013 g (24%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 460.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3313, 2923, 2854, 1358, 2341, 1633, 1575, 1354, 1261, 1112, 745, 698. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.28 (s, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 1H), 7.23 (d, <i>J</i> = 7.6 Hz, 1H), 7.17–7.04 (m, 5H), 6.95–6.82 (m, 3H), 6.64 (d, <i>J</i> = 8.2 Hz, 1H), 6.44 (s, 1H), 6.08 (br. s, 1H), 3.72–3.69 (m, 2H), 3.09–3.07 (m, 2H), 3.00–2.98 (m, 2H), 2.65 (t, <i>J</i> = 5.7 Hz, 2H), (NH, NH, NH<sub>2</sub> not visible).</div></div><div id="sec4_2_3_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 8-((2-Aminopheinyl)amino)-<i>N</i>-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>56</b>)</h3><div class="NLM_p last">Compound <b>56</b> was prepared according to General Procedure B using <b>53</b> (0.032 g, 0.09 mmol) and 2-morpholinoethan-1-amine (0.040 g, 0.31 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.029 g (70%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 471.2 [M + H]<sup>+</sup>. IR (ATR) [cm<sup>–1</sup>] 3304, 2921, 2852, 1633, 1602, 1574, 1498, 1353, 1264, 1112, 859, 745, 537. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55–8.52 (m, 1H), 8.33 (s, 1H), 8.04–7.99 (m, 2H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 7.8 Hz, 1H), 7.06 (d, <i>J</i> = 7.6 Hz, 1H), 6.98–6.94 (m, 1H), 6.80–6.78 (m, 1H), 6.66–6.58 (m, 2H), 6.48 (br. s, 1H), 4.88 (br. s, 2H), 3.57 (br. s, 4H), 3.40–3.37 (m, 2H), 3.11–3.09 (m, 2H), 3.01–2.99 (m, 2H), 2.46 (d, <i>J</i> = 6.9 Hz, 2H), 2.41 (br. s, 4H).</div></div><div id="sec4_2_3_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>N</i>-(2-(1<i>H</i>-Imidazol-5-yl)ethyl)-8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>57</b>)</h3><div class="NLM_p last">Compound <b>57</b> was prepared according to General Procedure B using <b>53</b> (0.050 g, 0.14 mmol) and histamine dihydrochloride (0.039 g, 0.21 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.028 g (46%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 450.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2920, 2851, 1602, 1557, 1495, 1353, 1263, 1112, 829, 746, 619. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 8.68 (t, <i>J</i> = 5.4 Hz, 1H), 8.32 (d, <i>J</i> = 1.6 Hz, 1H), 8.04 (s, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 1H), 7.89 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 7.53 (s, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.97–6.93 (m, 1H), 6.85–6.77 (m, H), 6.64 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.60–6.57 (m, 1H), 6.47 (d, <i>J</i> = 1.9 Hz, 1H), 4.86 (s, 2H), 3.49–3.46 (m, 2H, overlain by water), 3.10–3.08 (m, 2H), 3.00–2.98 (m, 2H), 2.77–2.74 (m, 2H).</div></div><div id="sec4_2_3_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>tert</i>-Butyl 4-(2-(8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)ethyl)piperazine-1-carboxylate (<b>58</b>)</h3><div class="NLM_p last">Compound <b>58</b> was prepared according to General Procedure B using <b>53</b> (0.110 g, 0.31 mmol) and <i>tert</i>-butyl 4-(2-aminoethyl)piperazine-1-carboxylate (0.077 g, 0.34 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.081 g (46%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 568.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3289, 2923, 1660, 1603, 1573, 1417, 1246, 1164, 1113, 860, 786. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (s, 1H), 8.17 (d, <i>J</i> = 8.7 Hz, 1H), 7.98 (dd, <i>J</i> = 1.5, 7.8 Hz, 1H), 7.31 (d, <i>J</i> = 7.0 Hz, 1H), 7.17–7.11 (m, 3H), 6.86–6.79 (m, 3H), 6.68 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 6.45 (d, <i>J</i> = 1.8 Hz, 1H), 5.66 (s, 1H), 3.65 (s, 2H), 3.55 (s, 4H), 3.18–3.14 (m, 2H), 3.11–3.08 (m, 2H), 2.75 (br. s, 2H), 2.60 (br. s, 4H), 1.48 (s, 9H).</div></div><div id="sec4_2_3_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 8-((2-Aminophenyl)amino)-<i>N</i>-(2-hydroxyethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>59</b>)</h3><div class="NLM_p last">Compound <b>59</b> was prepared according to General Procedure B using <b>53</b> (0.050 g, 0.14 mmol) and 2-aminoethanol (0.026 g, 0.42 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.007 g (13%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 400.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3305, 2923, 1603, 1557, 1498, 1354, 1266, 1216, 1113, 1065, 746, 451. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54–8.51 (m, 1H), 8.33 (s, 1H), 8.01–7.97 (m, 2H), 7.92–7.98 (m, 1H), 7.38 (d, <i>J</i> = 7.9 Hz, 1H), 7.02 (d, <i>J</i> = 7.7 Hz, 1H), 6.97–6.93 (m, 1H), 6.78 (d, <i>J</i> = 8.0 Hz, 1H), 6.65–6.62 (m, 1H), 6.60–6.57 (m, 1H), 6.47 (s, 1H), 4.84 (s, 2H), 4.75 (br. s, 1H), 3.53–3.48 (m, 2H), 3.35–3.30 (m, 2H), 3.10–3.08 (m, 2H), 3.00–2.98 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 166.2, 151.4, 145.8, 145.0, 144.1, 139.6, 134.0, 133.3, 130.7, 129.7, 129.2, 126.6, 126.4, 126.2, 125.3, 117.0, 116.0, 113.3, 112.3, 60.2, 42.7, 36.2, 34.3.</div></div><div id="sec4_2_3_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 8-((2-Aminophenyl)amino)-<i>N</i>-(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>60</b>)</h3><div class="NLM_p last">Compound <b>60</b> was prepared according to General Procedure B using <b>53</b> (0.040 g, 0.11 mmol) and 3-aminopropane-1,2-diol (0.011 g, 0.12 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.010 g (21%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 429.7 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3306, 2920, 2851, 1603, 1574, 1557, 1455, 1354, 1263, 1111, 1036, 745. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51–8.48 (m, 1H), 8.34–8.33 (m, 1H), 8.01–7.97 (m, 2H), 7.91 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.02 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 6.97–6.93 (m, 1H), 6.78 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 6.64 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.60–6.56 (m, 1H), 6.47 (d, <i>J</i> = 2.4 Hz, 1H), 4.86 (s, 2H), 4.82–4.81 (m, 1H), 4.57 (t, <i>J</i> = 5.7 Hz, 1H), 3.67–3.60 (m, 1H), 3.41–3.34 (m, 3H), 3.22–3.16 (m, 1H), 3.11–3.07 (m, 2H), 3.02–2.98 (m, 2H).</div></div><div id="sec4_2_3_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 8-((2-Aminophenyl)amino)-<i>N</i>-(1,3-dihydroxypropan-2-yl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>61</b>)</h3><div class="NLM_p last">Compound <b>61</b> was prepared according to General Procedure B using <b>53</b> (0.040 g, 0.11 mmol) and 2-aminopropane-1,3-diol (0.011 g, 0.12 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.011 g (22%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 430.3 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3307, 2918, 2850, 1603, 1574, 1557, 1456, 1353, 1266, 1036, 746, 565. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 1.7 Hz, 1H), 8.08 (d, <i>J</i> = 8.1 Hz, 1H), 8.01–7.97 (m, 2H), 7.92 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.03–7.00 (m, 1H), 6.97–6.93 (m, 1H), 6.78 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 6.64 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.60–6.56 (m, 1H), 6.47 (d, <i>J</i> = 2.0 Hz, 1H), 4.86 (s, 2H), 4.68–4.64 (m, 2H), 4.00–3.94 (m, 1H), 3.52–3.49 (m, 4H), 3.11–3.07 (m, 2H), 3.02–2.98 (m, 2H).</div></div><div id="sec4_2_3_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>62</b>)</h3><div class="NLM_p last">Compound <b>62</b> was prepared according to General Procedure B using <b>53</b> (0.050 g, 0.14 mmol) and aq. ammonia (0.019 g, 0.28 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH [7 N NH<sub>3</sub>] 1:0 to 9:1). Yield: 0.031 g (62%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 356.0 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3305, 2922, 2853, 1652, 1602, 1567, 1513, 1353, 1270, 1108, 830, 145, 524. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 1.4 Hz, 1H), 8.07 (s, 1H), 8.01 (s, 1H), 7.98 (d, <i>J</i> = 8.9 Hz, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.38–7.36 (m, 2H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.99–6.93 (m, 1H), 6.78 (d, <i>J</i> = 7.9 Hz, 1H), 6.63 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 6.61–6.56 (m, 1H), 6.47 (d, <i>J</i> = 1.7 Hz, 1H), 4.84 (s, 2H), 3.10–3.08 (m, 2H), 3.01–2.98 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 167.9, 151.4, 145.8, 145.1, 144.1, 139.6, 134.0, 133.0, 130.9, 130.1, 129.2, 126.6, 126.4, 126.2, 125.3, 117.0, 116.0, 113.3, 112.3, 36.2, 34.3.</div></div><div id="sec4_2_3_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>N</i>-(2-Aminoethyl)-8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>63</b>)</h3><div class="NLM_p last">Compound <b>63</b> was prepared according to General Procedure B using <b>53</b> (0.050 g, 0.14 mmol) and ethylene-1,2-diamine (0.025 g, 0.42 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH [7 N NH<sub>3</sub>] 1:0 to 9:1). Yield: 0.012 g (22%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 399.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 3290, 2920, 2851, 1602, 1564, 1495, 1352, 1262, 1112, 831, 745, 598. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.53 (s, 1H), 8.36–8.31(m, 1H), 8.07 (s, 1H), 8.00–7.96 (m, 1H), 7.91 (d, <i>J</i> = 7.7 Hz, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.97–6.95 (m, 1H), 6.78 (d, <i>J</i> = 7.9 Hz, 1H), 6.64 (dd, <i>J</i> = 1.8, 8.9 Hz, 1H), 6.60–6.57 (m, 1H), 6.47 (s, 1H), 4.87 (s, 2H), 3.50 (s, 2H), 3.27–3.23 (m, 2H), 3.10–3.08 (m, 2H), 3.00–2.97 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 166.2, 151.4, 145.8, 144.9, 144.1, 139.6, 134.0, 133.4, 130.7, 129.7, 129.1, 126.6, 126.3, 126.2, 125.3, 116.9, 116.0, 113.3, 112.3, 79.6, 70.3, 36.2, 34.3.</div></div><div id="sec4_2_3_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Dimethyl (8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-glutamate (<b>64</b>)</h3><div class="NLM_p last">Compound <b>64</b> was prepared according to General Procedure B using <b>53</b> (0.070 g, 0.20 mmol) and dimethyl <span class="smallcaps smallerCapital">l</span>-glutamate (0.045 g, 0.21 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.066 g (65%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 514.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2921, 2852, 1732, 1606, 1580, 1505, 1447, 1356, 1308, 1208, 1105, 848, 744. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.89 (d, <i>J</i> = 7.4 Hz, 1H), 8.36 (d, <i>J</i> = 1.8 Hz, 1H), 8.02 (s, 1H), 7.98 (d, <i>J</i> = 8.9 Hz, 1H), 7.92 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.03–7.00 (m, 1H), 6.97–6.93 (m, 1H), 6.78 (dd, <i>J</i> = 8.0, 1.1 Hz, 1H), 6.64 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.61–6.56 (m, 1H), 6.47 (d, <i>J</i> = 2.0 Hz, 1H), 4.84 (s, 2H), 4.50–4.44 (m, 1H), 3.64 (s, 3H), 3.58 (s, 3H), 3.12–3.09 (m, 2H), 3.00–2.98 (m, 2H), 2.44 (t, <i>J</i> = 7.5 Hz, 2H), 2.16–1.96 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 189.9, 172.7, 172.1, 166.1, 151.0, 145.3, 145.0, 143.6, 139.2, 133.5, 131.8, 130.5, 129.4, 128.7, 126.1, 125.9, 125.6, 124.7, 116.5, 115.5, 112.8, 111.8, 52.0, 51.9, 51.3, 35.7, 33.8, 29.9, 25.6.</div></div><div id="sec4_2_3_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Methyl 3-(8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoate (<b>65</b>)</h3><div class="NLM_p last">Compound <b>65</b> was prepared according to General Procedure B using <b>53</b> (0.050 g, 0.14 mmol) and methyl 3-aminopropanoate (0.021 g, 0.15 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.061 g (99%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 442.1 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.69–8. 67 (m, 1H), 8.32 (s, 1H), 8.03–7.98 (m, 2H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 7.8 Hz, 1H), 7.03 (d, <i>J</i> = 7.8 Hz, 1H), 6.98–6.94 (m, 1H), 6.80 (d, <i>J</i> = 7.8 Hz, 1H), 6.66–6.58 (m, 2H), 6.48 (br. s, 1H), 4.88 (br. s, 2H), 3.61 (s, 3H), 3.53–3.47 (m, 2H), 3.11–3.08 (m, 2H), 3.03–2.98 (m, 2H), 2.61 (t, <i>J</i> = 6.8 Hz, 2H).</div></div><div id="sec4_2_3_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Methyl (8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-methioninate (<b>66</b>)</h3><div class="NLM_p last">Compound <b>66</b> was prepared according to General Procedure B using <b>53</b> (0.070 g, 0.20 mmol) and <span class="smallcaps smallerCapital">l</span>-methionine methyl ester hydrochloride (0.043 g, 0.21 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.012 g (12%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 502.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2920, 2852, 1737, 1604, 1575, 1504, 1444, 1353, 1256, 1209, 742. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (s, 1H), 7.98 (d, <i>J</i> = 8.7 Hz, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.45–7.21 (m, 3H + solvent peak), 7.16–7.05 (m, 3H), 7.01–6.97 (m 1H), 6.66–6.64 (m, 1H), 6.48 (s, 1H), 4.95–4.90 (m, 2H), 3.80–3.73 (m, 4H), 3.05–3.03 (m, 2H), 2.95–2.93 (m, 2H), 2.59 (t, <i>J</i> = 7.4 Hz, 2H), 2.32–2.22 (m, 1H), 2.18–2.00 (m, 4H). <sup>13</sup>C NMR (100 MHzCDCl<sub>3</sub>) δ 191.3, 172.6, 166.5, 149.2, 145.5, 145.4, 143.6, 139.1, 138.0, 134.1, 132.2, 132.0, 131.7, 130.1, 129.3, 128.9, 128.1, 126.3, 126.1, 114.1, 113.0, 52.6, 52.1, 35.7, 34.6, 30.2, 29.7, 15.4.</div></div><div id="sec4_2_3_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Methyl <i>N</i>2-(((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)-<i>N</i>6-(8-((2-aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-lysinate (<b>67</b>)</h3><div class="NLM_p last">Compound <b>67</b> was prepared according to General Procedure B using <b>53</b> (0.100 g, 0.28 mmol) and <i>N</i>-α-Fmoc-<span class="smallcaps smallerCapital">l</span>-lysine methyl ester (<b>S1</b>) (0.234 g, 0.56 mmol). Product was used in the next step without further purification.</div></div><div id="sec4_2_3_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 8-((2-Aminophenyl)amino)-5-oxo-<i>N</i>-(2-(piperazin-1-yl)ethyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>68</b>)</h3><div class="NLM_p last">Compound <b>68</b> was prepared according to General Procedure C starting from <b>58</b> (0.010 g, 0.02 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH [7 N NH<sub>3</sub>] 1:0 to 9:1). Yield: 0.006 g (67%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 470.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 8.12 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (s, 1H), 7.16–7.06 (m, 2H), 6.84–6.75 (m, 2H), 6.64 (dd, <i>J</i> = 1.6, 8.6 Hz, 1H), 6.42 (d, <i>J</i> = 5.7 Hz, 1H), 3.55–3.51 (m, 2H), 3.16–3.06 (m, 8H), 2.68–2.64 (m, 6H), (NH, NH, NH, NH<sub>2</sub> not visible).</div></div><div id="sec4_2_3_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carbonyl)-<span class="smallcaps smallerCapital">l</span>-glutamic Acid (<b>69</b>)</h3><div class="NLM_p last">Compound <b>69</b> was prepared according to General Procedure A starting from carboxylic ester <b>64</b> (0.066 g, 0.13 mmol). Yield: 0.052 g (84%), yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 486.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 2922, 2852, 1714, 1603, 1519, 1451, 1394, 1266, 1101, 743. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (d, <i>J</i> = 7.7 Hz, 1H), 8.38 (d, <i>J</i> = 1.8 Hz, 1H), 8.03 (s, 1H), 8.00–7.97 (m, 2H), 7.94 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H), 7.73–7.71 (m, 1H), 7.57–7.53 (m, 1H), 7.43–7.40 (m, 2H), 7.04 (dd, <i>J</i> = 1.1, 7.7 Hz, 1H), 6.99–6.94 (m, 1H), 6.81 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 6.66–6.59 (m, 2H), 6.48 (d, <i>J</i> = 2.0 Hz, 1H), 4.44–4.38 (m, 1H), 3.12–3.09 (m, 2H), 3.01–2.99 (m, 2H), 2.35 (t, <i>J</i> = 7.4 Hz, 2H), 2.14–2.05 (m, 1H), 2.00–1.92 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.0, 173.8, 173.3, 166.0, 150.9, 145.3, 144.8, 143.0, 139.2, 133.5, 132.2, 130.5, 129.4, 128.7, 126.1, 125.9, 125.7, 124.6, 116.9, 115.9, 112.9, 111.9, 52.0, 35.7, 33.8, 30.4, 25.8.</div></div><div id="sec4_2_3_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 3-(8-((2-Aminophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamido)propanoic Acid (<b>70</b>)</h3><div class="NLM_p last">Compound <b>70</b> was prepared according to General Procedure A starting from carboxylic ester <b>65</b> (0.050 g, 0.12 mmol). Yield: 0.042 g (85%), yellow solid. MS (ESI<sub>pos</sub>) (<i>m</i>/<i>z</i>): 428.4 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 12.20 (br. s, 1H), 8.66–8.64 (m, 1H), 8.32 (s, 1H), 8.02–7.98 (m, 2H), 7.90 (d, <i>J</i> = 7.3 Hz, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.03 (d, <i>J</i> = 7.3 Hz, 1H), 6.97–6.93 (m, 1H), 6.79 (d, <i>J</i> = 7.8 Hz, 1H), 6.66–6.57 (m, 2H), 6.48 (br. s, 1H), 4.93 (br. s, 2H), 3.51–3.45 (m, 2H), 3.11–3.09 (m, 2H), 3.00–2.98 (m, 2H), 2.54–2.50 (m, 2H + solvent peak).</div></div><div id="sec4_2_3_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Methyl 8-((2-nitrophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>73</b>)</h3><div class="NLM_p last">2-Nitroaniline (0.247 g, 1.79 mmol) was dissolved in 12 mL of 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v) under an argon atmosphere. XPhos (0.025 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv), and Pd(OAc)<sub>2</sub> (0.05 equiv) followed by aryl chloride <b>3</b> (0.50 g, 1.79 mmol) were added, and the reaction mixture was heated for 1 h to 110 °C. The reaction was cooled to rt and filtered. The residue was washed several times with DCM, MeOH, and EtOAc. The combined organic extracts were evaporated, and the brown-black residue was purified by flash chromatography (SiO<sub>2</sub>, petroleum ether/ethyl acetate 3:1) to yield <b>73</b> as a yellow solid (0.48 g, 80%). MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 401.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1722, 1601, 1563, 1506, 1435, 1348, 1240, 1156, 838, 761, 640, 539. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.46 (d, <i>J</i> = 1.7 Hz, 1H), 8.10 (dd, <i>J</i> = 0.9, 8.3 Hz, 1H), 8.04–8.01 (m, 2H), 7.64–7.60 (m, 1H), 7.58–7.56 (m, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 7.14–7.09 (m, 2H), 3.87 (s, 3H), 3.21–3.19 (m, 2H), 3.14–3.12 (m, 2H), (NH not visible). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.8, 165.6, 147.1, 145.2, 144.8, 138.6, 137.7, 137.5, 135.3, 132.9, 132.2, 131.1, 130.6, 129.8, 128.1, 126.1, 121.2, 120.5, 118.9, 116.9, 52.0, 34.5, 33.9.</div></div><div id="sec4_2_3_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 8-((2-Nitrophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic Acid (<b>74</b>)</h3><div class="NLM_p last">Compound <b>74</b> was prepared according to General Procedure A starting from carboxylic ester <b>73</b> (0.15 g, 2.37 mmol). Yield: 0.137 g (95%), orange solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 387.0 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1690, 1598, 1571, 1495, 1345, 1253, 1115, 882, 741, 507. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.31 (s, 1H), 8.44 (d, <i>J</i> = 1.8 Hz, 1H), 8.10 (d, <i>J</i> = 8.4, 1.3 Hz, 1H), 8.04–8.00 (m, 2H), 7.65–7.61 (m, 1 H), 7.57–7.49 (m, 2H), 7.17 (dd, <i>J</i> = 2.1, 8.7 Hz, 1H), 7.14–7.10 (m, 2H), 3.12–3.10 (m, 2H), 3.21–3.18 (m, 2H), (COOH not visible). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.9, 165.7, 147.2, 145.6, 144.8, 138.7, 137.8, 137.8, 135.5, 133.0, 132.4, 131.2, 130 6, 130.0, 128.2, 126.2, 121.5, 120.9, 119.0, 117.0, 34.6, 34.0.</div></div><div id="sec4_2_3_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> <i>N</i>-Methyl-8-((2-nitrophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>75</b>)</h3><div class="NLM_p last">Compound <b>75</b> was prepared according to General Procedure B using <b>74</b> (0.050 g, 0.13 mmol) and methylamine (2 N THF) (0.010 g, 0.32 mmol). Purification: flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1). Yield: 0.045 g (87%), yellow solid. M (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 400.3 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.32 (s, 1H), 8.58–8.54 (m, 1H), 8.35 (s, 1H), 8.11 (d, <i>J</i> = 8.2 Hz, 1H), 8.02 (d, <i>J</i> = 8.6 Hz, 1H), 7.94 (d, <i>J</i> = 7.4 Hz, 1H), 7.65–7.61 (m, 1H), 7.57–7.55 (m, 1H), 7.44 (d, <i>J</i> = 7.9 Hz, 1H), 7.22–7.19 (m, 1H), 7.14–7.10 (m, 2H), 3.19–3.16 (m, 2H), 3.14–3.12 (m, 2H), 2.79 (d, <i>J</i> = 4.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 191.4, 165.8, 145.2, 144.7, 144.5, 138.4, 137.8, 137.6, 135.3, 132.9, 132.7, 130.9, 130.5, 129.2, 128.9, 126.1, 121.2, 120.6, 119.1, 117.0, 34.7, 33.7, 26.2.</div></div><div id="sec4_2_3_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 8-((2-Aminophenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>76</b>)</h3><div class="NLM_p last">The nitro compound <b>75</b> (0.030 g, 0.07 mmol) was dissolved in EtOH (40 mL) with heating (50 °C). SnCl<sub>2</sub> (3 equiv) was added in one portion, and the reaction was heated to reflux temperature. After completion of the reaction, the reaction was cooled to rt, and NaHCO<sub>3</sub> was carefully added and stirred for another 15 min. Then, EtOH was removed under reduced pressure, and the residue was extracted three times with EtOAc. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography (SiO<sub>2</sub>, DCM/MeOH 1:0 to 9:1) to yield <b>76</b> (0.020 mg, 69%) as a yellow solid. MS (ESI<sub>neg</sub>) (<i>m</i>/<i>z</i>): 370.1 [M – H]<sup>−</sup>. IR (ATR) [cm<sup>–1</sup>] 1633, 1603, 1574, 1455, 1403, 1353, 1262, 1111, 853, 745. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54–8.53 (m, 1H), 8.33 (s, 1H), 8.02 (s, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 1H), 7.92–7.84 (m, 1H), 7.38 (d, <i>J</i> = 7.9 Hz, 1H), 7.02 (d, <i>J</i> = 7.5 Hz, 1H), 6.95 (t, <i>J</i> = 7.4 Hz, 1H), 6.78 (d, <i>J</i> = 7.7 Hz, 1H), 6.64 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 6.61–6.57 (m, 1H), 6.48–6.47 (m, 1H), 4.86 (s, 2H), 3.11–3.07 (m, 2H), 3.02–2.99 (m, 2H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 189.9, 166.0, 150.9, 145.3, 144.4, 143.7, 139.1, 133.5, 132.8, 130.0, 129.1, 128.7, 126.1, 125.8, 125.7, 124.8, 116.4, 115.5, 112.8, 111.8, 35.7, 33.8, 26.2.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> p38α MAP Kinase Activity Assay</h3><div class="NLM_p last">The inhibitory activity of the final compounds was tested using a protocol reported by Goettert et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In detail, 96-well plates were coated with 50 μL/well (10 μg/mL) in Tris-buffered saline (TBS) of ATF-2 and stored overnight at 4 °C. In the next morning, each plate was washed with water (three times), and the remaining binding sites were blocked with blocking buffer (0.05% Tween 20, 0.025% bovine serum albumin (BSA), and 0.02% NaN<sub>3</sub> in TBS) for 30 min at rt and washed again with water (three times). A 10 mM stock solution of the test compound in DMSO was further diluted in a kinase buffer (12 ng/50 μL activated p38α MAPK, 50 mM Tris of pH 7.5, 10 mM MgCl<sub>2</sub>, 10 mM β-glycerophosphate, 100 μg/mL BSA, 1 mM dithiothreitol, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, and 100 μM ATP). 50 μL of each dilution was pipetted into the corresponding wells and incubated for 1 h at 37 °C. After washing with water (three times), blocking for 15 min, and washing with water (three times), a diluted monoclonal antiphospho-ATF-2 (Thyr69/71)-peroxidase-conjugated antibody (1:5000) in blocking buffer (50 μL) adjusted to a pH of 6.5 was added to each well. After incubation for 1 h at 37 °C, 3,3′,5,5′-tetramethylbenzidine (50 μL) was added to all wells, and the peroxide-labeled conjugates developed a definitive blue color that was measured photometrically at 650 nm.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01773" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01773?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01773</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Detailed procedures for the preparation of compounds <b>45</b>–<b>51</b>, <b>70</b>–<b>72</b>, and <b>S1</b>, CNS penetration studies, in vitro metabolic stability study, CYP and hERG inhibition, the selectivity screening as well as selected HPLC traces and NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES strings of tested compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf">jm0c01773_si_001.pdf (4.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_002.csv">jm0c01773_si_002.csv (5.98 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01773" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Koch</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical
Sciences, Eberhard Karls Universität
Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical/Medicinal Chemistry II, Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4620-4650" title="Orcid link">http://orcid.org/0000-0003-4620-4650</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4838212d3a3a2d6623272b20083d2621653c3d2d2a21262f2d26662c2d6838212d3a3a2d6623272b20083d3a662c2d"><span class="__cf_email__" data-cfemail="2e5e474b5c5c4b0045414d466e5b4047035a5b4b4c4740494b40004a4b">[email protected]</span> <span class="__cf_email__" data-cfemail="e1918884939384cf8a8e8289a19493cf8584">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Niklas M. Tormählen</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical
Sciences, Eberhard Karls Universität
Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariella Martorelli</span> - <span class="hlFld-Affiliation affiliation">Synovo
GmbH, Paul-Ehrlich-Str.
15, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annette Kuhn</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical
Sciences, Eberhard Karls Universität
Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florian Maier</span> - <span class="hlFld-Affiliation affiliation">Synovo
GmbH, Paul-Ehrlich-Str.
15, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jamil Guezguez</span> - <span class="hlFld-Affiliation affiliation">Synovo
GmbH, Paul-Ehrlich-Str.
15, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Burnet</span> - <span class="hlFld-Affiliation affiliation">Synovo
GmbH, Paul-Ehrlich-Str.
15, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wolfgang Albrecht</span> - <span class="hlFld-Affiliation affiliation">Teva-ratiopharm, Graf-Arco-Str. 3, 89079 Ulm, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan A. Laufer</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical
Sciences, Eberhard Karls Universität
Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>N.M.T. and M.M. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): M.M., F.M., J.G., and M.B. are employees of Synovo GmbH, a pharmaceutical company that has an interest in the development of this class of compounds.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7843-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Jens Strobach and Katharina Bauer for their assistance in the p38α MAP kinase ELISA activity assay. Dr. Michael Forster and Dr. Stanislav Andreev are gratefully acknowledged for synthetic and analytical support. We thank Mark Kudolo for his support with metabolism data of compounds <b>44</b> and <b>70</b>. This study was supported by the Federal Ministry of Education and Research (BMBF) within the BioPharma-Neuroallianz consortium (Neuro-T8B project). We also thank the pharmacology staff of Synovo GmbH, Luciano De Oliveira, Thilo Weinstein, Christina Frech, Natascha Cloos, and Santiago Cruces, for their assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">HBC</td><td class="NLM_def"><p class="first last">human buffy coat</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hydrophobic region</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatography mass spectrometry</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MWB</td><td class="NLM_def"><p class="first last">mouse whole blood</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mitogen-activated protein</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laydon, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keys, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landvatter, S. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A protein kinase involved in the regulation of inflammatory cytokine biosynthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1038/372739a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2F372739a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=7997261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=739-746&author=J.+C.+Leeauthor=J.+T.+Laydonauthor=P.+C.+McDonnellauthor=T.+F.+Gallagherauthor=S.+Kumarauthor=D.+Greenauthor=D.+McNultyauthor=M.+J.+Blumenthalauthor=J.+R.+Keysauthor=S.+W.+Landvatter&title=A+protein+kinase+involved+in+the+regulation+of+inflammatory+cytokine+biosynthesis&doi=10.1038%2F372739a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A protein kinase involved in the regulation of inflammatory cytokine biosynthesis</span></div><div class="casAuthors">Lee, John C.; Laydon, Jeffrey T.; McDonnell, Peter C.; Gallagher, Timothy F.; Kumar, Sanjay; Green, David; McNulty, Dean; Blumenthal, Mary Jane; Heyes, J. Richard; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">739-46</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Prodn. of interleukin-1 and tumor necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compds.  Using radiolabeled and radio-photoaffinity-labeled chem. probes, the target of these compds. was identified as a pair of closely related mitogen-activated protein kinase homologues, termed CSBPs.  Binding of the pyridinyl-imidazole compds. inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine prodn., suggesting that the CSBPs are crit. for cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExKJsn1CnWrVg90H21EOLACvtfcHk0lgN1iUFzDeQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu70%253D&md5=cfda8b8e5c29e323029c4f03056a1753</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F372739a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372739a0%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLaydon%26aufirst%3DJ.%2BT.%26aulast%3DMcDonnell%26aufirst%3DP.%2BC.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DMcNulty%26aufirst%3DD.%26aulast%3DBlumenthal%26aufirst%3DM.%2BJ.%26aulast%3DKeys%26aufirst%3DJ.%2BR.%26aulast%3DLandvatter%26aufirst%3DS.%2BW.%26atitle%3DA%2520protein%2520kinase%2520involved%2520in%2520the%2520regulation%2520of%2520inflammatory%2520cytokine%2520biosynthesis%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D739%26epage%3D746%26doi%3D10.1038%2F372739a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammit, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2009.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neuropharm.2009.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=19951717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtleqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=561-568&author=L.+Munozauthor=A.+J.+Ammit&title=Targeting+p38+MAPK+pathway+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neuropharm.2009.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting p38 MAPK pathway for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Munoz, Lenka; Ammit, Alaina J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">561-568</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence indicates that p38 mitogen-activated protein kinase (MAPK) could play more than one role in Alzheimer's disease (AD) pathophysiol. and that patients suffering from AD dementia could benefit from p38 MAPK inhibitors.  The p38 MAPK signaling has been widely accepted as a cascade contributing to neuroinflammation.  However, deepening insight into the underlying biol. of Alzheimer's disease reveals that p38 MAPK operates in other events related to AD, such as excitotoxicity, synaptic plasticity and tau phosphorylation.  Although quantification of behavioral improvements upon p38 MAPK inhibition and in vivo evaluation of p38 MAPK significance to various aspects of AD pathol. is still missing, the p38 MAPK is emerging as a new Alzheimer's disease treatment strategy.  Thus, we present here an update on the role of p38 MAPK in neurodegeneration, with a focus on Alzheimer's disease, by summarizing recent literature and several key papers from earlier years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4jWRQKVkrbVg90H21EOLACvtfcHk0lgB31dHO_t2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtleqtg%253D%253D&md5=04498c72e3a4b432f08b21a55de52bb0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2009.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2009.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DAmmit%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520p38%2520MAPK%2520pathway%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D58%26spage%3D561%26epage%3D568%26doi%3D10.1016%2Fj.neuropharm.2009.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-4-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2F1742-2094-4-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=17784957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=21&author=L.+Munozauthor=H.+Ranaivoauthor=S.+M.+Royauthor=W.+Huauthor=J.+M.+Craftauthor=L.+K.+McNamaraauthor=L.+W.+Chicoauthor=L.+J.+van+Eldikauthor=D.+M.+Watterson&title=A+novel+p38+alpha+MAPK+inhibitor+suppresses+brain+proinflammatory+cytokine+up-regulation+and+attenuates+synaptic+dysfunction+and+behavioral+deficits+in+an+Alzheimer%E2%80%99s+disease+mouse+model&doi=10.1186%2F1742-2094-4-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model</span></div><div class="casAuthors">Munoz Lenka; Ralay Ranaivo Hantamalala; Roy Saktimayee M; Hu Wenhui; Craft Jeffrey M; McNamara Laurie K; Chico Laura Wing; Van Eldik Linda J; Watterson D Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An accumulating body of evidence is consistent with the hypothesis that excessive or prolonged increases in proinflammatory cytokine production by activated glia is a contributor to the progression of pathophysiology that is causally linked to synaptic dysfunction and hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD).  This raises the opportunity for the development of new classes of potentially disease-modifying therapeutics.  A logical candidate CNS target is p38 alpha MAPK, a well-established drug discovery molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders.  Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell culture studies strongly implicate p38 MAPK in the increased production of proinflammatory cytokines by glia activated with human amyloid-beta (A beta) and other disease-relevant stressors.  However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative disorders.  The goal of this study was to test the hypothesis that brain p38 alpha MAPK is a potential in vivo target for orally bioavailable, small molecules capable of suppressing excessive cytokine production by activated glia back towards homeostasis, allowing an improvement in neurologic outcomes.  METHODS:  A novel synthetic small molecule based on a molecular scaffold used previously was designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability, metabolic stability, safety and brain uptake.  Testing for in vivo efficacy used an AD-relevant mouse model.  RESULTS:  A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38 alpha MAPK (MW01-2-069A-SRM) was developed.  Oral administration of the compound at a low dose (2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the hippocampus back towards normal in the animal model.  Animals with attenuated cytokine production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.  CONCLUSION:  The p38 alpha MAPK pathway is quantitatively important in the A beta-induced production of proinflammatory cytokines in hippocampus, and brain p38 alpha MAPK is a viable molecular target for future development of potential disease-modifying therapeutics in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsGGsjPM4Dps25P7XSLhESfW6udTcc2ebTX3vsceHa67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D&md5=e7768f444f68015f134d42880ed01f3b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-4-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-4-21%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DRanaivo%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCraft%26aufirst%3DJ.%2BM.%26aulast%3DMcNamara%26aufirst%3DL.%2BK.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3Dvan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520novel%2520p38%2520alpha%2520MAPK%2520inhibitor%2520suppresses%2520brain%2520proinflammatory%2520cytokine%2520up-regulation%2520and%2520attenuates%2520synaptic%2520dysfunction%2520and%2520behavioral%2520deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520mouse%2520model%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2007%26volume%3D4%26spage%3D21%26doi%3D10.1186%2F1742-2094-4-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takigami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, K.</span></span> <span> </span><span class="NLM_article-title">p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.2174/187152411794961040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.2174%2F187152411794961040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=20812905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=45-59&author=S.+Yasudaauthor=H.+Sugiuraauthor=H.+Tanakaauthor=S.+Takigamiauthor=K.+Yamagata&title=p38+MAP+kinase+inhibitors+as+potential+therapeutic+drugs+for+neural+diseases&doi=10.2174%2F187152411794961040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases</span></div><div class="casAuthors">Yasuda, S.; Sugiura, H.; Tanaka, H.; Takigami, S.; Yamagata, K.</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-59</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mammalian p38 mitogen-activated protein kinases (MAPKs) are activated by various cellular stresses, as well as in response to inflammatory cytokines.  In the central nervous systems (CNS), activation of the p38 MAPK pathway constitutes a key step in the development of several diseases, and the mol. mechanisms mediated by p38 MAPK signaling were defined.  Activation of this cascade releases pro-inflammatory cytokines that are known to be involved in cerebral ischemia, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), neuropathic pain, and depression.  In AD, stimulated p38 MAPK may trigger the hyperphosphorylation of a neural microtubule-assocd. protein, tau.  In addn., we have recently revealed that activation of p38 MAPK signaling decreases dendritic spine no., which may be assocd. with memory impairment after epileptic seizures.  Thus, p38 MAPK can serve as a target for novel drug development for neural diseases.  P38 MAPK inhibitors were studied extensively in both preclin. expts. and clin. trials for inflammatory diseases.  New p38 MAPK inhibitors are now being tested in phase II clin. trials for neuropathic pain and depression.  Here, we review current and possible future applications of p38 MAPK inhibitors as therapeutic agents in neural diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HV5bKiYj1rVg90H21EOLACvtfcHk0lgB31dHO_t2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOrs74%253D&md5=a0a649cb3eec96cf5a2c54676f3dc139</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F187152411794961040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152411794961040%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DS.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTakigami%26aufirst%3DS.%26aulast%3DYamagata%26aufirst%3DK.%26atitle%3Dp38%2520MAP%2520kinase%2520inhibitors%2520as%2520potential%2520therapeutic%2520drugs%2520for%2520neural%2520diseases%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D45%26epage%3D59%26doi%3D10.2174%2F187152411794961040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of alzheimer’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1287</span>, <span class="refDoi"> DOI: 10.3390/molecules22081287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fmolecules22081287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28767069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1287&author=J.+K.+Leeauthor=N.+J.+Kim&title=Recent+advances+in+the+inhibition+of+p38+MAPK+as+a+potential+strategy+for+the+treatment+of+alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules22081287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lee, Jong Kil; Kim, Nam-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1287/1-1287/23</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a crucial target for chronic inflammatory diseases.  Alzheimer's disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, as well as neurodegeneration, and there is no known cure.  Recent studies on the underlying biol. of AD in cellular and animal models have indicated that p38 MAPK is capable of orchestrating diverse events related to AD, such as tau phosphorylation, neurotoxicity, neuroinflammation and synaptic dysfunction.  Thus, the inhibition of p38 MAPK is considered a promising strategy for the treatment of AD.  In this review, we summarize recent advances in the targeting of p38 MAPK as a potential strategy for the treatment of AD and envision possibilities of p38 MAPK inhibitors as a fundamental therapeutics for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NNXguBzPobVg90H21EOLACvtfcHk0lhd2Sy6Jk6R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P&md5=9aa70ca6361ea8e5e3bf789fd5df58be</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DN.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520inhibition%2520of%2520p38%2520MAPK%2520as%2520a%2520potential%2520strategy%2520for%2520the%2520treatment%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1287%26doi%3D10.3390%2Fmolecules22081287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohush, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewiadomska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipek, A.</span></span> <span> </span><span class="NLM_article-title">Role of mitogen activated protein kinase signaling in parkinson’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2973</span>, <span class="refDoi"> DOI: 10.3390/ijms19102973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fijms19102973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Kit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2973&author=A.+Bohushauthor=G.+Niewiadomskaauthor=A.+Filipek&title=Role+of+mitogen+activated+protein+kinase+signaling+in+parkinson%E2%80%99s+disease&doi=10.3390%2Fijms19102973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mitogen activated protein kinase signaling in Parkinson's disease</span></div><div class="casAuthors">Bohush, Anastasiia; Niewiadomska, Grazyna; Filipek, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2973/1-2973/17</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a neurodegenerative disorder caused by insufficient dopamine prodn. due to the loss of 50% to 70% of dopaminergic neurons.  A shortage of dopamine, which is predominantly produced by the dopaminergic neurons within the substantia nigra, causes clin. symptoms such as redn. of muscle mass, impaired body balance, akinesia, bradykinesia, tremors, postural instability, etc.  Lastly, this can lead to a total loss of phys. movement and death.  Since no cure for PD has been developed up to now, researchers using cell cultures and animal models focus their work on searching for potential therapeutic targets in order to develop effective treatments.  In recent years, genetic studies have prominently advocated for the role of improper protein phosphorylation caused by a dysfunction in kinases and/or phosphatases as an important player in progression and pathogenesis of PD.  Thus, in this review, we focus on the role of selected MAP kinases such as JNKs, ERK1/2, and p38 MAP kinases in PD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3PM60Re5EgrVg90H21EOLACvtfcHk0lhd2Sy6Jk6R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Kit7s%253D&md5=c8555d7b0c4f33a1011121be8b857e58</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fijms19102973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19102973%26sid%3Dliteratum%253Aachs%26aulast%3DBohush%26aufirst%3DA.%26aulast%3DNiewiadomska%26aufirst%3DG.%26aulast%3DFilipek%26aufirst%3DA.%26atitle%3DRole%2520of%2520mitogen%2520activated%2520protein%2520kinase%2520signaling%2520in%2520parkinson%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2973%26doi%3D10.3390%2Fijms19102973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asih, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanoska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahel, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittner, A.</span></span> <span> </span><span class="NLM_article-title">Functions of p38 MAP kinases in the central nervous system</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">570586</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2020.570586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3389%2Ffnmol.2020.570586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=33013322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjtVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=570586&author=P.+R.+Asihauthor=E.+Prikasauthor=K.+Stefanoskaauthor=A.+R.+P.+Tanauthor=H.+I.+Ahelauthor=A.+Ittner&title=Functions+of+p38+MAP+kinases+in+the+central+nervous+system&doi=10.3389%2Ffnmol.2020.570586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of p38 MAP kinases in the central nervous system</span></div><div class="casAuthors">Asih, Prita R.; Prikas, Emmanuel; Stefanoska, Kristie; Tan, Amanda R. P.; Ahel, Holly I.; Ittner, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">570586</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Mitogen-activated protein (MAP) kinases are a central component in signaling networks in a multitude of mammalian cell types.  This review covers recent advances on specific functions of p38 MAP kinases in cells of the central nervous system.  Unique and specific functions of the four mammalian p38 kinases are found in all major cell types in the brain.  Mechanisms of p38 activation and downstream phosphorylation substrates in these different contexts are outlined and how they contribute to functions of p38 in physiol. and under disease conditions.  Results in different model organisms demonstrated that p38 kinases are involved in cognitive functions, including functions related to anxiety, addiction behavior, neurotoxicity, neurodegeneration, and decision making.  Finally, the role of p38 kinases in psychiatric and neurol. conditions and the current progress on therapeutic inhibitors targeting p38 kinases are covered and implicate p38 kinases in a multitude of CNS-related physiol. and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZhPYRMOh7Vg90H21EOLACvtfcHk0lhd2Sy6Jk6R4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjtVKgu78%253D&md5=0ae7f3111a03e64e4587f95dd81c274a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.570586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.570586%26sid%3Dliteratum%253Aachs%26aulast%3DAsih%26aufirst%3DP.%2BR.%26aulast%3DPrikas%26aufirst%3DE.%26aulast%3DStefanoska%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DA.%2BR.%2BP.%26aulast%3DAhel%26aufirst%3DH.%2BI.%26aulast%3DIttner%26aufirst%3DA.%26atitle%3DFunctions%2520of%2520p38%2520MAP%2520kinases%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26spage%3D570586%26doi%3D10.3389%2Ffnmol.2020.570586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">P38alpha MAPK signaling-a robust therapeutic target for rab5-mediated neurodegenerative disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5485</span>, <span class="refDoi"> DOI: 10.3390/ijms21155485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fijms21155485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitValu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5485&author=U.+A.+Germannauthor=J.+J.+Alam&title=P38alpha+MAPK+signaling-a+robust+therapeutic+target+for+rab5-mediated+neurodegenerative+disease&doi=10.3390%2Fijms21155485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">P38α MAPK signaling-A robust therapeutic target for Rab5-mediated neurodegenerative disease</span></div><div class="casAuthors">Germann, Ursula A.; Alam, John J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5485</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Multifactorial pathologies, involving one or more aggregated protein(s) and neuroinflammation are common in major neurodegenerative diseases, such as Alzheimer's disease and dementia with Lewy bodies.  This complexity of multiple pathogenic drivers is one potential explanation for the lack of success or, at best, the partial therapeutic effects, resp., with approaches that have targeted one specific driver, e.g., amyloid-beta, in Alzheimer's disease.  Since the endosome-assocd. protein Rab5 appears to be a convergence point for many, if not all the most prominent pathogenic drivers, it has emerged as a major therapeutic target for neurodegenerative disease.  Further, since the alpha isoform of p38 mitogen-activated protein kinase (p38α) is a major regulator of Rab5 activity and its effectors, a biol. that is distinct from the classical nuclear targets of p38 signaling, brain-penetrant selective p38α kinase inhibitors provide the opportunity for significant therapeutic advances in neurogenerative disease through normalizing dysregulated Rab5 activity.  In this review, we provide a brief summary of the role of Rab5 in the cell and its assocn. with neurodegenerative disease pathogenesis.  We then discuss the connection between Rab5 and p38α and summarize the evidence that through modulating Rab5 activity there are therapeutic opportunities in neurodegenerative diseases for p38α kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-fzrDckdwbVg90H21EOLACvtfcHk0lhGOSH9bM7qeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitValu77P&md5=d899501ec90d3241a4ea5a4b5f9220e6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fijms21155485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21155485%26sid%3Dliteratum%253Aachs%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DP38alpha%2520MAPK%2520signaling-a%2520robust%2520therapeutic%2520target%2520for%2520rab5-mediated%2520neurodegenerative%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5485%26doi%3D10.3390%2Fijms21155485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nael, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pye, Q. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geddes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markesbery, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">p38 Kinase is activated in the alzheimer’s disease brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2053</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1999.0722053.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1046%2Fj.1471-4159.1999.0722053.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10217284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADyaK1MXis12lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2053-2058&author=K.+Hensleyauthor=R.+A.+Floydauthor=N.-Y.+Zhengauthor=R.+Naelauthor=K.+A.+Robinsonauthor=X.+Nguyenauthor=Q.+N.+Pyeauthor=C.+A.+Stewartauthor=J.+Geddesauthor=W.+R.+Markesberyauthor=E.+Patelauthor=G.+V.+W.+Johnsonauthor=G.+Bing&title=p38+Kinase+is+activated+in+the+alzheimer%E2%80%99s+disease+brain&doi=10.1046%2Fj.1471-4159.1999.0722053.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">p38 kinase is activated in the Alzheimer's disease brain</span></div><div class="casAuthors">Hensley, Kenneth; Floyd, Robert A.; Zheng, Nai-Ying; Nael, Raha; Robinson, Kent A.; Nguyen, Xuan; Pye, Quentin N.; Stewart, Charles A.; Geddes, James; Markesbery, William R.; Patel, Ela; Johnson, Gail V. W.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2053-2058</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase is a stress-activated enzyme responsible for transducing inflammatory signals and initiating apoptosis.  In the Alzheimer's disease (AD) brain, increased levels of phosphorylated (active) p38 were detected relative to age-matched normal brain.  Intense phospho-p38 immunoreactivity was assocd. with neuritic plaques, neuropil threads, and neurofibrillary tangle-bearing neurons.  The antibody against phosphorylated p38 recognized many of the same structures as an antibody against aberrantly phosphorylated, paired helical filament (PHF) tau, although PHF-pos. tau did not cross-react with the phospho-p38 antibody.  These findings suggest a neuroinflammatory mechanism in the AD brain, in which aberrant protein phosphorylation affects signal transduction elements, including the p38 kinase cascade, as well as cytoskeletal components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSbqP_y3jp7Vg90H21EOLACvtfcHk0lhGOSH9bM7qeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12lt7g%253D&md5=11f53ea993906eec17fcaed8acf0dbba</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722053.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722053.x%26sid%3Dliteratum%253Aachs%26aulast%3DHensley%26aufirst%3DK.%26aulast%3DFloyd%26aufirst%3DR.%2BA.%26aulast%3DZheng%26aufirst%3DN.-Y.%26aulast%3DNael%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DX.%26aulast%3DPye%26aufirst%3DQ.%2BN.%26aulast%3DStewart%26aufirst%3DC.%2BA.%26aulast%3DGeddes%26aufirst%3DJ.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26aulast%3DPatel%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26aulast%3DBing%26aufirst%3DG.%26atitle%3Dp38%2520Kinase%2520is%2520activated%2520in%2520the%2520alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2053%26epage%3D2058%26doi%3D10.1046%2Fj.1471-4159.1999.0722053.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">P38 MAP kinase is activated at early stages in Alzheimer’s disease brain</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2FS0014-4886%2803%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=14552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2003&pages=394-405&author=A.+Sunauthor=M.+Liuauthor=X.+V.+Nguyenauthor=G.+Bing&title=P38+MAP+kinase+is+activated+at+early+stages+in+Alzheimer%E2%80%99s+disease+brain&doi=10.1016%2FS0014-4886%2803%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase is activated at early stages in Alzheimer's disease brain</span></div><div class="casAuthors">Sun, Anyang; Liu, Mei; Nguyen, Xuan V.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The regional, cellular, and subcellular localization of phosphorylated p38 MAPK (pp38) was examd. by immunocytochem., immuofluorescent multiple labeling, and immunoblotting of exts. as well as immunoppts. of human postmortem tissue from control and Alzheimer's disease (AD) cases at different Braak stages.  "Early AD" cases (Braak stages IV-V) and a subset of Braak stage VI cases have high levels of pp38 immunoreactivity, with the most dense immunoreactivity located in CA2 and subiculum followed by CA1 in the hippocampus.  On the contrary, very little pp38 was detected in age-matched controls (Braak stages 0-II).  More importantly, as revealed by various multiple labeling expts., pp38 immunoreactivity is mainly located in neurons bearing early neurofibrillary pathol., but not in typically fibrillar tangles that are densely stained by thioflavin-S.  Most pp38-pos. neurons only contain a small amt. of phospho-tau.  Addnl., pp38 immunoreactivity was not assocd. with senile plaques.  At the subcellular level, pp38-immunoreactive granules are usually larger than the granules stained with the lysosomal marker cathepsin D.  Immunoblotting with different extn. buffers and immunopptn. indicate that pp38 does not or only loosely binds to phospho-tau.  Taken together, this study demonstrates that p38 MAPK is activated at early stages of neurofibrillary degeneration in AD hippocampus.  The p38 activation may also be linked to neurodegeneration through mechanisms other than neurofibrillary tangle formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxxwaFL8EObVg90H21EOLACvtfcHk0lhGOSH9bM7qeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D&md5=9823c9aa4ce32ba4b9c68e005b198593</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DX.%2BV.%26aulast%3DBing%26aufirst%3DG.%26atitle%3DP38%2520MAP%2520kinase%2520is%2520activated%2520at%2520early%2520stages%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D183%26spage%3D394%26epage%3D405%26doi%3D10.1016%2FS0014-4886%2803%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta)</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">79</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-8-79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2F1742-2094-8-79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=21733175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Chsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=79&author=A.+D.+Bachstetterauthor=B.+Xingauthor=L.+de+Almeidaauthor=E.+R.+Dimayugaauthor=D.+M.+Wattersonauthor=L.+J.+van+Eldik&title=Microglial+p38alpha+MAPK+is+a+key+regulator+of+proinflammatory+cytokine+up-regulation+induced+by+toll-like+receptor+%28TLR%29+ligands+or+beta-amyloid+%28Abeta%29&doi=10.1186%2F1742-2094-8-79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or β-amyloid (Aβ)</span></div><div class="casAuthors">Bachstetter, Adam D.; Xing, Bin; de Almeida, Lucia; Dimayuga, Edgardo R.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Overprodn. of proinflammatory cytokines from activated microglia has been implicated as an important contributor to pathophysiol. progression in both acute and chronic neurodegenerative diseases.  Therefore, it is crit. to elucidate intracellular signaling pathways that are significant contributors to cytokine overprodn. in microglia exposed to specific stressors, esp. pathways amenable to drug interventions.  The serine/threonine protein kinase p38α MAPK is a key enzyme in the parallel and convergent intracellular signaling pathways involved in stressor-induced prodn. of IL-1β and TNFα in peripheral tissues, and is a drug development target for peripheral inflammatory diseases.  However, much less is known about the quant. importance of microglial p38α MAPK in stressor-induced cytokine overprodn., or the potential of microglial p38α MAPK to be a druggable target for CNS disorders.  Therefore, we examd. the contribution of microglial p38α MAPK to cytokine up-regulation, with a focus on the potential to suppress the cytokine increase by inhibition of the kinase with pharmacol. or genetic approaches.  Methods: The microglial cytokine response to TLR ligands 2/3/4/7/8/9 or to Aβ1-42 was tested in the presence of a CNS-penetrant p38α MAPK inhibitor, MW01-2-069A-SRM.  Primary microglia from mice genetically deficient in p38α MAPK were used to further establish a linkage between microglia p38α MAPK and cytokine overprodn.  The in vivo significance was detd. by p38α MAPK inhibitor treatment in a LPS-induced model of acute neuroinflammation.  Results: Increased IL-1β and TNFα prodn. by the BV-2 microglial cell line and by primary microglia cultures was inhibited in a concn.-dependent manner by the p38α MAPK-targeted inhibitor.  Cellular target engagement was demonstrated by the accompanying decrease in the phosphorylation state of two p38α MAPK protein substrates, MK2 and MSK1.  Consistent with the pharmacol. findings, microglia from p38α-deficient mice showed a diminished cytokine response to LPS.  Further, oral administration of the inhibitor blocked the increase of IL-1β in the cerebral cortex of mice stressed by i.p. injection of LPS.  Conclusion: The p38α MAPK pathway is an important contributor to the increased microglial prodn. of proinflammatory cytokines induced by diverse stressors.  The results also indicate the feasibility of targeting p38α MAPK to modulate CNS proinflammatory cytokine overprodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGord0XtmYvAdbVg90H21EOLACvtfcHk0lhIaYmHzFRpuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Chsrg%253D&md5=b8157c399f427d3ed42662ddb7c38ec9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-8-79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-8-79%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DXing%26aufirst%3DB.%26aulast%3Dde%2BAlmeida%26aufirst%3DL.%26aulast%3DDimayuga%26aufirst%3DE.%2BR.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3Dvan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DMicroglial%2520p38alpha%2520MAPK%2520is%2520a%2520key%2520regulator%2520of%2520proinflammatory%2520cytokine%2520up-regulation%2520induced%2520by%2520toll-like%2520receptor%2520%2528TLR%2529%2520ligands%2520or%2520beta-amyloid%2520%2528Abeta%2529%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2011%26volume%3D8%26spage%3D79%26doi%3D10.1186%2F1742-2094-8-79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eales, K. L.</span></span> <span> </span><span class="NLM_article-title">The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease</span>. <i>J. Signal Transduction</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">649079</span>, <span class="refDoi"> DOI: 10.1155/2012/649079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1155%2F2012%2F649079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=22792454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC38fps1ajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=649079&author=S.+A.+Correaauthor=K.+L.+Eales&title=The+role+of+p38+MAPK+and+its+substrates+in+neuronal+plasticity+and+neurodegenerative+disease&doi=10.1155%2F2012%2F649079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease</span></div><div class="casAuthors">Correa Sonia A L; Eales Katherine L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of signal transduction</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">649079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A significant amount of evidence suggests that the p38-mitogen-activated protein kinase (MAPK) signalling cascade plays a crucial role in synaptic plasticity and in neurodegenerative diseases.  In this review we will discuss the cellular localisation and activation of p38 MAPK and the recent advances on the molecular and cellular mechanisms of its substrates: MAPKAPK 2 (MK2) and tau protein.  In particular we will focus our attention on the understanding of the p38 MAPK-MK2 and p38 MAPK-tau activation axis in controlling neuroinflammation, actin remodelling and tau hyperphosphorylation, processes that are thought to be involved in normal ageing as well as in neurodegenerative diseases.  We will also give some insight into how elucidating the precise role of p38 MAPK-MK2 and p38 MAPK-tau signalling cascades may help to identify novel therapeutic targets to slow down the symptoms observed in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLN5iKnx8eIaNc3HjJRoFAfW6udTcc2eaa3mC00tOzarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fps1ajsg%253D%253D&md5=fdb09a2f06c0bcf8bc0dc6a90199c709</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1155%2F2012%2F649079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F649079%26sid%3Dliteratum%253Aachs%26aulast%3DCorrea%26aufirst%3DS.%2BA.%26aulast%3DEales%26aufirst%3DK.%2BL.%26atitle%3DThe%2520role%2520of%2520p38%2520MAPK%2520and%2520its%2520substrates%2520in%2520neuronal%2520plasticity%2520and%2520neurodegenerative%2520disease%26jtitle%3DJ.%2520Signal%2520Transduction%26date%3D2012%26volume%3D2012%26spage%3D649079%26doi%3D10.1155%2F2012%2F649079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evindar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taslimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M. S.</span></span> <span> </span><span class="NLM_article-title">The discovery of VX-745: a novel and selective p38alpha kinase inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/ml2001455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2001455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslyisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=758-63&author=J.+P.+Duffyauthor=E.+M.+Harringtonauthor=F.+G.+Salituroauthor=J.+E.+Cochranauthor=J.+Greenauthor=H.+Gaoauthor=G.+W.+Bemisauthor=G.+Evindarauthor=V.+P.+Galulloauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=K.+P.+Wilsonauthor=S.+F.+Bellonauthor=G.+Chenauthor=P.+Taslimiauthor=P.+Jonesauthor=C.+Huangauthor=S.+Pazhanisamyauthor=Y.+M.+Wangauthor=M.+A.+Murckoauthor=M.+S.+Su&title=The+discovery+of+VX-745%3A+a+novel+and+selective+p38alpha+kinase+inhibitor&doi=10.1021%2Fml2001455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor</span></div><div class="casAuthors">Duffy, John P.; Harrington, Edmund M.; Salituro, Francesco G.; Cochran, John E.; Green, Jeremy; Gao, Huai; Bemis, Guy W.; Evindar, Ghotas; Galullo, Vincent P.; Ford, Pamella J.; Germann, Ursula A.; Wilson, Keith P.; Bellon, Steven F.; Chen, Guanging; Taslimi, Paul; Jones, Peter; Huang, Cassey; Pazhanisamy, S.; Wang, Yow-Ming; Murcko, Mark A.; Su, Michael S. S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">758-763</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of novel, selective, orally active 2,5-disubstituted 6H-pyrimido[1,6-b]pyridazin-6-one p38α inhibitors is described.  Application of structural information from enzyme-ligand complexes guided the selection of screening compds., leading to the identification of a novel class of p38α inhibitors contg. a previously unreported bicyclic heterocycle core.  Advancing the SAR of this series led to the eventual discovery of 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one (VX-745).  VX-745 displays excellent enzyme activity and selectivity, has a favorable pharmacokinetic profile, and demonstrates good in vivo activity in models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaK679ix1VbVg90H21EOLACvtfcHk0lhIaYmHzFRpuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslyisr8%253D&md5=0d8f33f1602b60ec760702c29d0881b0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml2001455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2001455%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DHarrington%26aufirst%3DE.%2BM.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DCochran%26aufirst%3DJ.%2BE.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DGalullo%26aufirst%3DV.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DSu%26aufirst%3DM.%2BS.%26atitle%3DThe%2520discovery%2520of%2520VX-745%253A%2520a%2520novel%2520and%2520selective%2520p38alpha%2520kinase%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D758%26epage%3D63%26doi%3D10.1021%2Fml2001455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D.</span></span> <span> </span><span class="NLM_article-title">Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early alzheimer’s disease</span>. <i>J. Prev. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.14283/jpad.2017.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.14283%2Fjpad.2017.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=29181493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lsFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=273-278&issue=4&author=J.+Alamauthor=K.+Blackburnauthor=D.+Patrick&title=Neflamapimod%3A+clinical+phase+2b-ready+oral+small+molecule+inhibitor+of+p38alpha+to+reverse+synaptic+dysfunction+in+early+alzheimer%E2%80%99s+disease&doi=10.14283%2Fjpad.2017.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease</span></div><div class="casAuthors">Alam J; Blackburn K; Patrick D</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neflamapimod (previously code named VX-745) is a clinical phase 2b-ready highly specific inhibitor of the intra-cellular enzyme p38 mitogen activated protein kinase alpha ("p38α") that is being developed as a disease-modifying drug for Alzheimer's disease (AD) that acts via targeting synaptic dysfunction.  Neflamapimod was discovered through a proprietary structure-based drug discovery platform at Vertex Pharmaceuticals, and developed previously by Vertex through to phase 2a in rheumatoid arthritis.  EIP Pharma licensed the compound in 2014 for development and commercialization as a treatment of central nervous system (CNS) disorders.  Neflamapimod is the most advanced in the clinic drug that targets specific molecular mechanisms within neurons that leads to synaptic dysfunction, the pathogenic process that is now considered to be a major driver of the development of memory deficits and disease progression in the early stages of AD.  Based on the scientific rationale of targeting synaptic dysfunction and the preclinical data, neflamapimod has the potential to both reverse memory deficits and slow disease progression.  Phase 2a clinical data in patients with early-stage AD (MMSE 20-28, biomarker positive) provides evidence that the preclinical science may be translatable to human Alzheimer's, as 6- to 12-weeks of neflamapimod treatment led to significant improvement in episodic memory, the best clinical measure of synaptic dysfunction in AD.  A phase 2b six-month placebo-controlled 150-patient clinical study is anticipated to start by end of 2017.  This study is designed to definitively demonstrate that neflamapimod reverses memory deficits, and also to provide preliminary evidence that the drug slows disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQg8yIA1XjIYeLt9HypzAgQfW6udTcc2eYBA57blxEiqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lsFOruw%253D%253D&md5=c827d1da4d3ef35252dddeeb46eb5cc8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2017.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2017.41%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DPatrick%26aufirst%3DD.%26atitle%3DNeflamapimod%253A%2520clinical%2520phase%25202b-ready%2520oral%2520small%2520molecule%2520inhibitor%2520of%2520p38alpha%2520to%2520reverse%2520synaptic%2520dysfunction%2520in%2520early%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2017%26volume%3D4%26issue%3D4%26spage%3D273%26epage%3D278%26doi%3D10.14283%2Fjpad.2017.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.3233/JAD-150277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3233%2FJAD-150277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=26401942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=219-227&author=J.+J.+Alam&title=Selective+brain-targeted+antagonism+of+p38+MAPKalpha+reduces+hippocampal+IL-1beta+levels+and+improves+morris+water+maze+performance+in+aged+rats&doi=10.3233%2FJAD-150277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats</span></div><div class="casAuthors">Alam John J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  P38 mitogen activated protein kinase (MAPK) α modulates microglia-mediated inflammatory responses and a number of neuronal physiological processes.  OBJECTIVE:  To evaluate pre-clinically the pharmacological effects in the brain of p38 MAPKα inhibition with a brain-penetrant specific chemical antagonist.  METHODS:  VX-745, a blood-brain barrier penetrant, highly selective p38 MAPKα inhibitor, and clinical stage investigational drug, was utilized.  Initially, a pilot study in 26-month-old Tg2576 mice was conducted.  Subsequently, a definitive dose-response study was conducted in aged (20-22 months) rats with identified cognitive deficits; n = 15 per group: vehicle, 0.5, 1.5, and 4.5 mg/kg VX-745 by oral gavage twice daily for 3 weeks.  Assessments in aged rats included IL-1β, PSD-95, TNFα protein levels in hippocampus; and Morris water maze (MWM) test for cognitive performance.  RESULTS:  Drug effect could not be assessed in Tg2576 mice, as little inflammation was evident.  In cognitively-impaired aged rats, VX-745 led to significantly improved performance in the MWM and significant reduction in hippocampal IL-1β protein levels, though the effects were dissociated as the MWM effect was evident at a lower dose level than that required to lower IL-1β.  Drug concentration-effect relationships and predicted human doses were determined.  CONCLUSIONS:  Selective inhibition of p38 MAPKα with VX-745 in aged rats reduces hippocampal IL-1β levels and improves performance in the MWM.  As the two effects occur at different dose levels, the behavioral effect appears to be via a mechanism that is independent of reducing cytokine production.  The predicted human doses should minimize risks of systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxf6BottYdIAWfW6udTcc2eYaRYKE4eMotrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D&md5=cec29afedc9795bd0680734acc367146</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3233%2FJAD-150277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150277%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DSelective%2520brain-targeted%2520antagonism%2520of%2520p38%2520MAPKalpha%2520reduces%2520hippocampal%2520IL-1beta%2520levels%2520and%2520improves%2520morris%2520water%2520maze%2520performance%2520in%2520aged%2520rats%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26spage%3D219%26epage%3D227%26doi%3D10.3233%2FJAD-150277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting human central nervous system protein kinases: an isoform selective p38alphaMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=666-680&author=S.+M.+Royauthor=V.+L.+Grum-Tokarsauthor=J.+P.+Schavockyauthor=F.+Saeedauthor=A.+Staniszewskiauthor=A.+F.+Teichauthor=O.+Arancioauthor=A.+D.+Bachstetterauthor=S.+J.+Websterauthor=L.+J.+Van+Eldikauthor=G.+Minasovauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=Targeting+human+central+nervous+system+protein+kinases%3A+an+isoform+selective+p38alphaMAPK+inhibitor+that+attenuates+disease+progression+in+Alzheimer%E2%80%99s+disease+mouse+models&doi=10.1021%2Facschemneuro.5b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models</span></div><div class="casAuthors">Roy, Saktimayee M.; Grum-Tokars, Valerie L.; Schavocky, James P.; Saeed, Faisal; Staniszewski, Agnieszka; Teich, Andrew F.; Arancio, Ottavio; Bachstetter, Adam D.; Webster, Scott J.; Van Eldik, Linda J.; Minasov, George; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">666-680</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncol. indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications.  Stress kinases are of special interest in neurol. and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility.  Clin. and preclin. evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurol. indications.  Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacol. features.  Synaptic dysfunction disorders offer a potential for enhanced pharmacol. efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiol. axis, to be modulated.  We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models.  A synthetic scheme for biocompatible product and pos. outcomes from pharmacol. screens are presented.  The high-resoln. crystallog. structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity.  As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xfPVSbGEOrVg90H21EOLACvtfcHk0lgk9VzU0Krx1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D&md5=defac1ac010ab8a139647844153c7b86</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00002%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWebster%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520human%2520central%2520nervous%2520system%2520protein%2520kinases%253A%2520an%2520isoform%2520selective%2520p38alphaMAPK%2520inhibitor%2520that%2520attenuates%2520disease%2520progression%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520mouse%2520models%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D666%26epage%3D680%26doi%3D10.1021%2Facschemneuro.5b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski-Kurdziel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10245</span>– <span class="NLM_lpage">E10254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1809137115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1073%2Fpnas.1809137115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=30297392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10245-E10254&author=M.+J.+Robsonauthor=M.+A.+Quinlanauthor=K.+G.+Margolisauthor=P.+A.+Gajewski-Kurdzielauthor=J.+Veenstra-VanderWeeleauthor=M.+D.+Gershonauthor=D.+M.+Wattersonauthor=R.+D.+Blakely&title=p38alpha+MAPK+signaling+drives+pharmacologically+reversible+brain+and+gastrointestinal+phenotypes+in+the+SERT+Ala56+mouse&doi=10.1073%2Fpnas.1809137115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span></div><div class="casAuthors">Robson, Matthew J.; Quinlan, Meagan A.; Margolis, Kara Gross; Gajewski-Kurdziel, Paula A.; Veenstra-VanderWeele, Jeremy; Gershon, Michael D.; Watterson, D. Martin; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10245-E10254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a common neurobehavioral disorder with limited treatment options.  Activation of p38 MAPK signaling networks has been identified in ASD, and p38 MAPK signaling elevates serotonin (5-HT) transporter (SERT) activity, effects mimicked by multiple, hyperfunctional SERT coding variants identified in ASD subjects.  Mice expressing the most common of these variants (SERT Ala56) exhibit hyperserotonemia, a biomarker obsd. in ASD subjects, as well as p38 MAPK-dependent SERT hyperphosphorylation, elevated hippocampal 5-HT clearance, hypersensitivity of CNS 5-HT1A and 5-HT2A/2C receptors, and behavioral and gastrointestinal perturbations reminiscent of ASD.  As the α-isoform of p38 MAPK drives SERT activation, we tested the hypothesis that CNS-penetrant, α-isoform-specific p38 MAPK inhibitors might normalize SERT Ala56 phenotypes.  Strikingly, 1-wk treatment of adult SERT Ala56 mice with MW150, a selective p38α MAPK inhibitor, normalized hippocampal 5-HT clearance, CNS 5-HT1A and 5-HT2A/2C receptor sensitivities, social interactions, and colonic motility.  Conditional elimination of p389α MAPK in 5-HT neurons of SERT Ala56 mice restored 5-HT1A and 5-HT2A/2C receptor sensitivities as well as social interactions, mirroring effects of MW150.  Our findings support ongoing p38α MAPK activity as an important determinant of the physiol. and behavioral perturbations of SERT Ala56 mice and, more broadly, supports consideration of p38α MAPK inhibition as a potential treatment for core and comorbid phenotypes present in ASD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpZykHY5klbVg90H21EOLACvtfcHk0lgk9VzU0Krx1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N&md5=ea39d3218225fab9b9ef7a1465a80887</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1809137115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1809137115%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DQuinlan%26aufirst%3DM.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BG.%26aulast%3DGajewski-Kurdziel%26aufirst%3DP.%2BA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DGershon%26aufirst%3DM.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3Dp38alpha%2520MAPK%2520signaling%2520drives%2520pharmacologically%2520reversible%2520brain%2520and%2520gastrointestinal%2520phenotypes%2520in%2520the%2520SERT%2520Ala56%2520mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE10245%26epage%3DE10254%26doi%3D10.1073%2Fpnas.1809137115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spani, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.1186/s12974-017-0845-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2Fs12974-017-0845-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28381303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=75&author=Z.+Zhouauthor=A.+D.+Bachstetterauthor=C.+B.+Spaniauthor=S.+M.+Royauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Retention+of+normal+glia+function+by+an+isoform-selective+protein+kinase+inhibitor+drug+candidate+that+modulates+cytokine+production+and+cognitive+outcomes&doi=10.1186%2Fs12974-017-0845-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span></div><div class="casAuthors">Zhou, Zhengqiu; Bachstetter, Adam D.; Spani, Claudia B.; Roy, Saktimayee M.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75/1-75/12</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Brain p38α mitogen-activated protein kinase (MAPK), a potential therapeutic target for cognitive dysfunction based on the neuroinflammation-synaptic dysfunction cycle of pathophysiol. progression, offers an innovative pharmacol. strategy via inhibiting the same activated target in both glia and neurons, thereby enhancing the possibility for efficacy.  The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates.  Therefore, it is essential that the glial effects of this CNS-active kinase inhibitor be addressed in order to anticipate future use in clin. investigations.  Methods: We explored the effects of MW150 on glial biol. in the AD-relevant APP/PS1 knock-in (KI) mouse model where we previously showed efficacy in suppression of hippocampal-dependent associative and spatial memory deficits.  MW150 (2.5 mg/kg/day) was administered daily to 11-12-mo-old KI mice for 14 days, and levels of proinflammatory cytokines IL-1β, TNFα, and IL-6 measured in homogenates of mouse cortex using ELISA.  Glial markers IBA1, CD45, CD68, and GFAP were assessed by immunohistochem.  Microglia and amyloid plaques were quantified by immunofluorescence staining followed by confocal imaging.  Levels of sol. and insol. of Aβ40 and Aβ42 were measured by ELISA.  The studies of in vivo pharmacodynamic effects on markers of neuroinflammation were complemented by mechanistic studies in the murine microglia BV2 cell line, using live cell imaging techniques to monitor proliferation, migration, and phagocytosis activities.  Results: Intervention with MW150 in KI mice during the established therapeutic time window attenuated the increased levels of IL-1β and TNFα but not IL-6.  MW150 treatment also increased the IBA1+ microglia within a 15 μm radius of the amyloid plaques, without significantly affecting overall microglia or plaque vol.  Levels of IBA1, CD45, CD68, GFAP, and Aβ40 and Aβ42 were not affected by MW150 treatment.  MW150 did not significantly alter microglial migration, proliferation, or phagocytosis in BV2 cells.  Conclusions: Our results demonstrate that MW150 at an efficacious dose can selectively modulate neuroinflammatory responses assocd. with pathol. progression without pan-suppression of normal physiol. functions of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq16MlfxcvdbVg90H21EOLACvtfcHk0lhul7f-zOgNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK&md5=9137eff52c9715df75ca1ea1ac2a3656</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2Fs12974-017-0845-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-017-0845-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DSpani%26aufirst%3DC.%2BB.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DRetention%2520of%2520normal%2520glia%2520function%2520by%2520an%2520isoform-selective%2520protein%2520kinase%2520inhibitor%2520drug%2520candidate%2520that%2520modulates%2520cytokine%2520production%2520and%2520cognitive%2520outcomes%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2017%26volume%3D14%26spage%3D75%26doi%3D10.1186%2Fs12974-017-0845-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span> <span> </span><span class="NLM_article-title">An isoform-selective p38alpha mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer’s disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neurobiolaging.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=30007168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=86-91&author=G.+Rutiglianoauthor=M.+Staziauthor=O.+Arancioauthor=D.+M.+Wattersonauthor=N.+Origlia&title=An+isoform-selective+p38alpha+mitogen-activated+protein+kinase+inhibitor+rescues+early+entorhinal+cortex+dysfunctions+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Rutigliano, Grazia; Stazi, Martina; Arancio, Ottavio; Watterson, D. Martin; Origlia, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroinflammation is a fundamental mechanism in Alzheimer's disease (AD) progression.  The stress-induced activation of the p38α mitogen-activated protein kinase (MAPK) leads to increased prodn. of proinflammatory cytokines and neurodegeneration.  We investigated the effects of an isoform selective p38α MAPK inhibitor, MW01-18-150SRM (MW150), administered at 2.5 mg/kg/d (i.p.; 14 days) on early entorhinal cortex (EC) alterations in an AD mouse model carrying human mutations of the amyloid precursor protein (mhAPP).  We used electrophysiol. analyses with long-term potentiation induction in EC-contg. brain slices and EC-relevant associative memory tasks.  We found that MW150 was capable of rescuing long-term potentiation in 2-mo old mhAPP mice.  Acute delivery of MW150 to brain slices was similarly effective in rescuing long-term potentiation, with a comparable efficacy to that of the widely used multikinase inhibitor SB203580.  MW150-treated mhAPP mice demonstrated improved ability to discriminate novel assocns. between objects and their position/context.  Our findings suggest that the selective inhibition of the stress-activated p38α MAPK with MW150 can attenuate the EC dysfunctions assocd. with neuroinflammation in an early stage of AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-g02KszQjrrVg90H21EOLACvtfcHk0lhul7f-zOgNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI&md5=dc0717e4b389cb4191e52b15aaff96a6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DRutigliano%26aufirst%3DG.%26aulast%3DStazi%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DOriglia%26aufirst%3DN.%26atitle%3DAn%2520isoform-selective%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%2520rescues%2520early%2520entorhinal%2520cortex%2520dysfunctions%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D70%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.neurobiolaging.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A selective and brain penetrant p38alphaMAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntleisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5298-5311&author=S.+M.+Royauthor=G.+Minasovauthor=O.+Arancioauthor=L.+W.+Chicoauthor=L.+J.+Van+Eldikauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=A+selective+and+brain+penetrant+p38alphaMAPK+inhibitor+candidate+for+neurologic+and+neuropsychiatric+disorders+that+attenuates+neuroinflammation+and+cognitive+dysfunction&doi=10.1021%2Facs.jmedchem.9b00058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction</span></div><div class="casAuthors">Roy, Saktimayee M.; Minasov, George; Arancio, Ottavio; Chico, Laura W.; Van Eldik, Linda J.; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5298-5311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiol. changes.  A preponderance of preclin. data and clin. observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders.  We summarize the discovery of highly selective, brain-penetrant, small mol. p38αMAPK inhibitors that are efficacious in diverse animal models of neurol. disorders.  A crystallog. and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit.  The addn. of secondary pharmacol. screens to refinement delivered lead compds. with improved selectivity, appropriate pharmacodynamics, and efficacy.  Safety considerations and addnl. secondary pharmacol. screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqlxNAtJ0rrVg90H21EOLACvtfcHk0lhul7f-zOgNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntleisLs%253D&md5=501c82424ff421416e71b281f7504e21</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00058%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520selective%2520and%2520brain%2520penetrant%2520p38alphaMAPK%2520inhibitor%2520candidate%2520for%2520neurologic%2520and%2520neuropsychiatric%2520disorders%2520that%2520attenuates%2520neuroinflammation%2520and%2520cognitive%2520dysfunction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5298%26epage%3D5311%26doi%3D10.1021%2Facs.jmedchem.9b00058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/nchembio.761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2Fnchembio.761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=141-143&author=S.+C.+Koeberleauthor=J.+Romirauthor=S.+Fischerauthor=A.+Koeberleauthor=V.+Schattelauthor=W.+Albrechtauthor=C.+Grutterauthor=O.+Werzauthor=D.+Rauhauthor=T.+Stehleauthor=S.+A.+Laufer&title=Skepinone-L+is+a+selective+p38+mitogen-activated+protein+kinase+inhibitor&doi=10.1038%2Fnchembio.761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span></div><div class="casAuthors">Koeberle, Solveigh C.; Romir, Johannes; Fischer, Stefan; Koeberle, Andreas; Schattel, Verena; Albrecht, Wolfgang; Gruetter, Christian; Werz, Oliver; Rauh, Daniel; Stehle, Thilo; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-143</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Until now, a lack of inhibitors with high potency and selectivity in vivo has hampered investigation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  We describe the design of skepinone-L, which is, to our knowledge, the first ATP-competitive p38 MAPK inhibitor with excellent in vivo efficacy and selectivity.  Therefore, skepinone-L is a valuable probe for chem. biol. research, and it may foster the development of a unique class of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkdYtKPp4C1rVg90H21EOLACvtfcHk0lj7yRLkVnxkgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK&md5=17ca91bebd48a1804e31ebccc192aa93</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.761%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DRomir%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DWerz%26aufirst%3DO.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSkepinone-L%2520is%2520a%2520selective%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D141%26epage%3D143%26doi%3D10.1038%2Fnchembio.761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5868</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm300327h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300327h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFGktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5868-5877&author=S.+C.+Koeberleauthor=S.+Fischerauthor=D.+Schollmeyerauthor=V.+Schattelauthor=C.+Gr%C3%BCtterauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+disubstituted+dibenzosuberones+as+highly+potent+and+selective+inhibitors+of+p38+mitogen+activated+protein+kinase&doi=10.1021%2Fjm300327h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase</span></div><div class="casAuthors">Koeberle, Solveigh C.; Fischer, Stefan; Schollmeyer, Dieter; Schattel, Verena; Gruetter, Christian; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5868-5877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis, biol. testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivs. as p38 MAP kinase inhibitors are described.  Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, e.g., I, improving physicochem. properties as well as potency.  Extremely potent inhibitors were obtained, with half-maximal inhibitory concn. (IC50) values in the low nM range in a whole blood assay measuring the inhibition of cytokine release.  The high potency of the target compds. together with the outstanding selectivity of this novel class of compds. toward p38 mitogen activated protein (MAP) kinase as compared to other kinases indicate them to be most applicable as tools in pharmacol. research and eventually they may foster a new generation of anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobNOagvo4AArVg90H21EOLACvtfcHk0lj7yRLkVnxkgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFGktrs%253D&md5=65cea62d40cb6382c965d37ced8514d1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300327h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300327h%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520disubstituted%2520dibenzosuberones%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520p38%2520mitogen%2520activated%2520protein%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5868%26epage%3D5877%26doi%3D10.1021%2Fjm300327h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paige, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruthy, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span> <span> </span><span class="NLM_article-title">Spinal inhibition of P2XR or p38 signaling disrupts hyperalgesic priming in male, but not female, mice</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2018.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neuroscience.2018.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=29913243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOku7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2018&pages=133-142&author=C.+Paigeauthor=G.+B.+Maruthyauthor=G.+Mejiaauthor=G.+Dussorauthor=T.+Price&title=Spinal+inhibition+of+P2XR+or+p38+signaling+disrupts+hyperalgesic+priming+in+male%2C+but+not+female%2C+mice&doi=10.1016%2Fj.neuroscience.2018.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal Inhibition of P2XR or p38 Signaling Disrupts Hyperalgesic Priming in Male, but not Female, Mice</span></div><div class="casAuthors">Paige, Candler; Maruthy, Gayathri Batchalli; Mejia, Galo; Dussor, Gregory; Price, Theodore</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent studies have demonstrated sexual dimorphisms in the mechanisms contributing to the development of chronic pain.  Here we tested the hypothesis that microglia might preferentially regulate hyperalgesic priming in male mice.  We based this hypothesis on evidence that microglia preferentially contribute to neuropathic pain in male mice via ionotropic purinergic receptor (P2XR) or p38 mitogen-activated protein kinase (p38) signaling.  Mice given a single-priming injection of the sol. human interleukin-6 receptor (IL-6r) and then a second injection of prostaglandin E2 (PGE2), which unmasks hyperalgesic priming, shows a significant increase in levels of activated microglia at 3h following the PGE2 injection in both male and female mice.  There was no change in microglia following PGE2.  Neither TNP-ATP nor skepinone could reverse priming once it had already been established in male mice suggesting that these pathways must be inhibited early in the development of hyperalgesic priming to have an effect.  Our work is consistent with previous findings that P2XR and p38 inhibition can lead to male-specific effects on pain behaviors in mice.  However, given that we did not observe microglial activation at time points where these drugs were effective, our work also questions whether these effects can be completely attributed to microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3_SBBRBTsbVg90H21EOLACvtfcHk0lj7yRLkVnxkgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOku7%252FO&md5=5b568a6133bd63eec80d460a8d082cd6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2018.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2018.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DPaige%26aufirst%3DC.%26aulast%3DMaruthy%26aufirst%3DG.%2BB.%26aulast%3DMejia%26aufirst%3DG.%26aulast%3DDussor%26aufirst%3DG.%26aulast%3DPrice%26aufirst%3DT.%26atitle%3DSpinal%2520inhibition%2520of%2520P2XR%2520or%2520p38%2520signaling%2520disrupts%2520hyperalgesic%2520priming%2520in%2520male%252C%2520but%2520not%2520female%252C%2520mice%26jtitle%3DNeuroscience%26date%3D2018%26volume%3D385%26spage%3D133%26epage%3D142%26doi%3D10.1016%2Fj.neuroscience.2018.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenthoer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reischl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Menendez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneilling, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis</span>. <i>Inflammopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1007/s10787-019-00593-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1007%2Fs10787-019-00593-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=31037574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1217-1227&author=P.+Guenthoerauthor=K.+Fuchsauthor=G.+Reischlauthor=L.+Quintanilla-Martinezauthor=I.+Gonzalez-Menendezauthor=S.+Lauferauthor=B.+J.+Pichlerauthor=M.+Kneilling&title=Evaluation+of+the+therapeutic+potential+of+the+selective+p38+MAPK+inhibitor+Skepinone-L+and+the+dual+p38%2FJNK+3+inhibitor+LN+950+in+experimental+K%2FBxN+serum+transfer+arthritis&doi=10.1007%2Fs10787-019-00593-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis</span></div><div class="casAuthors">Guenthoer, Philipp; Fuchs, Kerstin; Reischl, Gerald; Quintanilla-Martinez, Leticia; Gonzalez-Menendez, Irene; Laufer, Stefan; Pichler, Bernd J.; Kneilling, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Inflammopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1227</span>CODEN:
                <span class="NLM_cas:coden">IAOAES</span>;
        ISSN:<span class="NLM_cas:issn">0925-4692</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA.  Addnl., we aimed to monitor MAPK treatment non-invasively in vivo using the hypoxia tracer [18F]fluoromisonidazole ([18F]FMISO) and positron emission tomog. (PET).  MAPK inhibitor or Sham treatment was administered per os once daily.  On days 3 and 6 after arthritis induction, we conducted PET imaging with [18F]FMISO.  At the end of the expt., ankles were harvested for histopathol. anal.  Results: Skepinone-L and LN 950 were applicable to suppress the severity of exptl. arthritis confirmed by reduced ankle swelling and histopathol. anal.  Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis.  Hypoxia imaging with [18F]FMISO revealed non-conclusive results and might not be an appropriate tool to monitor MAPK therapy in exptl. RA.  Conclusion: Both the selective p38 MAPK inhibitor Skepinone-L and the dual (p38 MAPK and JNK 3) inhibitor LN 950 exhibited significant therapeutic effects during exptl. arthritis.  Thus, our study contributes to the ongoing discussion on the use of p38 MAPK as a potential target in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAwl5kyY-pbVg90H21EOLACvtfcHk0lh1-5mgSYt0OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsbbF&md5=1c16ac6e94085ae9ed5e14f36167c15f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10787-019-00593-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10787-019-00593-6%26sid%3Dliteratum%253Aachs%26aulast%3DGuenthoer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DK.%26aulast%3DReischl%26aufirst%3DG.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DGonzalez-Menendez%26aufirst%3DI.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DB.%2BJ.%26aulast%3DKneilling%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520therapeutic%2520potential%2520of%2520the%2520selective%2520p38%2520MAPK%2520inhibitor%2520Skepinone-L%2520and%2520the%2520dual%2520p38%252FJNK%25203%2520inhibitor%2520LN%2520950%2520in%2520experimental%2520K%252FBxN%2520serum%2520transfer%2520arthritis%26jtitle%3DInflammopharmacology%26date%3D2019%26volume%3D27%26spage%3D1217%26epage%3D1227%26doi%3D10.1007%2Fs10787-019-00593-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigalke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span> <span> </span><span class="NLM_article-title">Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1159/000350110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1159%2F000350110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=23817201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFClsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=914-924&author=O.+Borstauthor=B.+Walkerauthor=P.+Munzerauthor=A.+Russoauthor=E.+Schmidauthor=C.+Faggioauthor=B.+Bigalkeauthor=S.+Lauferauthor=M.+Gawazauthor=F.+Lang&title=Skepinone-L%2C+a+novel+potent+and+highly+selective+inhibitor+of+p38+MAP+kinase%2C+effectively+impairs+platelet+activation+and+thrombus+formation&doi=10.1159%2F000350110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation</span></div><div class="casAuthors">Borst, Oliver; Walker, Britta; Muenzer, Patrick; Russo, Antonella; Schmid, Evi; Faggio, Caterina; Bigalke, Boris; Laufer, Stefan; Gawaz, Meinrad; Lang, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">914-924</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Platelets are critically important for primary hemostasis and the major players in thrombotic vascular occlusion.  Platelets are activated by agonists, such as thrombin and collagen-related peptide as well as second-wave mediators including thromboxane A2 via different intracellular signaling pathways resulting in degranulation, aggregation and thrombus formation.  Platelet activation is paralleled by phosphorylation and activation of p38 MAPK.  The limited specificity of hitherto known p38 MAPK inhibitors precluded safe conclusions on the precise role of p38 MAPK in the regulation of platelet function.  The present study examd. the impact of Skepinone-L, a novel and highly selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), on platelet activation and thrombus formation.  Methods: Expts. were performed in freshly isolated human platelets.  Protein phosphorylation was quantified by Western blotting, thromboxane B2 synthesis by enzyme immunoassay, ATP release by ChronoLume luciferin assay, cytosolic Ca2+ concn. by Fura-2 fluorescence-measurements, platelet aggregation by a light transmissions measurement and in vitro thrombus formation by a flow chamber.  Results: Skepinone-L (1 μM) virtually abrogated the phosphorylation of platelet p38 MAPK substrate Hsp27 following stimulation with CRP (1 μg/mL), thrombin (5 mU/mL) or thromboxane A2 analog U-46619 (1 μM).  Furthermore, Skepinone-L significantly blunted activation-dependent platelet secretion and aggregation following threshold concns. of CRP, thrombin and thromboxane A2 analog U-46619.  Skepinone-L did not impair platelet Ca2+ signaling but prevented agonist-induced thromboxane A2 synthesis through abrogation of p38 MAPK-dependent phosphorylation of platelet cytosolic phospholipase A2 (cPLA2).  Skepinone-L further markedly blunted thrombus formation under low (500-s) and high (1700-s) arterial shear rates.  Conclusions: The present study discloses a powerful inhibiting effect of p38 MAPK-blocker Skepinone-L on platelet activation and thrombus formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT5ug7OMXgh7Vg90H21EOLACvtfcHk0lh1-5mgSYt0OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFClsrzJ&md5=bdfe52760e5dd535f2910675bb961dac</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000350110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000350110%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DMunzer%26aufirst%3DP.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DE.%26aulast%3DFaggio%26aufirst%3DC.%26aulast%3DBigalke%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DGawaz%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DF.%26atitle%3DSkepinone-L%252C%2520a%2520novel%2520potent%2520and%2520highly%2520selective%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%252C%2520effectively%2520impairs%2520platelet%2520activation%2520and%2520thrombus%2520formation%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2013%26volume%3D31%26spage%3D914%26epage%3D924%26doi%3D10.1159%2F000350110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudalska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longerich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McJunkin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuestefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Thun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirmacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span> <span> </span><span class="NLM_article-title">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/nm.3679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2Fnm.3679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=25216638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1138-1146&author=R.+Rudalskaauthor=D.+Dauchauthor=T.+Longerichauthor=K.+McJunkinauthor=T.+Wuestefeldauthor=T.+W.+Kangauthor=A.+Hohmeyerauthor=M.+Pesicauthor=J.+Leiboldauthor=A.+von+Thunauthor=P.+Schirmacherauthor=J.+Zuberauthor=K.+H.+Weissauthor=S.+Powersauthor=N.+P.+Malekauthor=M.+Eilersauthor=B.+Siposauthor=S.+W.+Loweauthor=R.+Geffersauthor=S.+Lauferauthor=L.+Zender&title=In+vivo+RNAi+screening+identifies+a+mechanism+of+sorafenib+resistance+in+liver+cancer&doi=10.1038%2Fnm.3679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span></div><div class="casAuthors">Rudalska, Ramona; Dauch, Daniel; Longerich, Thomas; McJunkin, Katherine; Wuestefeld, Torsten; Kang, Tae-Won; Hohmeyer, Anja; Pesic, Marina; Leibold, Josef; von Thun, Anne; Schirmacher, Peter; Zuber, Johannes; Weiss, Karl-Heinz; Powers, Scott; Malek, Nisar P.; Eilers, Martin; Sipos, Bence; Lowe, Scott W.; Geffers, Robert; Laufer, Stefan; Zender, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In solid tumors, resistance to therapy inevitably develops upon treatment with cytotoxic drugs or molecularly targeted therapies.  Here, we describe a system that enables pooled shRNA screening directly in mouse hepatocellular carcinomas (HCC) in vivo to identify genes likely to be involved in therapy resistance.  Using a focused shRNA library targeting genes located within focal genomic amplifications of human HCC, we screened for genes whose inhibition increased the therapeutic efficacy of the multikinase inhibitor sorafenib.  Both shRNA-mediated and pharmacol. silencing of Mapk14 (p38α) were found to sensitize mouse HCC to sorafenib therapy and prolong survival by abrogating Mapk14-dependent activation of Mek-Erk and Atf2 signaling.  Elevated Mapk14-Atf2 signaling predicted poor response to sorafenib therapy in human HCC, and sorafenib resistance of p-Mapk14-expressing HCC cells could be reverted by silencing Mapk14.  Our results suggest that a combination of sorafenib and Mapk14 blockade is a promising approach to overcoming therapy resistance of human HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquN9Poy48vIbVg90H21EOLACvtfcHk0lh1-5mgSYt0OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL&md5=a843ee6d8060b9dcd04083cf1991f97c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.3679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3679%26sid%3Dliteratum%253Aachs%26aulast%3DRudalska%26aufirst%3DR.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DLongerich%26aufirst%3DT.%26aulast%3DMcJunkin%26aufirst%3DK.%26aulast%3DWuestefeld%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DT.%2BW.%26aulast%3DHohmeyer%26aufirst%3DA.%26aulast%3DPesic%26aufirst%3DM.%26aulast%3DLeibold%26aufirst%3DJ.%26aulast%3Dvon%2BThun%26aufirst%3DA.%26aulast%3DSchirmacher%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DK.%2BH.%26aulast%3DPowers%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DN.%2BP.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSipos%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DZender%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520RNAi%2520screening%2520identifies%2520a%2520mechanism%2520of%2520sorafenib%2520resistance%2520in%2520liver%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1138%26epage%3D1146%26doi%3D10.1038%2Fnm.3679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span> <span> </span><span class="NLM_article-title">Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2439</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1096/fj.14-268474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1096%2Ffj.14-268474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=25678624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaqu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2439-2449&author=A.+Koeberleauthor=C.+Pergolaauthor=H.+Shindouauthor=S.+C.+Koeberleauthor=T.+Shimizuauthor=S.+A.+Lauferauthor=O.+Werz&title=Role+of+p38+mitogen-activated+protein+kinase+in+linking+stearoyl-CoA+desaturase-1+activity+with+endoplasmic+reticulum+homeostasis&doi=10.1096%2Ffj.14-268474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis</span></div><div class="casAuthors">Koeberle, Andreas; Pergola, Carlo; Shindou, Hideo; Koeberle, Solveigh C.; Shimizu, Takao; Laufer, Stefan A.; Werz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2439-2449</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Endoplasmic reticulum (ER) homeostasis is regulated by a network of signaling pathways to which stearoyl-CoA desaturase (SCD)-1, p38 mitogen-activated protein kinase (MAPK) and the unfolded protein response (UPR) belong.  Because all these pathways are located at the interface of cell cycle control and cell stress, we hypothesized a cross-regulation.  Interference with SCD-1, either by small interfering (si)RNA or the specific SCD-1 inhibitor CAY10566 (EC50 1 μM; ≥ 24 h), specifically induced phosphorylation and thus activation of p38 MAPK in NIH-3T3 mouse fibroblasts (1.5- to 2-fold; 48 h).  During lipotoxic and cell cycle stress, prolonged activation of p38 MAPK due to SCD-1 inhibition induced ER stress, the UPR, and ER/Golgi remodeling as shown by Western blot and immunofluorescence microscopy (1.2- to 3.5-fold). Specific inhibition of p38 MAPK by Skepinone-L [half maximal inhibitory concn. (IC50) 25-50 nM] reversed these effects (at 1 μM; 48 h).  The specificity by which SCD-1 modulates the phospholipid compn. and inhibits p38 MAPK signaling (among survival/stress pathways), thereby preventing ER stress (but not other SCD-1-dependent responses), suggests selective protein-lipid interactions.  Palmitoleoyl/oleoyl-phosphatidylinositol (PI) was accordingly identified as potential lipid mediator using chromatog.-coupled ESI tandem mass spectrometry.  We conclude that the neg. regulation of p38 MAPK mediates the protective effects of SCD-1 on ER homeostasis under distinct stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBvBgoVZ1-erVg90H21EOLACvtfcHk0lgAkEBvtVaduA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaqu7vO&md5=55e26d6d8bbe5d747b1417dba573be1c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-268474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-268474%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DPergola%26aufirst%3DC.%26aulast%3DShindou%26aufirst%3DH.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DWerz%26aufirst%3DO.%26atitle%3DRole%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520in%2520linking%2520stearoyl-CoA%2520desaturase-1%2520activity%2520with%2520endoplasmic%2520reticulum%2520homeostasis%26jtitle%3DFASEB%2520J.%26date%3D2015%26volume%3D29%26spage%3D2439%26epage%3D2449%26doi%3D10.1096%2Ffj.14-268474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel type I(1)/2 p38alpha MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time by interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+B%C3%BChrmannauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+L%C3%A4mmerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+type+I%281%29%2F2+p38alpha+MAP+kinase+inhibitors+with+excellent+selectivity%2C+high+potency%2C+and+prolonged+target+residence+time+by+interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0lgAkEBvtVaduA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520type%2520I%25281%2529%252F2%2520p38alpha%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520selectivity%252C%2520high%2520potency%252C%2520and%2520prolonged%2520target%2520residence%2520time%2520by%2520interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Optimized target residence time: type I1/2 Inhibitors for p38alpha MAP kinase with improved binding kinetics through direct interaction with the R-spine</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5363</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+B%C3%BChrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+target+residence+time%3A+type+I1%2F2+Inhibitors+for+p38alpha+MAP+kinase+with+improved+binding+kinetics+through+direct+interaction+with+the+R-spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0lhHl7P0v_QENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520target%2520residence%2520time%253A%2520type%2520I1%252F2%2520Inhibitors%2520for%2520p38alpha%2520MAP%2520kinase%2520with%2520improved%2520binding%2520kinetics%2520through%2520direct%2520interaction%2520with%2520the%2520R-spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niess, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1021/jm301539x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301539x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=241-253&author=S.+Fischerauthor=H.+K.+Wentschauthor=S.+C.+Mayer-Wrangowskiauthor=M.+Zimmermannauthor=S.+M.+Bauerauthor=K.+Storchauthor=R.+Niessauthor=S.+C.+Koeberleauthor=C.+Grutterauthor=F.+M.+Boecklerauthor=D.+Rauhauthor=S.+A.+Laufer&title=Dibenzosuberones+as+p38+mitogen-activated+protein+kinase+inhibitors+with+low+ATP+competitiveness+and+outstanding+whole+blood+activity&doi=10.1021%2Fjm301539x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity</span></div><div class="casAuthors">Fischer, Stefan; Wentsch, Heike K.; Mayer-Wrangowski, Svenja C.; Zimmermann, Markus; Bauer, Silke M.; Storch, Kirsten; Niess, Raimund; Koeberle, Solveigh C.; Gruetter, Christian; Boeckler, Frank M.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-253</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases.  Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market.  This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biol. systems and selectivity.  Herein an approach to the development of such inhibitors on the basis of the highly selective mol. probe Skepinone-L (I) is described.  Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compds.  Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compds. in a whole blood assay.  Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biol. systems and in therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbi31syvBEYrVg90H21EOLACvtfcHk0lhHl7P0v_QENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP&md5=bfce0ba26af365a1d218095e54ba169f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm301539x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301539x%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DZimmermann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DNiess%26aufirst%3DR.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDibenzosuberones%2520as%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520with%2520low%2520ATP%2520competitiveness%2520and%2520outstanding%2520whole%2520blood%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D241%26epage%3D253%26doi%3D10.1021%2Fjm301539x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=20638357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+nonradioactive+immunosorbent+assay+for+p38alpha+mitogen-activated+protein+kinase+activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity</span></div><div class="casAuthors">Goettert, Marcia; Graeser, Ralph; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, the authors describe the optimization of a nonradioactive immunosorbent p38α-MAP kinase (MAPK) activity assay to det. the inhibitory potency of small mol. inhibitors.  The assay omitted the secondary antibody and, therefore, was shorter, more accurate, and easier to handle (total assay time of 3 h).  This direct assay used a new monoclonal anti-phospho-ATF-2 (Thr69/71) peroxidase-conjugated antibody, increasing the specificity and eliminating problems with cross-reactivities of secondary antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu4ELn6_1brVg90H21EOLACvtfcHk0lhHl7P0v_QENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP&md5=23b6434a50195acd27895d7d2205556c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520nonradioactive%2520immunosorbent%2520assay%2520for%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of c-Jun N-terminal kinases: an update</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/jm501212r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501212r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=72-95&author=P.+Kochauthor=M.+Gehringerauthor=S.+A.+Laufer&title=Inhibitors+of+c-Jun+N-terminal+kinases%3A+an+update&doi=10.1021%2Fjm501212r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of c-Jun N-Terminal Kinases: An Update</span></div><div class="casAuthors">Koch, Pierre; Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-95</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The c-Jun N-terminal kinases (JNKs) are serine/threonine kinases implicated in the pathogenesis of various diseases.  Recent advances in the development of novel inhibitors of JNKs will be reviewed.  Significant progress in the design of JNK inhibitors displaying selectivity vs. other kinases has been achieved within the past 4 years.  However, the development of isoform selective JNK inhibitors is still an open task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_LzW9t04ImLVg90H21EOLACvtfcHk0lhWjypzlaR7UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb%252FN&md5=0d1c32e1463de951c8b47f35882f90ab</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm501212r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501212r%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DInhibitors%2520of%2520c-Jun%2520N-terminal%2520kinases%253A%2520an%2520update%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D72%26epage%3D95%26doi%3D10.1021%2Fjm501212r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulle, S.</span></span> <span> </span><span class="NLM_article-title">KinMap: a web-based tool for interactive navigation through human kinome data</span>. <i>BMC Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/s12859-016-1433-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2Fs12859-016-1433-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28056780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=16&author=S.+Eidauthor=S.+Turkauthor=A.+Volkamerauthor=F.+Rippmannauthor=S.+Fulle&title=KinMap%3A+a+web-based+tool+for+interactive+navigation+through+human+kinome+data&doi=10.1186%2Fs12859-016-1433-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">KinMap: a web-based tool for interactive navigation through human kinome data</span></div><div class="casAuthors">Eid, Sameh; Turk, Samo; Volkamer, Andrea; Rippmann, Friedrich; Fulle, Simone</div><div class="citationInfo"><span class="NLM_cas:title">BMC Bioinformatics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16/1-16/6</span>CODEN:
                <span class="NLM_cas:coden">BBMIC4</span>;
        ISSN:<span class="NLM_cas:issn">1471-2105</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Annotations of the phylogenetic tree of the human kinome is an intuitive way to visualize compd. profiling data, structural features of kinases or functional relationships within this important class of proteins.  The increasing vol. and complexity of kinase-related data underlines the need for a tool that enables complex queries pertaining to kinase disease involvement and potential therapeutic uses of kinase inhibitors.  Results: Here, we present KinMap, a user-friendly online tool that facilitates the interactive navigation through kinase knowledge by linking biochem., structural, and disease assocn. data to the human kinome tree.  To this end, preprocessed data from freely-available sources, such as ChEMBL, the Protein Data Bank, and the Center for Therapeutic Target Validation platform are integrated into KinMap and can easily be complemented by proprietary data.  The value of KinMap will be exemplarily demonstrated for uncovering new therapeutic indications of known kinase inhibitors and for prioritizing kinases for drug development efforts.  Conclusions: KinMap represents a new generation of kinome tree viewers which facilitates interactive exploration of the human kinome.  KinMap enables generation of high-quality annotated images of the human kinome tree as well as exchange of kinome-related data in scientific communications.  Furthermore, KinMap supports multiple input and output formats and recognizes alternative kinase names and links them to a unified naming scheme, which makes it a useful tool across different disciplines and applications.  A web-service of KinMap is freely available at http://www.kinhub.org/kinmap/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1M2aa8fuKALVg90H21EOLACvtfcHk0lhWjypzlaR7UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCjtLc%253D&md5=29737c7cda8d9caf75018e0d29e9a459</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs12859-016-1433-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12859-016-1433-7%26sid%3Dliteratum%253Aachs%26aulast%3DEid%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DRippmann%26aufirst%3DF.%26aulast%3DFulle%26aufirst%3DS.%26atitle%3DKinMap%253A%2520a%2520web-based%2520tool%2520for%2520interactive%2520navigation%2520through%2520human%2520kinome%2520data%26jtitle%3DBMC%2520Bioinf.%26date%3D2017%26volume%3D18%26spage%3D16%26doi%3D10.1186%2Fs12859-016-1433-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of p38α MAP kinase inhibitors Neflamapimod (<b>1a</b>, VX-745),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> MW150 (<b>1b</b>),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Skepinone-L (<b>2a</b>), and Skepinone-N (<b>2b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode of Skepinone-L (<b>2a</b>) within the ATP binding site of p38α MAP kinase (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE">3QUE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Dibenzosuberones <b>6</b>–<b>40</b> (Skepinone-L Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2,4-difluoroaniline, Cs<sub>2</sub>CO<sub>3</sub>, XPhos, Pd(OAc)<sub>2</sub>, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 110 °C. (ii) KOH, MeOH, reflux temperature. (iii) CDI, DMF, 50 °C. For the detailed structures of compounds <b>6</b>–<b>51</b>, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2,2,2-trifluoroacetic acid (TFA), dichloromethane (DCM), room temperature (rt).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>42</b>–<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Dibenzosuberones <b>54</b>–<b>67</b> (Skepinone-N Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>o</i>-phenylenediamine, Cs<sub>2</sub>CO<sub>3</sub>, XPhos-Pd second generation, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 60 °C. (ii) KOH, MeOH, reflux temperature. (iii) CDI, DMF, 50 °C. For the detailed structures of compounds <b>54</b>–<b>67</b> and <b>71</b>–<b>72</b>, see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf" class="ext-link">SI</a>.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TFA, DCM, rt.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>70</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) KOH, MeOH, reflux temperature.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0011.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Dibenzosuberone <b>76</b> (Skepinone-N Series)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 2-nitroaniline, Cs<sub>2</sub>CO<sub>3</sub>, XPhos, Pd(OAc)<sub>2</sub>, 1,4-dioxane/<i>t</i>-BuOH (5:1, v/v), 110 °C. (ii) KOH, MeOH, reflux temperature. (iii) Methylamine (2 N THF), CDI, DMF, 50 °C. (iv) SnCl<sub>2</sub>, EtOH, reflux temperature.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/medium/jm0c01773_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0003.jpeg" id="rightTab-GRAPHIC-d7e2752-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity profile of carboxylic acids <b>43</b> (left) and <b>70</b> (right). Tested kinases are highlighted with circles and colored according to their inhibition at 1 μM inhibitor concentration. This figure was generated with the help of the KinMap.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01773/20210511/images/large/jm0c01773_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01773&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i106">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88442" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88442" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laydon, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keys, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landvatter, S. W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A protein kinase involved in the regulation of inflammatory cytokine biosynthesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1038/372739a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2F372739a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=7997261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADyaK2MXisl2qu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=1994&pages=739-746&author=J.+C.+Leeauthor=J.+T.+Laydonauthor=P.+C.+McDonnellauthor=T.+F.+Gallagherauthor=S.+Kumarauthor=D.+Greenauthor=D.+McNultyauthor=M.+J.+Blumenthalauthor=J.+R.+Keysauthor=S.+W.+Landvatter&title=A+protein+kinase+involved+in+the+regulation+of+inflammatory+cytokine+biosynthesis&doi=10.1038%2F372739a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A protein kinase involved in the regulation of inflammatory cytokine biosynthesis</span></div><div class="casAuthors">Lee, John C.; Laydon, Jeffrey T.; McDonnell, Peter C.; Gallagher, Timothy F.; Kumar, Sanjay; Green, David; McNulty, Dean; Blumenthal, Mary Jane; Heyes, J. Richard; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6508</span>),
    <span class="NLM_cas:pages">739-46</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Prodn. of interleukin-1 and tumor necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compds.  Using radiolabeled and radio-photoaffinity-labeled chem. probes, the target of these compds. was identified as a pair of closely related mitogen-activated protein kinase homologues, termed CSBPs.  Binding of the pyridinyl-imidazole compds. inhibited CSBP kinase activity and could be directly correlated with their ability to inhibit cytokine prodn., suggesting that the CSBPs are crit. for cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExKJsn1CnWrVg90H21EOLACvtfcHk0lg9BA5ZuWeQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXisl2qu70%253D&md5=cfda8b8e5c29e323029c4f03056a1753</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F372739a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F372739a0%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLaydon%26aufirst%3DJ.%2BT.%26aulast%3DMcDonnell%26aufirst%3DP.%2BC.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DD.%26aulast%3DMcNulty%26aufirst%3DD.%26aulast%3DBlumenthal%26aufirst%3DM.%2BJ.%26aulast%3DKeys%26aufirst%3DJ.%2BR.%26aulast%3DLandvatter%26aufirst%3DS.%2BW.%26atitle%3DA%2520protein%2520kinase%2520involved%2520in%2520the%2520regulation%2520of%2520inflammatory%2520cytokine%2520biosynthesis%26jtitle%3DNature%26date%3D1994%26volume%3D372%26spage%3D739%26epage%3D746%26doi%3D10.1038%2F372739a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammit, A. J.</span></span> <span> </span><span class="NLM_article-title">Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2009.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neuropharm.2009.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=19951717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtleqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=561-568&author=L.+Munozauthor=A.+J.+Ammit&title=Targeting+p38+MAPK+pathway+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neuropharm.2009.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting p38 MAPK pathway for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Munoz, Lenka; Ammit, Alaina J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">561-568</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence indicates that p38 mitogen-activated protein kinase (MAPK) could play more than one role in Alzheimer's disease (AD) pathophysiol. and that patients suffering from AD dementia could benefit from p38 MAPK inhibitors.  The p38 MAPK signaling has been widely accepted as a cascade contributing to neuroinflammation.  However, deepening insight into the underlying biol. of Alzheimer's disease reveals that p38 MAPK operates in other events related to AD, such as excitotoxicity, synaptic plasticity and tau phosphorylation.  Although quantification of behavioral improvements upon p38 MAPK inhibition and in vivo evaluation of p38 MAPK significance to various aspects of AD pathol. is still missing, the p38 MAPK is emerging as a new Alzheimer's disease treatment strategy.  Thus, we present here an update on the role of p38 MAPK in neurodegeneration, with a focus on Alzheimer's disease, by summarizing recent literature and several key papers from earlier years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4jWRQKVkrbVg90H21EOLACvtfcHk0lg9BA5ZuWeQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtleqtg%253D%253D&md5=04498c72e3a4b432f08b21a55de52bb0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2009.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2009.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DAmmit%26aufirst%3DA.%2BJ.%26atitle%3DTargeting%2520p38%2520MAPK%2520pathway%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D58%26spage%3D561%26epage%3D568%26doi%3D10.1016%2Fj.neuropharm.2009.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranaivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer’s disease mouse model</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-4-21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2F1742-2094-4-21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=17784957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=21&author=L.+Munozauthor=H.+Ranaivoauthor=S.+M.+Royauthor=W.+Huauthor=J.+M.+Craftauthor=L.+K.+McNamaraauthor=L.+W.+Chicoauthor=L.+J.+van+Eldikauthor=D.+M.+Watterson&title=A+novel+p38+alpha+MAPK+inhibitor+suppresses+brain+proinflammatory+cytokine+up-regulation+and+attenuates+synaptic+dysfunction+and+behavioral+deficits+in+an+Alzheimer%E2%80%99s+disease+mouse+model&doi=10.1186%2F1742-2094-4-21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model</span></div><div class="casAuthors">Munoz Lenka; Ralay Ranaivo Hantamalala; Roy Saktimayee M; Hu Wenhui; Craft Jeffrey M; McNamara Laurie K; Chico Laura Wing; Van Eldik Linda J; Watterson D Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An accumulating body of evidence is consistent with the hypothesis that excessive or prolonged increases in proinflammatory cytokine production by activated glia is a contributor to the progression of pathophysiology that is causally linked to synaptic dysfunction and hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD).  This raises the opportunity for the development of new classes of potentially disease-modifying therapeutics.  A logical candidate CNS target is p38 alpha MAPK, a well-established drug discovery molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders.  Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell culture studies strongly implicate p38 MAPK in the increased production of proinflammatory cytokines by glia activated with human amyloid-beta (A beta) and other disease-relevant stressors.  However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative disorders.  The goal of this study was to test the hypothesis that brain p38 alpha MAPK is a potential in vivo target for orally bioavailable, small molecules capable of suppressing excessive cytokine production by activated glia back towards homeostasis, allowing an improvement in neurologic outcomes.  METHODS:  A novel synthetic small molecule based on a molecular scaffold used previously was designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability, metabolic stability, safety and brain uptake.  Testing for in vivo efficacy used an AD-relevant mouse model.  RESULTS:  A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38 alpha MAPK (MW01-2-069A-SRM) was developed.  Oral administration of the compound at a low dose (2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the hippocampus back towards normal in the animal model.  Animals with attenuated cytokine production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.  CONCLUSION:  The p38 alpha MAPK pathway is quantitatively important in the A beta-induced production of proinflammatory cytokines in hippocampus, and brain p38 alpha MAPK is a viable molecular target for future development of potential disease-modifying therapeutics in AD and related neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsGGsjPM4Dps25P7XSLhESfW6udTcc2eYrD06gaDKet7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sngtlyluw%253D%253D&md5=e7768f444f68015f134d42880ed01f3b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-4-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-4-21%26sid%3Dliteratum%253Aachs%26aulast%3DMunoz%26aufirst%3DL.%26aulast%3DRanaivo%26aufirst%3DH.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCraft%26aufirst%3DJ.%2BM.%26aulast%3DMcNamara%26aufirst%3DL.%2BK.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3Dvan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520novel%2520p38%2520alpha%2520MAPK%2520inhibitor%2520suppresses%2520brain%2520proinflammatory%2520cytokine%2520up-regulation%2520and%2520attenuates%2520synaptic%2520dysfunction%2520and%2520behavioral%2520deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520mouse%2520model%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2007%26volume%3D4%26spage%3D21%26doi%3D10.1186%2F1742-2094-4-21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takigami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, K.</span></span> <span> </span><span class="NLM_article-title">p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.2174/187152411794961040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.2174%2F187152411794961040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=20812905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVOrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=45-59&author=S.+Yasudaauthor=H.+Sugiuraauthor=H.+Tanakaauthor=S.+Takigamiauthor=K.+Yamagata&title=p38+MAP+kinase+inhibitors+as+potential+therapeutic+drugs+for+neural+diseases&doi=10.2174%2F187152411794961040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases</span></div><div class="casAuthors">Yasuda, S.; Sugiura, H.; Tanaka, H.; Takigami, S.; Yamagata, K.</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-59</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mammalian p38 mitogen-activated protein kinases (MAPKs) are activated by various cellular stresses, as well as in response to inflammatory cytokines.  In the central nervous systems (CNS), activation of the p38 MAPK pathway constitutes a key step in the development of several diseases, and the mol. mechanisms mediated by p38 MAPK signaling were defined.  Activation of this cascade releases pro-inflammatory cytokines that are known to be involved in cerebral ischemia, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), neuropathic pain, and depression.  In AD, stimulated p38 MAPK may trigger the hyperphosphorylation of a neural microtubule-assocd. protein, tau.  In addn., we have recently revealed that activation of p38 MAPK signaling decreases dendritic spine no., which may be assocd. with memory impairment after epileptic seizures.  Thus, p38 MAPK can serve as a target for novel drug development for neural diseases.  P38 MAPK inhibitors were studied extensively in both preclin. expts. and clin. trials for inflammatory diseases.  New p38 MAPK inhibitors are now being tested in phase II clin. trials for neuropathic pain and depression.  Here, we review current and possible future applications of p38 MAPK inhibitors as therapeutic agents in neural diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HV5bKiYj1rVg90H21EOLACvtfcHk0liTQzuJEY06zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVOrs74%253D&md5=a0a649cb3eec96cf5a2c54676f3dc139</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F187152411794961040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152411794961040%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DS.%26aulast%3DSugiura%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DTakigami%26aufirst%3DS.%26aulast%3DYamagata%26aufirst%3DK.%26atitle%3Dp38%2520MAP%2520kinase%2520inhibitors%2520as%2520potential%2520therapeutic%2520drugs%2520for%2520neural%2520diseases%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D45%26epage%3D59%26doi%3D10.2174%2F187152411794961040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of alzheimer’s disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1287</span>, <span class="refDoi"> DOI: 10.3390/molecules22081287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fmolecules22081287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28767069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1287&author=J.+K.+Leeauthor=N.+J.+Kim&title=Recent+advances+in+the+inhibition+of+p38+MAPK+as+a+potential+strategy+for+the+treatment+of+alzheimer%E2%80%99s+disease&doi=10.3390%2Fmolecules22081287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lee, Jong Kil; Kim, Nam-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1287/1-1287/23</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a crucial target for chronic inflammatory diseases.  Alzheimer's disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, as well as neurodegeneration, and there is no known cure.  Recent studies on the underlying biol. of AD in cellular and animal models have indicated that p38 MAPK is capable of orchestrating diverse events related to AD, such as tau phosphorylation, neurotoxicity, neuroinflammation and synaptic dysfunction.  Thus, the inhibition of p38 MAPK is considered a promising strategy for the treatment of AD.  In this review, we summarize recent advances in the targeting of p38 MAPK as a potential strategy for the treatment of AD and envision possibilities of p38 MAPK inhibitors as a fundamental therapeutics for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NNXguBzPobVg90H21EOLACvtfcHk0liTQzuJEY06zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cls77P&md5=9aa70ca6361ea8e5e3bf789fd5df58be</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22081287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22081287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DN.%2BJ.%26atitle%3DRecent%2520advances%2520in%2520the%2520inhibition%2520of%2520p38%2520MAPK%2520as%2520a%2520potential%2520strategy%2520for%2520the%2520treatment%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1287%26doi%3D10.3390%2Fmolecules22081287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohush, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewiadomska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipek, A.</span></span> <span> </span><span class="NLM_article-title">Role of mitogen activated protein kinase signaling in parkinson’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2973</span>, <span class="refDoi"> DOI: 10.3390/ijms19102973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fijms19102973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Kit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2973&author=A.+Bohushauthor=G.+Niewiadomskaauthor=A.+Filipek&title=Role+of+mitogen+activated+protein+kinase+signaling+in+parkinson%E2%80%99s+disease&doi=10.3390%2Fijms19102973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of mitogen activated protein kinase signaling in Parkinson's disease</span></div><div class="casAuthors">Bohush, Anastasiia; Niewiadomska, Grazyna; Filipek, Anna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2973/1-2973/17</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is a neurodegenerative disorder caused by insufficient dopamine prodn. due to the loss of 50% to 70% of dopaminergic neurons.  A shortage of dopamine, which is predominantly produced by the dopaminergic neurons within the substantia nigra, causes clin. symptoms such as redn. of muscle mass, impaired body balance, akinesia, bradykinesia, tremors, postural instability, etc.  Lastly, this can lead to a total loss of phys. movement and death.  Since no cure for PD has been developed up to now, researchers using cell cultures and animal models focus their work on searching for potential therapeutic targets in order to develop effective treatments.  In recent years, genetic studies have prominently advocated for the role of improper protein phosphorylation caused by a dysfunction in kinases and/or phosphatases as an important player in progression and pathogenesis of PD.  Thus, in this review, we focus on the role of selected MAP kinases such as JNKs, ERK1/2, and p38 MAP kinases in PD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3PM60Re5EgrVg90H21EOLACvtfcHk0lj3Q70QVRtC4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Kit7s%253D&md5=c8555d7b0c4f33a1011121be8b857e58</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3390%2Fijms19102973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19102973%26sid%3Dliteratum%253Aachs%26aulast%3DBohush%26aufirst%3DA.%26aulast%3DNiewiadomska%26aufirst%3DG.%26aulast%3DFilipek%26aufirst%3DA.%26atitle%3DRole%2520of%2520mitogen%2520activated%2520protein%2520kinase%2520signaling%2520in%2520parkinson%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D2973%26doi%3D10.3390%2Fijms19102973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asih, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prikas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanoska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahel, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ittner, A.</span></span> <span> </span><span class="NLM_article-title">Functions of p38 MAP kinases in the central nervous system</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">570586</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2020.570586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3389%2Ffnmol.2020.570586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=33013322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjtVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=570586&author=P.+R.+Asihauthor=E.+Prikasauthor=K.+Stefanoskaauthor=A.+R.+P.+Tanauthor=H.+I.+Ahelauthor=A.+Ittner&title=Functions+of+p38+MAP+kinases+in+the+central+nervous+system&doi=10.3389%2Ffnmol.2020.570586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of p38 MAP kinases in the central nervous system</span></div><div class="casAuthors">Asih, Prita R.; Prikas, Emmanuel; Stefanoska, Kristie; Tan, Amanda R. P.; Ahel, Holly I.; Ittner, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">570586</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Mitogen-activated protein (MAP) kinases are a central component in signaling networks in a multitude of mammalian cell types.  This review covers recent advances on specific functions of p38 MAP kinases in cells of the central nervous system.  Unique and specific functions of the four mammalian p38 kinases are found in all major cell types in the brain.  Mechanisms of p38 activation and downstream phosphorylation substrates in these different contexts are outlined and how they contribute to functions of p38 in physiol. and under disease conditions.  Results in different model organisms demonstrated that p38 kinases are involved in cognitive functions, including functions related to anxiety, addiction behavior, neurotoxicity, neurodegeneration, and decision making.  Finally, the role of p38 kinases in psychiatric and neurol. conditions and the current progress on therapeutic inhibitors targeting p38 kinases are covered and implicate p38 kinases in a multitude of CNS-related physiol. and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZhPYRMOh7Vg90H21EOLACvtfcHk0lj3Q70QVRtC4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjtVKgu78%253D&md5=0ae7f3111a03e64e4587f95dd81c274a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.570586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.570586%26sid%3Dliteratum%253Aachs%26aulast%3DAsih%26aufirst%3DP.%2BR.%26aulast%3DPrikas%26aufirst%3DE.%26aulast%3DStefanoska%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DA.%2BR.%2BP.%26aulast%3DAhel%26aufirst%3DH.%2BI.%26aulast%3DIttner%26aufirst%3DA.%26atitle%3DFunctions%2520of%2520p38%2520MAP%2520kinases%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26spage%3D570586%26doi%3D10.3389%2Ffnmol.2020.570586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">P38alpha MAPK signaling-a robust therapeutic target for rab5-mediated neurodegenerative disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5485</span>, <span class="refDoi"> DOI: 10.3390/ijms21155485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3390%2Fijms21155485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitValu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5485&author=U.+A.+Germannauthor=J.+J.+Alam&title=P38alpha+MAPK+signaling-a+robust+therapeutic+target+for+rab5-mediated+neurodegenerative+disease&doi=10.3390%2Fijms21155485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">P38α MAPK signaling-A robust therapeutic target for Rab5-mediated neurodegenerative disease</span></div><div class="casAuthors">Germann, Ursula A.; Alam, John J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5485</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Multifactorial pathologies, involving one or more aggregated protein(s) and neuroinflammation are common in major neurodegenerative diseases, such as Alzheimer's disease and dementia with Lewy bodies.  This complexity of multiple pathogenic drivers is one potential explanation for the lack of success or, at best, the partial therapeutic effects, resp., with approaches that have targeted one specific driver, e.g., amyloid-beta, in Alzheimer's disease.  Since the endosome-assocd. protein Rab5 appears to be a convergence point for many, if not all the most prominent pathogenic drivers, it has emerged as a major therapeutic target for neurodegenerative disease.  Further, since the alpha isoform of p38 mitogen-activated protein kinase (p38α) is a major regulator of Rab5 activity and its effectors, a biol. that is distinct from the classical nuclear targets of p38 signaling, brain-penetrant selective p38α kinase inhibitors provide the opportunity for significant therapeutic advances in neurogenerative disease through normalizing dysregulated Rab5 activity.  In this review, we provide a brief summary of the role of Rab5 in the cell and its assocn. with neurodegenerative disease pathogenesis.  We then discuss the connection between Rab5 and p38α and summarize the evidence that through modulating Rab5 activity there are therapeutic opportunities in neurodegenerative diseases for p38α kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6-fzrDckdwbVg90H21EOLACvtfcHk0lj3Q70QVRtC4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitValu77P&md5=d899501ec90d3241a4ea5a4b5f9220e6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fijms21155485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21155485%26sid%3Dliteratum%253Aachs%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DP38alpha%2520MAPK%2520signaling-a%2520robust%2520therapeutic%2520target%2520for%2520rab5-mediated%2520neurodegenerative%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5485%26doi%3D10.3390%2Fijms21155485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nael, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pye, Q. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geddes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markesbery, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">p38 Kinase is activated in the alzheimer’s disease brain</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2053</span>– <span class="NLM_lpage">2058</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1999.0722053.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1046%2Fj.1471-4159.1999.0722053.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10217284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADyaK1MXis12lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2053-2058&author=K.+Hensleyauthor=R.+A.+Floydauthor=N.-Y.+Zhengauthor=R.+Naelauthor=K.+A.+Robinsonauthor=X.+Nguyenauthor=Q.+N.+Pyeauthor=C.+A.+Stewartauthor=J.+Geddesauthor=W.+R.+Markesberyauthor=E.+Patelauthor=G.+V.+W.+Johnsonauthor=G.+Bing&title=p38+Kinase+is+activated+in+the+alzheimer%E2%80%99s+disease+brain&doi=10.1046%2Fj.1471-4159.1999.0722053.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">p38 kinase is activated in the Alzheimer's disease brain</span></div><div class="casAuthors">Hensley, Kenneth; Floyd, Robert A.; Zheng, Nai-Ying; Nael, Raha; Robinson, Kent A.; Nguyen, Xuan; Pye, Quentin N.; Stewart, Charles A.; Geddes, James; Markesbery, William R.; Patel, Ela; Johnson, Gail V. W.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2053-2058</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase is a stress-activated enzyme responsible for transducing inflammatory signals and initiating apoptosis.  In the Alzheimer's disease (AD) brain, increased levels of phosphorylated (active) p38 were detected relative to age-matched normal brain.  Intense phospho-p38 immunoreactivity was assocd. with neuritic plaques, neuropil threads, and neurofibrillary tangle-bearing neurons.  The antibody against phosphorylated p38 recognized many of the same structures as an antibody against aberrantly phosphorylated, paired helical filament (PHF) tau, although PHF-pos. tau did not cross-react with the phospho-p38 antibody.  These findings suggest a neuroinflammatory mechanism in the AD brain, in which aberrant protein phosphorylation affects signal transduction elements, including the p38 kinase cascade, as well as cytoskeletal components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSbqP_y3jp7Vg90H21EOLACvtfcHk0lg8_ILzRBsmnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12lt7g%253D&md5=11f53ea993906eec17fcaed8acf0dbba</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722053.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722053.x%26sid%3Dliteratum%253Aachs%26aulast%3DHensley%26aufirst%3DK.%26aulast%3DFloyd%26aufirst%3DR.%2BA.%26aulast%3DZheng%26aufirst%3DN.-Y.%26aulast%3DNael%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DK.%2BA.%26aulast%3DNguyen%26aufirst%3DX.%26aulast%3DPye%26aufirst%3DQ.%2BN.%26aulast%3DStewart%26aufirst%3DC.%2BA.%26aulast%3DGeddes%26aufirst%3DJ.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26aulast%3DPatel%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26aulast%3DBing%26aufirst%3DG.%26atitle%3Dp38%2520Kinase%2520is%2520activated%2520in%2520the%2520alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2053%26epage%3D2058%26doi%3D10.1046%2Fj.1471-4159.1999.0722053.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, X. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bing, G.</span></span> <span> </span><span class="NLM_article-title">P38 MAP kinase is activated at early stages in Alzheimer’s disease brain</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1016/S0014-4886(03)00180-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2FS0014-4886%2803%2900180-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=14552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2003&pages=394-405&author=A.+Sunauthor=M.+Liuauthor=X.+V.+Nguyenauthor=G.+Bing&title=P38+MAP+kinase+is+activated+at+early+stages+in+Alzheimer%E2%80%99s+disease+brain&doi=10.1016%2FS0014-4886%2803%2900180-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinase is activated at early stages in Alzheimer's disease brain</span></div><div class="casAuthors">Sun, Anyang; Liu, Mei; Nguyen, Xuan V.; Bing, Guoying</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">394-405</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The regional, cellular, and subcellular localization of phosphorylated p38 MAPK (pp38) was examd. by immunocytochem., immuofluorescent multiple labeling, and immunoblotting of exts. as well as immunoppts. of human postmortem tissue from control and Alzheimer's disease (AD) cases at different Braak stages.  "Early AD" cases (Braak stages IV-V) and a subset of Braak stage VI cases have high levels of pp38 immunoreactivity, with the most dense immunoreactivity located in CA2 and subiculum followed by CA1 in the hippocampus.  On the contrary, very little pp38 was detected in age-matched controls (Braak stages 0-II).  More importantly, as revealed by various multiple labeling expts., pp38 immunoreactivity is mainly located in neurons bearing early neurofibrillary pathol., but not in typically fibrillar tangles that are densely stained by thioflavin-S.  Most pp38-pos. neurons only contain a small amt. of phospho-tau.  Addnl., pp38 immunoreactivity was not assocd. with senile plaques.  At the subcellular level, pp38-immunoreactive granules are usually larger than the granules stained with the lysosomal marker cathepsin D.  Immunoblotting with different extn. buffers and immunopptn. indicate that pp38 does not or only loosely binds to phospho-tau.  Taken together, this study demonstrates that p38 MAPK is activated at early stages of neurofibrillary degeneration in AD hippocampus.  The p38 activation may also be linked to neurodegeneration through mechanisms other than neurofibrillary tangle formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxxwaFL8EObVg90H21EOLACvtfcHk0lg8_ILzRBsmnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVykt7c%253D&md5=9823c9aa4ce32ba4b9c68e005b198593</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0014-4886%2803%2900180-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4886%252803%252900180-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DX.%2BV.%26aulast%3DBing%26aufirst%3DG.%26atitle%3DP38%2520MAP%2520kinase%2520is%2520activated%2520at%2520early%2520stages%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brain%26jtitle%3DExp.%2520Neurol.%26date%3D2003%26volume%3D183%26spage%3D394%26epage%3D405%26doi%3D10.1016%2FS0014-4886%2803%2900180-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimayuga, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta)</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">79</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-8-79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2F1742-2094-8-79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=21733175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Chsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=79&author=A.+D.+Bachstetterauthor=B.+Xingauthor=L.+de+Almeidaauthor=E.+R.+Dimayugaauthor=D.+M.+Wattersonauthor=L.+J.+van+Eldik&title=Microglial+p38alpha+MAPK+is+a+key+regulator+of+proinflammatory+cytokine+up-regulation+induced+by+toll-like+receptor+%28TLR%29+ligands+or+beta-amyloid+%28Abeta%29&doi=10.1186%2F1742-2094-8-79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or β-amyloid (Aβ)</span></div><div class="casAuthors">Bachstetter, Adam D.; Xing, Bin; de Almeida, Lucia; Dimayuga, Edgardo R.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Overprodn. of proinflammatory cytokines from activated microglia has been implicated as an important contributor to pathophysiol. progression in both acute and chronic neurodegenerative diseases.  Therefore, it is crit. to elucidate intracellular signaling pathways that are significant contributors to cytokine overprodn. in microglia exposed to specific stressors, esp. pathways amenable to drug interventions.  The serine/threonine protein kinase p38α MAPK is a key enzyme in the parallel and convergent intracellular signaling pathways involved in stressor-induced prodn. of IL-1β and TNFα in peripheral tissues, and is a drug development target for peripheral inflammatory diseases.  However, much less is known about the quant. importance of microglial p38α MAPK in stressor-induced cytokine overprodn., or the potential of microglial p38α MAPK to be a druggable target for CNS disorders.  Therefore, we examd. the contribution of microglial p38α MAPK to cytokine up-regulation, with a focus on the potential to suppress the cytokine increase by inhibition of the kinase with pharmacol. or genetic approaches.  Methods: The microglial cytokine response to TLR ligands 2/3/4/7/8/9 or to Aβ1-42 was tested in the presence of a CNS-penetrant p38α MAPK inhibitor, MW01-2-069A-SRM.  Primary microglia from mice genetically deficient in p38α MAPK were used to further establish a linkage between microglia p38α MAPK and cytokine overprodn.  The in vivo significance was detd. by p38α MAPK inhibitor treatment in a LPS-induced model of acute neuroinflammation.  Results: Increased IL-1β and TNFα prodn. by the BV-2 microglial cell line and by primary microglia cultures was inhibited in a concn.-dependent manner by the p38α MAPK-targeted inhibitor.  Cellular target engagement was demonstrated by the accompanying decrease in the phosphorylation state of two p38α MAPK protein substrates, MK2 and MSK1.  Consistent with the pharmacol. findings, microglia from p38α-deficient mice showed a diminished cytokine response to LPS.  Further, oral administration of the inhibitor blocked the increase of IL-1β in the cerebral cortex of mice stressed by i.p. injection of LPS.  Conclusion: The p38α MAPK pathway is an important contributor to the increased microglial prodn. of proinflammatory cytokines induced by diverse stressors.  The results also indicate the feasibility of targeting p38α MAPK to modulate CNS proinflammatory cytokine overprodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGord0XtmYvAdbVg90H21EOLACvtfcHk0lg8_ILzRBsmnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Chsrg%253D&md5=b8157c399f427d3ed42662ddb7c38ec9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-8-79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-8-79%26sid%3Dliteratum%253Aachs%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DXing%26aufirst%3DB.%26aulast%3Dde%2BAlmeida%26aufirst%3DL.%26aulast%3DDimayuga%26aufirst%3DE.%2BR.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3Dvan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DMicroglial%2520p38alpha%2520MAPK%2520is%2520a%2520key%2520regulator%2520of%2520proinflammatory%2520cytokine%2520up-regulation%2520induced%2520by%2520toll-like%2520receptor%2520%2528TLR%2529%2520ligands%2520or%2520beta-amyloid%2520%2528Abeta%2529%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2011%26volume%3D8%26spage%3D79%26doi%3D10.1186%2F1742-2094-8-79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eales, K. L.</span></span> <span> </span><span class="NLM_article-title">The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease</span>. <i>J. Signal Transduction</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">649079</span>, <span class="refDoi"> DOI: 10.1155/2012/649079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1155%2F2012%2F649079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=22792454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC38fps1ajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=649079&author=S.+A.+Correaauthor=K.+L.+Eales&title=The+role+of+p38+MAPK+and+its+substrates+in+neuronal+plasticity+and+neurodegenerative+disease&doi=10.1155%2F2012%2F649079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease</span></div><div class="casAuthors">Correa Sonia A L; Eales Katherine L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of signal transduction</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">649079</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A significant amount of evidence suggests that the p38-mitogen-activated protein kinase (MAPK) signalling cascade plays a crucial role in synaptic plasticity and in neurodegenerative diseases.  In this review we will discuss the cellular localisation and activation of p38 MAPK and the recent advances on the molecular and cellular mechanisms of its substrates: MAPKAPK 2 (MK2) and tau protein.  In particular we will focus our attention on the understanding of the p38 MAPK-MK2 and p38 MAPK-tau activation axis in controlling neuroinflammation, actin remodelling and tau hyperphosphorylation, processes that are thought to be involved in normal ageing as well as in neurodegenerative diseases.  We will also give some insight into how elucidating the precise role of p38 MAPK-MK2 and p38 MAPK-tau signalling cascades may help to identify novel therapeutic targets to slow down the symptoms observed in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLN5iKnx8eIaNc3HjJRoFAfW6udTcc2eZVuDaWLy6dRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fps1ajsg%253D%253D&md5=fdb09a2f06c0bcf8bc0dc6a90199c709</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1155%2F2012%2F649079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F649079%26sid%3Dliteratum%253Aachs%26aulast%3DCorrea%26aufirst%3DS.%2BA.%26aulast%3DEales%26aufirst%3DK.%2BL.%26atitle%3DThe%2520role%2520of%2520p38%2520MAPK%2520and%2520its%2520substrates%2520in%2520neuronal%2520plasticity%2520and%2520neurodegenerative%2520disease%26jtitle%3DJ.%2520Signal%2520Transduction%26date%3D2012%26volume%3D2012%26spage%3D649079%26doi%3D10.1155%2F2012%2F649079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evindar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germann, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taslimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M. S.</span></span> <span> </span><span class="NLM_article-title">The discovery of VX-745: a novel and selective p38alpha kinase inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/ml2001455</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2001455" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslyisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=758-63&author=J.+P.+Duffyauthor=E.+M.+Harringtonauthor=F.+G.+Salituroauthor=J.+E.+Cochranauthor=J.+Greenauthor=H.+Gaoauthor=G.+W.+Bemisauthor=G.+Evindarauthor=V.+P.+Galulloauthor=P.+J.+Fordauthor=U.+A.+Germannauthor=K.+P.+Wilsonauthor=S.+F.+Bellonauthor=G.+Chenauthor=P.+Taslimiauthor=P.+Jonesauthor=C.+Huangauthor=S.+Pazhanisamyauthor=Y.+M.+Wangauthor=M.+A.+Murckoauthor=M.+S.+Su&title=The+discovery+of+VX-745%3A+a+novel+and+selective+p38alpha+kinase+inhibitor&doi=10.1021%2Fml2001455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor</span></div><div class="casAuthors">Duffy, John P.; Harrington, Edmund M.; Salituro, Francesco G.; Cochran, John E.; Green, Jeremy; Gao, Huai; Bemis, Guy W.; Evindar, Ghotas; Galullo, Vincent P.; Ford, Pamella J.; Germann, Ursula A.; Wilson, Keith P.; Bellon, Steven F.; Chen, Guanging; Taslimi, Paul; Jones, Peter; Huang, Cassey; Pazhanisamy, S.; Wang, Yow-Ming; Murcko, Mark A.; Su, Michael S. S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">758-763</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of novel, selective, orally active 2,5-disubstituted 6H-pyrimido[1,6-b]pyridazin-6-one p38α inhibitors is described.  Application of structural information from enzyme-ligand complexes guided the selection of screening compds., leading to the identification of a novel class of p38α inhibitors contg. a previously unreported bicyclic heterocycle core.  Advancing the SAR of this series led to the eventual discovery of 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one (VX-745).  VX-745 displays excellent enzyme activity and selectivity, has a favorable pharmacokinetic profile, and demonstrates good in vivo activity in models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtaK679ix1VbVg90H21EOLACvtfcHk0liQjU5GtmkTPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslyisr8%253D&md5=0d8f33f1602b60ec760702c29d0881b0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml2001455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2001455%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DJ.%2BP.%26aulast%3DHarrington%26aufirst%3DE.%2BM.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DCochran%26aufirst%3DJ.%2BE.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DGalullo%26aufirst%3DV.%2BP.%26aulast%3DFord%26aufirst%3DP.%2BJ.%26aulast%3DGermann%26aufirst%3DU.%2BA.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DSu%26aufirst%3DM.%2BS.%26atitle%3DThe%2520discovery%2520of%2520VX-745%253A%2520a%2520novel%2520and%2520selective%2520p38alpha%2520kinase%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D758%26epage%3D63%26doi%3D10.1021%2Fml2001455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D.</span></span> <span> </span><span class="NLM_article-title">Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early alzheimer’s disease</span>. <i>J. Prev. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.14283/jpad.2017.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.14283%2Fjpad.2017.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=29181493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lsFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=273-278&issue=4&author=J.+Alamauthor=K.+Blackburnauthor=D.+Patrick&title=Neflamapimod%3A+clinical+phase+2b-ready+oral+small+molecule+inhibitor+of+p38alpha+to+reverse+synaptic+dysfunction+in+early+alzheimer%E2%80%99s+disease&doi=10.14283%2Fjpad.2017.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease</span></div><div class="casAuthors">Alam J; Blackburn K; Patrick D</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neflamapimod (previously code named VX-745) is a clinical phase 2b-ready highly specific inhibitor of the intra-cellular enzyme p38 mitogen activated protein kinase alpha ("p38α") that is being developed as a disease-modifying drug for Alzheimer's disease (AD) that acts via targeting synaptic dysfunction.  Neflamapimod was discovered through a proprietary structure-based drug discovery platform at Vertex Pharmaceuticals, and developed previously by Vertex through to phase 2a in rheumatoid arthritis.  EIP Pharma licensed the compound in 2014 for development and commercialization as a treatment of central nervous system (CNS) disorders.  Neflamapimod is the most advanced in the clinic drug that targets specific molecular mechanisms within neurons that leads to synaptic dysfunction, the pathogenic process that is now considered to be a major driver of the development of memory deficits and disease progression in the early stages of AD.  Based on the scientific rationale of targeting synaptic dysfunction and the preclinical data, neflamapimod has the potential to both reverse memory deficits and slow disease progression.  Phase 2a clinical data in patients with early-stage AD (MMSE 20-28, biomarker positive) provides evidence that the preclinical science may be translatable to human Alzheimer's, as 6- to 12-weeks of neflamapimod treatment led to significant improvement in episodic memory, the best clinical measure of synaptic dysfunction in AD.  A phase 2b six-month placebo-controlled 150-patient clinical study is anticipated to start by end of 2017.  This study is designed to definitively demonstrate that neflamapimod reverses memory deficits, and also to provide preliminary evidence that the drug slows disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQg8yIA1XjIYeLt9HypzAgQfW6udTcc2eZhJWVyiJAGjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lsFOruw%253D%253D&md5=c827d1da4d3ef35252dddeeb46eb5cc8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2017.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2017.41%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%26aulast%3DBlackburn%26aufirst%3DK.%26aulast%3DPatrick%26aufirst%3DD.%26atitle%3DNeflamapimod%253A%2520clinical%2520phase%25202b-ready%2520oral%2520small%2520molecule%2520inhibitor%2520of%2520p38alpha%2520to%2520reverse%2520synaptic%2520dysfunction%2520in%2520early%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2017%26volume%3D4%26issue%3D4%26spage%3D273%26epage%3D278%26doi%3D10.14283%2Fjpad.2017.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J. J.</span></span> <span> </span><span class="NLM_article-title">Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.3233/JAD-150277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.3233%2FJAD-150277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=26401942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=219-227&author=J.+J.+Alam&title=Selective+brain-targeted+antagonism+of+p38+MAPKalpha+reduces+hippocampal+IL-1beta+levels+and+improves+morris+water+maze+performance+in+aged+rats&doi=10.3233%2FJAD-150277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats</span></div><div class="casAuthors">Alam John J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  P38 mitogen activated protein kinase (MAPK) α modulates microglia-mediated inflammatory responses and a number of neuronal physiological processes.  OBJECTIVE:  To evaluate pre-clinically the pharmacological effects in the brain of p38 MAPKα inhibition with a brain-penetrant specific chemical antagonist.  METHODS:  VX-745, a blood-brain barrier penetrant, highly selective p38 MAPKα inhibitor, and clinical stage investigational drug, was utilized.  Initially, a pilot study in 26-month-old Tg2576 mice was conducted.  Subsequently, a definitive dose-response study was conducted in aged (20-22 months) rats with identified cognitive deficits; n = 15 per group: vehicle, 0.5, 1.5, and 4.5 mg/kg VX-745 by oral gavage twice daily for 3 weeks.  Assessments in aged rats included IL-1β, PSD-95, TNFα protein levels in hippocampus; and Morris water maze (MWM) test for cognitive performance.  RESULTS:  Drug effect could not be assessed in Tg2576 mice, as little inflammation was evident.  In cognitively-impaired aged rats, VX-745 led to significantly improved performance in the MWM and significant reduction in hippocampal IL-1β protein levels, though the effects were dissociated as the MWM effect was evident at a lower dose level than that required to lower IL-1β.  Drug concentration-effect relationships and predicted human doses were determined.  CONCLUSIONS:  Selective inhibition of p38 MAPKα with VX-745 in aged rats reduces hippocampal IL-1β levels and improves performance in the MWM.  As the two effects occur at different dose levels, the behavioral effect appears to be via a mechanism that is independent of reducing cytokine production.  The predicted human doses should minimize risks of systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfUvQHd8XXxf6BottYdIAWfW6udTcc2eZhJWVyiJAGjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283lsF2kuw%253D%253D&md5=cec29afedc9795bd0680734acc367146</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3233%2FJAD-150277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150277%26sid%3Dliteratum%253Aachs%26aulast%3DAlam%26aufirst%3DJ.%2BJ.%26atitle%3DSelective%2520brain-targeted%2520antagonism%2520of%2520p38%2520MAPKalpha%2520reduces%2520hippocampal%2520IL-1beta%2520levels%2520and%2520improves%2520morris%2520water%2520maze%2520performance%2520in%2520aged%2520rats%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26spage%3D219%26epage%3D227%26doi%3D10.3233%2FJAD-150277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schavocky, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">Targeting human central nervous system protein kinases: an isoform selective p38alphaMAPK inhibitor that attenuates disease progression in Alzheimer’s disease mouse models</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">680</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=666-680&author=S.+M.+Royauthor=V.+L.+Grum-Tokarsauthor=J.+P.+Schavockyauthor=F.+Saeedauthor=A.+Staniszewskiauthor=A.+F.+Teichauthor=O.+Arancioauthor=A.+D.+Bachstetterauthor=S.+J.+Websterauthor=L.+J.+Van+Eldikauthor=G.+Minasovauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=Targeting+human+central+nervous+system+protein+kinases%3A+an+isoform+selective+p38alphaMAPK+inhibitor+that+attenuates+disease+progression+in+Alzheimer%E2%80%99s+disease+mouse+models&doi=10.1021%2Facschemneuro.5b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models</span></div><div class="casAuthors">Roy, Saktimayee M.; Grum-Tokars, Valerie L.; Schavocky, James P.; Saeed, Faisal; Staniszewski, Agnieszka; Teich, Andrew F.; Arancio, Ottavio; Bachstetter, Adam D.; Webster, Scott J.; Van Eldik, Linda J.; Minasov, George; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">666-680</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncol. indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications.  Stress kinases are of special interest in neurol. and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility.  Clin. and preclin. evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurol. indications.  Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacol. features.  Synaptic dysfunction disorders offer a potential for enhanced pharmacol. efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiol. axis, to be modulated.  We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models.  A synthetic scheme for biocompatible product and pos. outcomes from pharmacol. screens are presented.  The high-resoln. crystallog. structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity.  As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xfPVSbGEOrVg90H21EOLACvtfcHk0lgn6VXX4ZiwXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Kgu70%253D&md5=defac1ac010ab8a139647844153c7b86</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00002%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DGrum-Tokars%26aufirst%3DV.%2BL.%26aulast%3DSchavocky%26aufirst%3DJ.%2BP.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DWebster%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DTargeting%2520human%2520central%2520nervous%2520system%2520protein%2520kinases%253A%2520an%2520isoform%2520selective%2520p38alphaMAPK%2520inhibitor%2520that%2520attenuates%2520disease%2520progression%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520mouse%2520models%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D666%26epage%3D680%26doi%3D10.1021%2Facschemneuro.5b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski-Kurdziel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra-VanderWeele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10245</span>– <span class="NLM_lpage">E10254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1809137115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1073%2Fpnas.1809137115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=30297392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10245-E10254&author=M.+J.+Robsonauthor=M.+A.+Quinlanauthor=K.+G.+Margolisauthor=P.+A.+Gajewski-Kurdzielauthor=J.+Veenstra-VanderWeeleauthor=M.+D.+Gershonauthor=D.+M.+Wattersonauthor=R.+D.+Blakely&title=p38alpha+MAPK+signaling+drives+pharmacologically+reversible+brain+and+gastrointestinal+phenotypes+in+the+SERT+Ala56+mouse&doi=10.1073%2Fpnas.1809137115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse</span></div><div class="casAuthors">Robson, Matthew J.; Quinlan, Meagan A.; Margolis, Kara Gross; Gajewski-Kurdziel, Paula A.; Veenstra-VanderWeele, Jeremy; Gershon, Michael D.; Watterson, D. Martin; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10245-E10254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a common neurobehavioral disorder with limited treatment options.  Activation of p38 MAPK signaling networks has been identified in ASD, and p38 MAPK signaling elevates serotonin (5-HT) transporter (SERT) activity, effects mimicked by multiple, hyperfunctional SERT coding variants identified in ASD subjects.  Mice expressing the most common of these variants (SERT Ala56) exhibit hyperserotonemia, a biomarker obsd. in ASD subjects, as well as p38 MAPK-dependent SERT hyperphosphorylation, elevated hippocampal 5-HT clearance, hypersensitivity of CNS 5-HT1A and 5-HT2A/2C receptors, and behavioral and gastrointestinal perturbations reminiscent of ASD.  As the α-isoform of p38 MAPK drives SERT activation, we tested the hypothesis that CNS-penetrant, α-isoform-specific p38 MAPK inhibitors might normalize SERT Ala56 phenotypes.  Strikingly, 1-wk treatment of adult SERT Ala56 mice with MW150, a selective p38α MAPK inhibitor, normalized hippocampal 5-HT clearance, CNS 5-HT1A and 5-HT2A/2C receptor sensitivities, social interactions, and colonic motility.  Conditional elimination of p389α MAPK in 5-HT neurons of SERT Ala56 mice restored 5-HT1A and 5-HT2A/2C receptor sensitivities as well as social interactions, mirroring effects of MW150.  Our findings support ongoing p38α MAPK activity as an important determinant of the physiol. and behavioral perturbations of SERT Ala56 mice and, more broadly, supports consideration of p38α MAPK inhibition as a potential treatment for core and comorbid phenotypes present in ASD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpZykHY5klbVg90H21EOLACvtfcHk0ljuElxeyO4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb7N&md5=ea39d3218225fab9b9ef7a1465a80887</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1809137115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1809137115%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%2BJ.%26aulast%3DQuinlan%26aufirst%3DM.%2BA.%26aulast%3DMargolis%26aufirst%3DK.%2BG.%26aulast%3DGajewski-Kurdziel%26aufirst%3DP.%2BA.%26aulast%3DVeenstra-VanderWeele%26aufirst%3DJ.%26aulast%3DGershon%26aufirst%3DM.%2BD.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3Dp38alpha%2520MAPK%2520signaling%2520drives%2520pharmacologically%2520reversible%2520brain%2520and%2520gastrointestinal%2520phenotypes%2520in%2520the%2520SERT%2520Ala56%2520mouse%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE10245%26epage%3DE10254%26doi%3D10.1073%2Fpnas.1809137115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachstetter, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spani, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span> <span> </span><span class="NLM_article-title">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">75</span>, <span class="refDoi"> DOI: 10.1186/s12974-017-0845-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2Fs12974-017-0845-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28381303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=75&author=Z.+Zhouauthor=A.+D.+Bachstetterauthor=C.+B.+Spaniauthor=S.+M.+Royauthor=D.+M.+Wattersonauthor=L.+J.+Van+Eldik&title=Retention+of+normal+glia+function+by+an+isoform-selective+protein+kinase+inhibitor+drug+candidate+that+modulates+cytokine+production+and+cognitive+outcomes&doi=10.1186%2Fs12974-017-0845-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes</span></div><div class="casAuthors">Zhou, Zhengqiu; Bachstetter, Adam D.; Spani, Claudia B.; Roy, Saktimayee M.; Watterson, D. Martin; Van Eldik, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75/1-75/12</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Brain p38α mitogen-activated protein kinase (MAPK), a potential therapeutic target for cognitive dysfunction based on the neuroinflammation-synaptic dysfunction cycle of pathophysiol. progression, offers an innovative pharmacol. strategy via inhibiting the same activated target in both glia and neurons, thereby enhancing the possibility for efficacy.  The highly selective, brain-penetrant p38αMAPK inhibitor MW150 attenuates cognitive dysfunction in two distinct Alzheimer's disease (AD)-relevant models and avoids the problems encountered with previous mixed-kinase inhibitor drug candidates.  Therefore, it is essential that the glial effects of this CNS-active kinase inhibitor be addressed in order to anticipate future use in clin. investigations.  Methods: We explored the effects of MW150 on glial biol. in the AD-relevant APP/PS1 knock-in (KI) mouse model where we previously showed efficacy in suppression of hippocampal-dependent associative and spatial memory deficits.  MW150 (2.5 mg/kg/day) was administered daily to 11-12-mo-old KI mice for 14 days, and levels of proinflammatory cytokines IL-1β, TNFα, and IL-6 measured in homogenates of mouse cortex using ELISA.  Glial markers IBA1, CD45, CD68, and GFAP were assessed by immunohistochem.  Microglia and amyloid plaques were quantified by immunofluorescence staining followed by confocal imaging.  Levels of sol. and insol. of Aβ40 and Aβ42 were measured by ELISA.  The studies of in vivo pharmacodynamic effects on markers of neuroinflammation were complemented by mechanistic studies in the murine microglia BV2 cell line, using live cell imaging techniques to monitor proliferation, migration, and phagocytosis activities.  Results: Intervention with MW150 in KI mice during the established therapeutic time window attenuated the increased levels of IL-1β and TNFα but not IL-6.  MW150 treatment also increased the IBA1+ microglia within a 15 μm radius of the amyloid plaques, without significantly affecting overall microglia or plaque vol.  Levels of IBA1, CD45, CD68, GFAP, and Aβ40 and Aβ42 were not affected by MW150 treatment.  MW150 did not significantly alter microglial migration, proliferation, or phagocytosis in BV2 cells.  Conclusions: Our results demonstrate that MW150 at an efficacious dose can selectively modulate neuroinflammatory responses assocd. with pathol. progression without pan-suppression of normal physiol. functions of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq16MlfxcvdbVg90H21EOLACvtfcHk0ljuElxeyO4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVans7%252FK&md5=9137eff52c9715df75ca1ea1ac2a3656</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2Fs12974-017-0845-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-017-0845-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DBachstetter%26aufirst%3DA.%2BD.%26aulast%3DSpani%26aufirst%3DC.%2BB.%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26atitle%3DRetention%2520of%2520normal%2520glia%2520function%2520by%2520an%2520isoform-selective%2520protein%2520kinase%2520inhibitor%2520drug%2520candidate%2520that%2520modulates%2520cytokine%2520production%2520and%2520cognitive%2520outcomes%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2017%26volume%3D14%26spage%3D75%26doi%3D10.1186%2Fs12974-017-0845-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span> <span> </span><span class="NLM_article-title">An isoform-selective p38alpha mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer’s disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2018.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neurobiolaging.2018.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=30007168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=86-91&author=G.+Rutiglianoauthor=M.+Staziauthor=O.+Arancioauthor=D.+M.+Wattersonauthor=N.+Origlia&title=An+isoform-selective+p38alpha+mitogen-activated+protein+kinase+inhibitor+rescues+early+entorhinal+cortex+dysfunctions+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2018.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Rutigliano, Grazia; Stazi, Martina; Arancio, Ottavio; Watterson, D. Martin; Origlia, Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-91</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroinflammation is a fundamental mechanism in Alzheimer's disease (AD) progression.  The stress-induced activation of the p38α mitogen-activated protein kinase (MAPK) leads to increased prodn. of proinflammatory cytokines and neurodegeneration.  We investigated the effects of an isoform selective p38α MAPK inhibitor, MW01-18-150SRM (MW150), administered at 2.5 mg/kg/d (i.p.; 14 days) on early entorhinal cortex (EC) alterations in an AD mouse model carrying human mutations of the amyloid precursor protein (mhAPP).  We used electrophysiol. analyses with long-term potentiation induction in EC-contg. brain slices and EC-relevant associative memory tasks.  We found that MW150 was capable of rescuing long-term potentiation in 2-mo old mhAPP mice.  Acute delivery of MW150 to brain slices was similarly effective in rescuing long-term potentiation, with a comparable efficacy to that of the widely used multikinase inhibitor SB203580.  MW150-treated mhAPP mice demonstrated improved ability to discriminate novel assocns. between objects and their position/context.  Our findings suggest that the selective inhibition of the stress-activated p38α MAPK with MW150 can attenuate the EC dysfunctions assocd. with neuroinflammation in an early stage of AD progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-g02KszQjrrVg90H21EOLACvtfcHk0ljuElxeyO4iAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1eis7%252FI&md5=dc0717e4b389cb4191e52b15aaff96a6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2018.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2018.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DRutigliano%26aufirst%3DG.%26aulast%3DStazi%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26aulast%3DOriglia%26aufirst%3DN.%26atitle%3DAn%2520isoform-selective%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%2520rescues%2520early%2520entorhinal%2520cortex%2520dysfunctions%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2018%26volume%3D70%26spage%3D86%26epage%3D91%26doi%3D10.1016%2Fj.neurobiolaging.2018.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chico, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eldik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, D. M.</span></span> <span> </span><span class="NLM_article-title">A selective and brain penetrant p38alphaMAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntleisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5298-5311&author=S.+M.+Royauthor=G.+Minasovauthor=O.+Arancioauthor=L.+W.+Chicoauthor=L.+J.+Van+Eldikauthor=W.+F.+Andersonauthor=J.+C.+Pelletierauthor=D.+M.+Watterson&title=A+selective+and+brain+penetrant+p38alphaMAPK+inhibitor+candidate+for+neurologic+and+neuropsychiatric+disorders+that+attenuates+neuroinflammation+and+cognitive+dysfunction&doi=10.1021%2Facs.jmedchem.9b00058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction</span></div><div class="casAuthors">Roy, Saktimayee M.; Minasov, George; Arancio, Ottavio; Chico, Laura W.; Van Eldik, Linda J.; Anderson, Wayne F.; Pelletier, Jeffrey C.; Watterson, D. Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5298-5311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The p38αMAPK is a serine/threonine protein kinase and a key node in the intracellular signaling networks that transduce and amplify stress signals into physiol. changes.  A preponderance of preclin. data and clin. observations established p38αMAPK as a brain drug discovery target involved in neuroinflammatory responses and synaptic dysfunction in multiple degenerative and neuropsychiatric brain disorders.  We summarize the discovery of highly selective, brain-penetrant, small mol. p38αMAPK inhibitors that are efficacious in diverse animal models of neurol. disorders.  A crystallog. and pharmacoinformatic approach to fragment expansion enabled the discovery of an efficacious hit.  The addn. of secondary pharmacol. screens to refinement delivered lead compds. with improved selectivity, appropriate pharmacodynamics, and efficacy.  Safety considerations and addnl. secondary pharmacol. screens drove optimization that delivered the drug candidate MW01-18-150SRM (MW150), currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqlxNAtJ0rrVg90H21EOLACvtfcHk0lggOwpB3f6fMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntleisLs%253D&md5=501c82424ff421416e71b281f7504e21</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00058%26sid%3Dliteratum%253Aachs%26aulast%3DRoy%26aufirst%3DS.%2BM.%26aulast%3DMinasov%26aufirst%3DG.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DChico%26aufirst%3DL.%2BW.%26aulast%3DVan%2BEldik%26aufirst%3DL.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DWatterson%26aufirst%3DD.%2BM.%26atitle%3DA%2520selective%2520and%2520brain%2520penetrant%2520p38alphaMAPK%2520inhibitor%2520candidate%2520for%2520neurologic%2520and%2520neuropsychiatric%2520disorders%2520that%2520attenuates%2520neuroinflammation%2520and%2520cognitive%2520dysfunction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5298%26epage%3D5311%26doi%3D10.1021%2Facs.jmedchem.9b00058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romir, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/nchembio.761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2Fnchembio.761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=141-143&author=S.+C.+Koeberleauthor=J.+Romirauthor=S.+Fischerauthor=A.+Koeberleauthor=V.+Schattelauthor=W.+Albrechtauthor=C.+Grutterauthor=O.+Werzauthor=D.+Rauhauthor=T.+Stehleauthor=S.+A.+Laufer&title=Skepinone-L+is+a+selective+p38+mitogen-activated+protein+kinase+inhibitor&doi=10.1038%2Fnchembio.761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span></div><div class="casAuthors">Koeberle, Solveigh C.; Romir, Johannes; Fischer, Stefan; Koeberle, Andreas; Schattel, Verena; Albrecht, Wolfgang; Gruetter, Christian; Werz, Oliver; Rauh, Daniel; Stehle, Thilo; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-143</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Until now, a lack of inhibitors with high potency and selectivity in vivo has hampered investigation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  We describe the design of skepinone-L, which is, to our knowledge, the first ATP-competitive p38 MAPK inhibitor with excellent in vivo efficacy and selectivity.  Therefore, skepinone-L is a valuable probe for chem. biol. research, and it may foster the development of a unique class of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkdYtKPp4C1rVg90H21EOLACvtfcHk0lggOwpB3f6fMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK&md5=17ca91bebd48a1804e31ebccc192aa93</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.761%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DRomir%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DWerz%26aufirst%3DO.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSkepinone-L%2520is%2520a%2520selective%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D141%26epage%3D143%26doi%3D10.1038%2Fnchembio.761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5868</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm300327h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300327h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFGktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5868-5877&author=S.+C.+Koeberleauthor=S.+Fischerauthor=D.+Schollmeyerauthor=V.+Schattelauthor=C.+Gr%C3%BCtterauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+disubstituted+dibenzosuberones+as+highly+potent+and+selective+inhibitors+of+p38+mitogen+activated+protein+kinase&doi=10.1021%2Fjm300327h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase</span></div><div class="casAuthors">Koeberle, Solveigh C.; Fischer, Stefan; Schollmeyer, Dieter; Schattel, Verena; Gruetter, Christian; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5868-5877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis, biol. testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivs. as p38 MAP kinase inhibitors are described.  Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, e.g., I, improving physicochem. properties as well as potency.  Extremely potent inhibitors were obtained, with half-maximal inhibitory concn. (IC50) values in the low nM range in a whole blood assay measuring the inhibition of cytokine release.  The high potency of the target compds. together with the outstanding selectivity of this novel class of compds. toward p38 mitogen activated protein (MAP) kinase as compared to other kinases indicate them to be most applicable as tools in pharmacol. research and eventually they may foster a new generation of anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobNOagvo4AArVg90H21EOLACvtfcHk0lggOwpB3f6fMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFGktrs%253D&md5=65cea62d40cb6382c965d37ced8514d1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300327h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300327h%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520disubstituted%2520dibenzosuberones%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520p38%2520mitogen%2520activated%2520protein%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5868%26epage%3D5877%26doi%3D10.1021%2Fjm300327h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paige, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruthy, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span> <span> </span><span class="NLM_article-title">Spinal inhibition of P2XR or p38 signaling disrupts hyperalgesic priming in male, but not female, mice</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2018.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.neuroscience.2018.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=29913243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOku7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2018&pages=133-142&author=C.+Paigeauthor=G.+B.+Maruthyauthor=G.+Mejiaauthor=G.+Dussorauthor=T.+Price&title=Spinal+inhibition+of+P2XR+or+p38+signaling+disrupts+hyperalgesic+priming+in+male%2C+but+not+female%2C+mice&doi=10.1016%2Fj.neuroscience.2018.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal Inhibition of P2XR or p38 Signaling Disrupts Hyperalgesic Priming in Male, but not Female, Mice</span></div><div class="casAuthors">Paige, Candler; Maruthy, Gayathri Batchalli; Mejia, Galo; Dussor, Gregory; Price, Theodore</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-142</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent studies have demonstrated sexual dimorphisms in the mechanisms contributing to the development of chronic pain.  Here we tested the hypothesis that microglia might preferentially regulate hyperalgesic priming in male mice.  We based this hypothesis on evidence that microglia preferentially contribute to neuropathic pain in male mice via ionotropic purinergic receptor (P2XR) or p38 mitogen-activated protein kinase (p38) signaling.  Mice given a single-priming injection of the sol. human interleukin-6 receptor (IL-6r) and then a second injection of prostaglandin E2 (PGE2), which unmasks hyperalgesic priming, shows a significant increase in levels of activated microglia at 3h following the PGE2 injection in both male and female mice.  There was no change in microglia following PGE2.  Neither TNP-ATP nor skepinone could reverse priming once it had already been established in male mice suggesting that these pathways must be inhibited early in the development of hyperalgesic priming to have an effect.  Our work is consistent with previous findings that P2XR and p38 inhibition can lead to male-specific effects on pain behaviors in mice.  However, given that we did not observe microglial activation at time points where these drugs were effective, our work also questions whether these effects can be completely attributed to microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3_SBBRBTsbVg90H21EOLACvtfcHk0ljg8MmT-uIAng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOku7%252FO&md5=5b568a6133bd63eec80d460a8d082cd6</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2018.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2018.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DPaige%26aufirst%3DC.%26aulast%3DMaruthy%26aufirst%3DG.%2BB.%26aulast%3DMejia%26aufirst%3DG.%26aulast%3DDussor%26aufirst%3DG.%26aulast%3DPrice%26aufirst%3DT.%26atitle%3DSpinal%2520inhibition%2520of%2520P2XR%2520or%2520p38%2520signaling%2520disrupts%2520hyperalgesic%2520priming%2520in%2520male%252C%2520but%2520not%2520female%252C%2520mice%26jtitle%3DNeuroscience%26date%3D2018%26volume%3D385%26spage%3D133%26epage%3D142%26doi%3D10.1016%2Fj.neuroscience.2018.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guenthoer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reischl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintanilla-Martinez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Menendez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneilling, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis</span>. <i>Inflammopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1217</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1007/s10787-019-00593-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1007%2Fs10787-019-00593-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=31037574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1217-1227&author=P.+Guenthoerauthor=K.+Fuchsauthor=G.+Reischlauthor=L.+Quintanilla-Martinezauthor=I.+Gonzalez-Menendezauthor=S.+Lauferauthor=B.+J.+Pichlerauthor=M.+Kneilling&title=Evaluation+of+the+therapeutic+potential+of+the+selective+p38+MAPK+inhibitor+Skepinone-L+and+the+dual+p38%2FJNK+3+inhibitor+LN+950+in+experimental+K%2FBxN+serum+transfer+arthritis&doi=10.1007%2Fs10787-019-00593-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis</span></div><div class="casAuthors">Guenthoer, Philipp; Fuchs, Kerstin; Reischl, Gerald; Quintanilla-Martinez, Leticia; Gonzalez-Menendez, Irene; Laufer, Stefan; Pichler, Bernd J.; Kneilling, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Inflammopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1227</span>CODEN:
                <span class="NLM_cas:coden">IAOAES</span>;
        ISSN:<span class="NLM_cas:issn">0925-4692</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA.  Addnl., we aimed to monitor MAPK treatment non-invasively in vivo using the hypoxia tracer [18F]fluoromisonidazole ([18F]FMISO) and positron emission tomog. (PET).  MAPK inhibitor or Sham treatment was administered per os once daily.  On days 3 and 6 after arthritis induction, we conducted PET imaging with [18F]FMISO.  At the end of the expt., ankles were harvested for histopathol. anal.  Results: Skepinone-L and LN 950 were applicable to suppress the severity of exptl. arthritis confirmed by reduced ankle swelling and histopathol. anal.  Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis.  Hypoxia imaging with [18F]FMISO revealed non-conclusive results and might not be an appropriate tool to monitor MAPK therapy in exptl. RA.  Conclusion: Both the selective p38 MAPK inhibitor Skepinone-L and the dual (p38 MAPK and JNK 3) inhibitor LN 950 exhibited significant therapeutic effects during exptl. arthritis.  Thus, our study contributes to the ongoing discussion on the use of p38 MAPK as a potential target in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAwl5kyY-pbVg90H21EOLACvtfcHk0lhoX-nwi_p2mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmsbbF&md5=1c16ac6e94085ae9ed5e14f36167c15f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10787-019-00593-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10787-019-00593-6%26sid%3Dliteratum%253Aachs%26aulast%3DGuenthoer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DK.%26aulast%3DReischl%26aufirst%3DG.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DGonzalez-Menendez%26aufirst%3DI.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DPichler%26aufirst%3DB.%2BJ.%26aulast%3DKneilling%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520therapeutic%2520potential%2520of%2520the%2520selective%2520p38%2520MAPK%2520inhibitor%2520Skepinone-L%2520and%2520the%2520dual%2520p38%252FJNK%25203%2520inhibitor%2520LN%2520950%2520in%2520experimental%2520K%252FBxN%2520serum%2520transfer%2520arthritis%26jtitle%3DInflammopharmacology%26date%3D2019%26volume%3D27%26spage%3D1217%26epage%3D1227%26doi%3D10.1007%2Fs10787-019-00593-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigalke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gawaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span> <span> </span><span class="NLM_article-title">Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1159/000350110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1159%2F000350110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=23817201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFClsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=914-924&author=O.+Borstauthor=B.+Walkerauthor=P.+Munzerauthor=A.+Russoauthor=E.+Schmidauthor=C.+Faggioauthor=B.+Bigalkeauthor=S.+Lauferauthor=M.+Gawazauthor=F.+Lang&title=Skepinone-L%2C+a+novel+potent+and+highly+selective+inhibitor+of+p38+MAP+kinase%2C+effectively+impairs+platelet+activation+and+thrombus+formation&doi=10.1159%2F000350110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation</span></div><div class="casAuthors">Borst, Oliver; Walker, Britta; Muenzer, Patrick; Russo, Antonella; Schmid, Evi; Faggio, Caterina; Bigalke, Boris; Laufer, Stefan; Gawaz, Meinrad; Lang, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">914-924</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Platelets are critically important for primary hemostasis and the major players in thrombotic vascular occlusion.  Platelets are activated by agonists, such as thrombin and collagen-related peptide as well as second-wave mediators including thromboxane A2 via different intracellular signaling pathways resulting in degranulation, aggregation and thrombus formation.  Platelet activation is paralleled by phosphorylation and activation of p38 MAPK.  The limited specificity of hitherto known p38 MAPK inhibitors precluded safe conclusions on the precise role of p38 MAPK in the regulation of platelet function.  The present study examd. the impact of Skepinone-L, a novel and highly selective inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), on platelet activation and thrombus formation.  Methods: Expts. were performed in freshly isolated human platelets.  Protein phosphorylation was quantified by Western blotting, thromboxane B2 synthesis by enzyme immunoassay, ATP release by ChronoLume luciferin assay, cytosolic Ca2+ concn. by Fura-2 fluorescence-measurements, platelet aggregation by a light transmissions measurement and in vitro thrombus formation by a flow chamber.  Results: Skepinone-L (1 μM) virtually abrogated the phosphorylation of platelet p38 MAPK substrate Hsp27 following stimulation with CRP (1 μg/mL), thrombin (5 mU/mL) or thromboxane A2 analog U-46619 (1 μM).  Furthermore, Skepinone-L significantly blunted activation-dependent platelet secretion and aggregation following threshold concns. of CRP, thrombin and thromboxane A2 analog U-46619.  Skepinone-L did not impair platelet Ca2+ signaling but prevented agonist-induced thromboxane A2 synthesis through abrogation of p38 MAPK-dependent phosphorylation of platelet cytosolic phospholipase A2 (cPLA2).  Skepinone-L further markedly blunted thrombus formation under low (500-s) and high (1700-s) arterial shear rates.  Conclusions: The present study discloses a powerful inhibiting effect of p38 MAPK-blocker Skepinone-L on platelet activation and thrombus formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT5ug7OMXgh7Vg90H21EOLACvtfcHk0lhoX-nwi_p2mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFClsrzJ&md5=bdfe52760e5dd535f2910675bb961dac</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1159%2F000350110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000350110%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DMunzer%26aufirst%3DP.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DE.%26aulast%3DFaggio%26aufirst%3DC.%26aulast%3DBigalke%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DGawaz%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DF.%26atitle%3DSkepinone-L%252C%2520a%2520novel%2520potent%2520and%2520highly%2520selective%2520inhibitor%2520of%2520p38%2520MAP%2520kinase%252C%2520effectively%2520impairs%2520platelet%2520activation%2520and%2520thrombus%2520formation%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2013%26volume%3D31%26spage%3D914%26epage%3D924%26doi%3D10.1159%2F000350110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudalska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longerich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McJunkin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuestefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Thun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirmacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span> <span> </span><span class="NLM_article-title">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/nm.3679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1038%2Fnm.3679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=25216638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=1138-1146&author=R.+Rudalskaauthor=D.+Dauchauthor=T.+Longerichauthor=K.+McJunkinauthor=T.+Wuestefeldauthor=T.+W.+Kangauthor=A.+Hohmeyerauthor=M.+Pesicauthor=J.+Leiboldauthor=A.+von+Thunauthor=P.+Schirmacherauthor=J.+Zuberauthor=K.+H.+Weissauthor=S.+Powersauthor=N.+P.+Malekauthor=M.+Eilersauthor=B.+Siposauthor=S.+W.+Loweauthor=R.+Geffersauthor=S.+Lauferauthor=L.+Zender&title=In+vivo+RNAi+screening+identifies+a+mechanism+of+sorafenib+resistance+in+liver+cancer&doi=10.1038%2Fnm.3679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</span></div><div class="casAuthors">Rudalska, Ramona; Dauch, Daniel; Longerich, Thomas; McJunkin, Katherine; Wuestefeld, Torsten; Kang, Tae-Won; Hohmeyer, Anja; Pesic, Marina; Leibold, Josef; von Thun, Anne; Schirmacher, Peter; Zuber, Johannes; Weiss, Karl-Heinz; Powers, Scott; Malek, Nisar P.; Eilers, Martin; Sipos, Bence; Lowe, Scott W.; Geffers, Robert; Laufer, Stefan; Zender, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In solid tumors, resistance to therapy inevitably develops upon treatment with cytotoxic drugs or molecularly targeted therapies.  Here, we describe a system that enables pooled shRNA screening directly in mouse hepatocellular carcinomas (HCC) in vivo to identify genes likely to be involved in therapy resistance.  Using a focused shRNA library targeting genes located within focal genomic amplifications of human HCC, we screened for genes whose inhibition increased the therapeutic efficacy of the multikinase inhibitor sorafenib.  Both shRNA-mediated and pharmacol. silencing of Mapk14 (p38α) were found to sensitize mouse HCC to sorafenib therapy and prolong survival by abrogating Mapk14-dependent activation of Mek-Erk and Atf2 signaling.  Elevated Mapk14-Atf2 signaling predicted poor response to sorafenib therapy in human HCC, and sorafenib resistance of p-Mapk14-expressing HCC cells could be reverted by silencing Mapk14.  Our results suggest that a combination of sorafenib and Mapk14 blockade is a promising approach to overcoming therapy resistance of human HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquN9Poy48vIbVg90H21EOLACvtfcHk0ljL7npGO-3Snw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlt7rL&md5=a843ee6d8060b9dcd04083cf1991f97c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.3679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3679%26sid%3Dliteratum%253Aachs%26aulast%3DRudalska%26aufirst%3DR.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DLongerich%26aufirst%3DT.%26aulast%3DMcJunkin%26aufirst%3DK.%26aulast%3DWuestefeld%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DT.%2BW.%26aulast%3DHohmeyer%26aufirst%3DA.%26aulast%3DPesic%26aufirst%3DM.%26aulast%3DLeibold%26aufirst%3DJ.%26aulast%3Dvon%2BThun%26aufirst%3DA.%26aulast%3DSchirmacher%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DK.%2BH.%26aulast%3DPowers%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DN.%2BP.%26aulast%3DEilers%26aufirst%3DM.%26aulast%3DSipos%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DZender%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520RNAi%2520screening%2520identifies%2520a%2520mechanism%2520of%2520sorafenib%2520resistance%2520in%2520liver%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D1138%26epage%3D1146%26doi%3D10.1038%2Fnm.3679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pergola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span> <span> </span><span class="NLM_article-title">Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2439</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1096/fj.14-268474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1096%2Ffj.14-268474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=25678624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaqu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2439-2449&author=A.+Koeberleauthor=C.+Pergolaauthor=H.+Shindouauthor=S.+C.+Koeberleauthor=T.+Shimizuauthor=S.+A.+Lauferauthor=O.+Werz&title=Role+of+p38+mitogen-activated+protein+kinase+in+linking+stearoyl-CoA+desaturase-1+activity+with+endoplasmic+reticulum+homeostasis&doi=10.1096%2Ffj.14-268474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of p38 mitogen-activated protein kinase in linking stearoyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis</span></div><div class="casAuthors">Koeberle, Andreas; Pergola, Carlo; Shindou, Hideo; Koeberle, Solveigh C.; Shimizu, Takao; Laufer, Stefan A.; Werz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2439-2449</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Endoplasmic reticulum (ER) homeostasis is regulated by a network of signaling pathways to which stearoyl-CoA desaturase (SCD)-1, p38 mitogen-activated protein kinase (MAPK) and the unfolded protein response (UPR) belong.  Because all these pathways are located at the interface of cell cycle control and cell stress, we hypothesized a cross-regulation.  Interference with SCD-1, either by small interfering (si)RNA or the specific SCD-1 inhibitor CAY10566 (EC50 1 μM; ≥ 24 h), specifically induced phosphorylation and thus activation of p38 MAPK in NIH-3T3 mouse fibroblasts (1.5- to 2-fold; 48 h).  During lipotoxic and cell cycle stress, prolonged activation of p38 MAPK due to SCD-1 inhibition induced ER stress, the UPR, and ER/Golgi remodeling as shown by Western blot and immunofluorescence microscopy (1.2- to 3.5-fold). Specific inhibition of p38 MAPK by Skepinone-L [half maximal inhibitory concn. (IC50) 25-50 nM] reversed these effects (at 1 μM; 48 h).  The specificity by which SCD-1 modulates the phospholipid compn. and inhibits p38 MAPK signaling (among survival/stress pathways), thereby preventing ER stress (but not other SCD-1-dependent responses), suggests selective protein-lipid interactions.  Palmitoleoyl/oleoyl-phosphatidylinositol (PI) was accordingly identified as potential lipid mediator using chromatog.-coupled ESI tandem mass spectrometry.  We conclude that the neg. regulation of p38 MAPK mediates the protective effects of SCD-1 on ER homeostasis under distinct stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBvBgoVZ1-erVg90H21EOLACvtfcHk0ljL7npGO-3Snw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaqu7vO&md5=55e26d6d8bbe5d747b1417dba573be1c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-268474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-268474%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DPergola%26aufirst%3DC.%26aulast%3DShindou%26aufirst%3DH.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DWerz%26aufirst%3DO.%26atitle%3DRole%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520in%2520linking%2520stearoyl-CoA%2520desaturase-1%2520activity%2520with%2520endoplasmic%2520reticulum%2520homeostasis%26jtitle%3DFASEB%2520J.%26date%3D2015%26volume%3D29%26spage%3D2439%26epage%3D2449%26doi%3D10.1096%2Ffj.14-268474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel type I(1)/2 p38alpha MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time by interfering with the R-spine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8027</span>– <span class="NLM_lpage">8054</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00745</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8027-8054&author=N.+M.+Walterauthor=H.+K.+Wentschauthor=M.+B%C3%BChrmannauthor=S.+M.+Bauerauthor=E.+D%C3%B6ringauthor=S.+Mayer-Wrangowskiauthor=A.+Sievers-Englerauthor=N.+Willemsen-Seegersauthor=G.+Zamanauthor=R.+Buijsmanauthor=M.+L%C3%A4mmerhoferauthor=D.+Rauhauthor=S.+A.+Laufer&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+type+I%281%29%2F2+p38alpha+MAP+kinase+inhibitors+with+excellent+selectivity%2C+high+potency%2C+and+prolonged+target+residence+time+by+interfering+with+the+R-spine&doi=10.1021%2Facs.jmedchem.7b00745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></div><div class="casAuthors">Walter, Niklas M.; Wentsch, Heike K.; Buehrmann, Mike; Bauer, Silke M.; Doering, Eva; Mayer-Wrangowski, Svenja; Sievers-Engler, Adrian; Willemsen-Seegers, Nicole; Zaman, Guido; Buijsman, Rogier; Laemmerhofer, Michael; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8027-8054</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time.  Thus, the scope was to develop a new class of advanced compds. maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II.  Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine.  By synthesizing 69 compds., we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM.  This new binding mode was validated by cocrystn., showing all binding interactions typifying type I1/2 binding.  Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAGz7uVuEJALVg90H21EOLACvtfcHk0ljL7npGO-3Snw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOksb3M&md5=99afecb58a5cf1fff6d9a905eb9f3aca</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DZaman%26aufirst%3DG.%26aulast%3DBuijsman%26aufirst%3DR.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520type%2520I%25281%2529%252F2%2520p38alpha%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520selectivity%252C%2520high%2520potency%252C%2520and%2520prolonged%2520target%2520residence%2520time%2520by%2520interfering%2520with%2520the%2520R-spine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8027%26epage%3D8054%26doi%3D10.1021%2Facs.jmedchem.7b00745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zender, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Optimized target residence time: type I1/2 Inhibitors for p38alpha MAP kinase with improved binding kinetics through direct interaction with the R-spine</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5363</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+B%C3%BChrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+target+residence+time%3A+type+I1%2F2+Inhibitors+for+p38alpha+MAP+kinase+with+improved+binding+kinetics+through+direct+interaction+with+the+R-spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0lhgIcxpuFTYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520target%2520residence%2520time%253A%2520type%2520I1%252F2%2520Inhibitors%2520for%2520p38alpha%2520MAP%2520kinase%2520with%2520improved%2520binding%2520kinetics%2520through%2520direct%2520interaction%2520with%2520the%2520R-spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wentsch, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer-Wrangowski, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niess, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1021/jm301539x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301539x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=241-253&author=S.+Fischerauthor=H.+K.+Wentschauthor=S.+C.+Mayer-Wrangowskiauthor=M.+Zimmermannauthor=S.+M.+Bauerauthor=K.+Storchauthor=R.+Niessauthor=S.+C.+Koeberleauthor=C.+Grutterauthor=F.+M.+Boecklerauthor=D.+Rauhauthor=S.+A.+Laufer&title=Dibenzosuberones+as+p38+mitogen-activated+protein+kinase+inhibitors+with+low+ATP+competitiveness+and+outstanding+whole+blood+activity&doi=10.1021%2Fjm301539x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity</span></div><div class="casAuthors">Fischer, Stefan; Wentsch, Heike K.; Mayer-Wrangowski, Svenja C.; Zimmermann, Markus; Bauer, Silke M.; Storch, Kirsten; Niess, Raimund; Koeberle, Solveigh C.; Gruetter, Christian; Boeckler, Frank M.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-253</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases.  Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market.  This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biol. systems and selectivity.  Herein an approach to the development of such inhibitors on the basis of the highly selective mol. probe Skepinone-L (I) is described.  Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compds.  Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compds. in a whole blood assay.  Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biol. systems and in therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbi31syvBEYrVg90H21EOLACvtfcHk0lhgIcxpuFTYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP&md5=bfce0ba26af365a1d218095e54ba169f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm301539x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301539x%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DZimmermann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DNiess%26aufirst%3DR.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDibenzosuberones%2520as%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520with%2520low%2520ATP%2520competitiveness%2520and%2520outstanding%2520whole%2520blood%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D241%26epage%3D253%26doi%3D10.1021%2Fjm301539x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=20638357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+nonradioactive+immunosorbent+assay+for+p38alpha+mitogen-activated+protein+kinase+activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity</span></div><div class="casAuthors">Goettert, Marcia; Graeser, Ralph; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, the authors describe the optimization of a nonradioactive immunosorbent p38α-MAP kinase (MAPK) activity assay to det. the inhibitory potency of small mol. inhibitors.  The assay omitted the secondary antibody and, therefore, was shorter, more accurate, and easier to handle (total assay time of 3 h).  This direct assay used a new monoclonal anti-phospho-ATF-2 (Thr69/71) peroxidase-conjugated antibody, increasing the specificity and eliminating problems with cross-reactivities of secondary antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu4ELn6_1brVg90H21EOLACvtfcHk0lhNVB4vT8WuyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP&md5=23b6434a50195acd27895d7d2205556c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520nonradioactive%2520immunosorbent%2520assay%2520for%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of c-Jun N-terminal kinases: an update</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1021/jm501212r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501212r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=72-95&author=P.+Kochauthor=M.+Gehringerauthor=S.+A.+Laufer&title=Inhibitors+of+c-Jun+N-terminal+kinases%3A+an+update&doi=10.1021%2Fjm501212r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of c-Jun N-Terminal Kinases: An Update</span></div><div class="casAuthors">Koch, Pierre; Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-95</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The c-Jun N-terminal kinases (JNKs) are serine/threonine kinases implicated in the pathogenesis of various diseases.  Recent advances in the development of novel inhibitors of JNKs will be reviewed.  Significant progress in the design of JNK inhibitors displaying selectivity vs. other kinases has been achieved within the past 4 years.  However, the development of isoform selective JNK inhibitors is still an open task.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_LzW9t04ImLVg90H21EOLACvtfcHk0lhNVB4vT8WuyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb%252FN&md5=0d1c32e1463de951c8b47f35882f90ab</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm501212r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501212r%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DInhibitors%2520of%2520c-Jun%2520N-terminal%2520kinases%253A%2520an%2520update%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D72%26epage%3D95%26doi%3D10.1021%2Fjm501212r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rippmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulle, S.</span></span> <span> </span><span class="NLM_article-title">KinMap: a web-based tool for interactive navigation through human kinome data</span>. <i>BMC Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/s12859-016-1433-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=10.1186%2Fs12859-016-1433-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=28056780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsFCjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=16&author=S.+Eidauthor=S.+Turkauthor=A.+Volkamerauthor=F.+Rippmannauthor=S.+Fulle&title=KinMap%3A+a+web-based+tool+for+interactive+navigation+through+human+kinome+data&doi=10.1186%2Fs12859-016-1433-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">KinMap: a web-based tool for interactive navigation through human kinome data</span></div><div class="casAuthors">Eid, Sameh; Turk, Samo; Volkamer, Andrea; Rippmann, Friedrich; Fulle, Simone</div><div class="citationInfo"><span class="NLM_cas:title">BMC Bioinformatics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16/1-16/6</span>CODEN:
                <span class="NLM_cas:coden">BBMIC4</span>;
        ISSN:<span class="NLM_cas:issn">1471-2105</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Annotations of the phylogenetic tree of the human kinome is an intuitive way to visualize compd. profiling data, structural features of kinases or functional relationships within this important class of proteins.  The increasing vol. and complexity of kinase-related data underlines the need for a tool that enables complex queries pertaining to kinase disease involvement and potential therapeutic uses of kinase inhibitors.  Results: Here, we present KinMap, a user-friendly online tool that facilitates the interactive navigation through kinase knowledge by linking biochem., structural, and disease assocn. data to the human kinome tree.  To this end, preprocessed data from freely-available sources, such as ChEMBL, the Protein Data Bank, and the Center for Therapeutic Target Validation platform are integrated into KinMap and can easily be complemented by proprietary data.  The value of KinMap will be exemplarily demonstrated for uncovering new therapeutic indications of known kinase inhibitors and for prioritizing kinases for drug development efforts.  Conclusions: KinMap represents a new generation of kinome tree viewers which facilitates interactive exploration of the human kinome.  KinMap enables generation of high-quality annotated images of the human kinome tree as well as exchange of kinome-related data in scientific communications.  Furthermore, KinMap supports multiple input and output formats and recognizes alternative kinase names and links them to a unified naming scheme, which makes it a useful tool across different disciplines and applications.  A web-service of KinMap is freely available at http://www.kinhub.org/kinmap/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1M2aa8fuKALVg90H21EOLACvtfcHk0lhNVB4vT8WuyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsFCjtLc%253D&md5=29737c7cda8d9caf75018e0d29e9a459</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs12859-016-1433-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12859-016-1433-7%26sid%3Dliteratum%253Aachs%26aulast%3DEid%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DS.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DRippmann%26aufirst%3DF.%26aulast%3DFulle%26aufirst%3DS.%26atitle%3DKinMap%253A%2520a%2520web-based%2520tool%2520for%2520interactive%2520navigation%2520through%2520human%2520kinome%2520data%26jtitle%3DBMC%2520Bioinf.%26date%3D2017%26volume%3D18%26spage%3D16%26doi%3D10.1186%2Fs12859-016-1433-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE','PDB','3QUE'); return false;">PDB: 3QUE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i102"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01773">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_64874"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01773?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01773</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Detailed procedures for the preparation of compounds <b>45</b>–<b>51</b>, <b>70</b>–<b>72</b>, and <b>S1</b>, CNS penetration studies, in vitro metabolic stability study, CYP and hERG inhibition, the selectivity screening as well as selected HPLC traces and NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES strings of tested compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_001.pdf">jm0c01773_si_001.pdf (4.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01773/suppl_file/jm0c01773_si_002.csv">jm0c01773_si_002.csv (5.98 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01773&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01773%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01773" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799951eea943d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
